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Chapter 1
Introducti on, aim and outline of this thesis

13
INTRoDUCTIoN, AIM AND oUTLINE oF THIS THESIS | 
Intellectual disability
Intellectual disability (ID) is a common form of cognitive impairment that affects 
2-3% of the general population, and places a large burden on the families, societies 
and the health care system.1-3 Affected individuals have an intelligence quotient 
(IQ) below 70, onset before the age of 18 years and significant limitations in two or 
more adaptive skills, such as self care, communication skills, problem solving and 
logical thinking.4 ID is usually further sub-classified according to the IQ level: mild (IQ 
level 50 to 69), moderate (IQ level 35 to 49), severe (IQ level 20-34) and profound ID 
(IQ level below 20).1,5,6 The prevalence of mild ID is 85%, that of moderate ID 10%, 
whereas only 5% of the patients are classified as severe/profound ID.7,8 The term 
“ID” can be dissected into syndromic ID (sID) and non-syndromic ID (nsID). Patients 
with sID, have other associated abnormalities such as structural brain and skeletal 
anomalies, metabolic defects and facial dysmorphisms, while patients with nsID only 
have ID in common without consistent recognizable associated features.9 
Causes of ID
ID is an extremely heterogeneous group of disorders. Genetic factors and non-
genetic factors contribute approximately equally to the development and to the 
prevalence of ID.10 Non-genetic factors include environmental insults, nutritional 
factors, toxic exposure during pregnancy, obstetric-related complications, and 
socio-economic factors - such as level of income, family circumstances, and cultural 
environment. The prevalence of ID is two- to threefold higher in the poor and 
underdeveloped World as compared to Western countries.11 In poor countries 
malnutrition is one of the main risk factors. Prenatal and perinatal complications 
such as hypoxia, fetal brain damage due to the maternal transmission of infectious 
diseases (e.g. rubella, toxoplasmosis and cytomegalovirus infection), trauma and low 
birth weight are also important contributors to the prevalence of ID. In developed 
countries, especially in US, fetal alcohol syndrome (FAS) has a prevalence of 0.5-2 
cases per 1,000 live births and is the most common avoidable cause of ID.11-13 About 
50% of all ID patients are due to such types of environmental insults.10 
The genetic causes of ID can be subdivided into chromosomal abnormalities and 
monogenic disorders, including metabolic defects. Chromosomal anomalies are of 
different types such as aneuploidies (numerical disorders), submicroscopic deletions 
and duplications or copy number variations (CNV), and balanced/unbalanced 
translocations. Despite recent advances, genetic causes of about 40% of ID remain 
unexplored.14 Chromosomal anomalies are a major cause of ID as 22% of severe 
ID cases has an underlying chromosomal defect.15 The most common cause of ID 
among chromosomal aneuploidies is trisomy 21 (Down syndrome), with a high 
prevalence rate of 1/1000 live births.16,17 CNVs can cause recurrent conditions of 
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ID usually associated with other features such as in Williams-Beuren syndrome, 
Prader-Willi syndrome and Smith-Magenis syndrome.18 These CNVs can affect 
several kilobases to megabases of DNA that give rise to a contiguous gene syndrome 
involving altered dosage of several genes. However, in some cases it has been shown 
that haploinsufficiency of a single dosage-sensitive gene can explain the ID; such 
as EHMT1 in Kleefstra syndrome,19 KANSL1 in Koolen-de Vries syndrome,20 RAI1 
in Smith-Magenis syndrome,21 LIS1 in the 17p13.3 microdeletion syndrome,22 and 
MECP2 in the MECP2 duplication syndrome.23
Metabolic disorders are often associated with ID. In a large study, screening 
of the known metabolic conditions revealed that congenital metabolic disorders 
account for ~3% of the cases with unexplained ID.24 The clinical features of some of 
the metabolic disorders can be prevented, such as hypothyroidism, phenylketonuria 
and others.25 In developed countries, specific programs have been installed - such as 
the heel prick/Guthrie card test as a neonatal screening program in the UK and the 
Netherlands - for early detection and treatment of such disorders.11 Unfortunately, 
in most developing countries, there is no systematic neonatal screening program 
employed yet.12 
To date, more than 520 genes have been implicated in ID (of which ~450 genes 
are proven to be causal:26 Dr. T. Kleefstra, Dr. A. Schenck, Dr. H. Ijntema, personal 
communication). over 100 of these genes are associated with nsID, and approximately 
400 genes are involved in sID.26 These monogenic causes of ID can be classified into 
X-linked, autosomal dominant and autosomal recessive ID.
X-linked intellectual disability 
The elucidation of the genetic defects in X-linked intellectual disability (XLID) has 
been extensively pursued in past and recent years.27 Because of the 30-40% male 
excess in individuals with ID, it has been commonly believed that defects on the X 
chromosome are a frequent cause of ID in males.28-30 The most frequent cause of 
XLID and the most common single-gene disorder for ID as well as autism is fragile 
X syndrome (FXS), with the prevalence of 1/5,000-6,000 in males.31,32 FXS is caused 
by the expansion of a CGG trinucleotide tandem repeat in the promoter region of 
the FMR1 gene. FMR1 encodes for FMRP protein which is involved in development 
of synapses and cell-to-cell communication.2,33 The accessibility of large numbers 
of families with apparent X-linked inheritance of an ID phenotype has led to the 
establishment of several large-scale consortia such as EURo-MRX and iGoLD, aiming 
to identify the X-chromosomal causes of ID.34,35 Thanks to such programs, a total of 
112 genes have been associated with XLID (Statistics January 2013; Kalscheuer et 
al., submitted), of which approximately half of the genes have been implicated in 
syndromic XLID (sXLID) and the other half in non-syndromic XLID (nsXLID). Based on 
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these studies it is now estimated that XLID accounts for 10-12% of all males with ID.33,36 
This number is indeed larger than expected by random chromosomal distribution, 
because the X chromosome harbors about 4% of all genes,37 and constitutes ~5% of 
the entire genome. The estimated total number of genes underlying ID (dominant 
and recessive) is in the range of 2000-3000.26 
Autosomal dominant intellectual disability 
As autosomal dominant ID (ADID) mostly results in reduced fecundity, it is very 
rare to find large kindreds with ADID that are suitable for traditional genetic studies, 
such as linkage analysis. Isolated occurrence is most commonly seen in clinical 
practice in Western countries. This may suggest that de novo DNA rearrangements 
and variations are a common cause of ADID.38,39 Analyses in various large patient 
cohorts reveal that CNVs may account for 15-20% of ID individuals, depending on the 
selection of the patients used.40,41 Recurrent microdeletions and duplications have 
allowed the definition of new ID disease entities, for example Kleefstra syndrome 
(9q34.4),19 Koolen-de Vries syndrome (17q21.31),20 Angelman syndrome (15q11.2),42 
and Pit-Hopkins syndrome (18q21.1).43,44 Recently, exome sequencing and whole-
genome sequencing approaches have been applied to identify de novo DNA variants 
in ID and autism patients.45-50 Vissers et al. performed exome sequencing in ten 
isolated idiopathic ID cases and their normal parents. This study revealed de novo 
point mutations in six unrelated cases.48 Following the same strategy, Rauch et al. 
studied a cohort of 51 isolated ID cases. They reported six possible novel genes 
carrying de novo truncating mutations and six potential new genes carrying de novo 
missense mutations51. Similarly, de Ligt and colleagues conducted a massive study 
on 100 idiopathic ID cases. They reported three novel genes in which recurrent 
de novo mutations were identified in patients with similar phenotypic features. 
Potentially causative de novo mutations in plausible candidate genes were detected 
in 22 patients.45 Using these studies, ~22% of the total diagnostic yield can be 
estimated.45,48,51 If CNVs are excluded, these studies estimate that severe ID could be 
caused by potential de novo variants in approximately 35-45% of isolated patients.45,51 
With these recent advances, genomic analyses have successfully identified a plethora 
of novel ID (candidate) genes and bypassed the need for large families for genetic 
studies. The majority of genetic factors contributing to the prevalence of ADID has 
yet to be elucidated.38,39,52 Thus, the identification of the causative mutations in non-
syndromic ADID (nsADID) will remain challenging because of the lack of multiple 
patients with a similar etiology and the absence of rare recurrent genetic defects. 
However, some genes carrying recurrent mutations in ID and/or autism have already 
been identified, such as SYNGAP1,39 CHD8, DYRK1A, GRIN2B, and PTEN.46 
16
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Autosomal recessive intellectual disability
The discovery of causative gene mutations in autosomal recessive ID (ARID) has 
been hampered by the paucity of large families and the large heterogeneity of the 
condition. For this reason, the identification of causative genes in syndromic forms 
of ARID (sARID) has been most successful, as it allowed the identification of multiple 
families with apparently the same condition and hence the pooling of genetic 
data. Consequently, a considerable number of genes (>250 genes; Dr. T. Kleefstra, 
personal communication) has been identified in syndromic form of ARID (sARID). By 
contrast, the identification of genes for non-syndromic ARID (nsARID) is lagging far 
behind.11,26,33,53 So far, >40 novel loci have been reported for nsARID which suggests 
that no frequent genetic defect is to be expected, at least in the studied cohorts.54-59 
In 2006, only three genes (PRSS12, CRBN and CC2D1A) had been implicated in 
nsARID.55 In 2007, Najmabadi et al. started a project exploiting consanguineous 
marriages in the Iranian population (consanguinity rate >40%), and identified eight 
novel loci for nsARID.58 In the subsequent studies they identified several novel genes 
such as GRIK2,60 TUSC3,61 TRAPPC9,57 ST3GAL3,62 and ZC3H14,63  with homozygous 
mutations associated with nsARID. Subsequently, mutations in several other genes 
were linked to nsARID: TECR, in a consanguineous Israelian family,64 KIAA1033, in a 
large consanguineous family from oman,65 and finally MED23 was assigned as 11th 
gene of nsARID.66 
With the advent of high-throughput techniques in the field of DNA sequencing, 
much more ARID genes have been identified. Recently, targeted next generation 
sequencing was applied to 136 consanguineous families of Iranian population, in 
which mostly a single locus had previously been identified by homozygosity mapping. 
This study revealed segregating variants in 29 known ARID genes and another 50 
variants in genes that had not previously been linked to ARID. of the latter group, 
29 genes were implicated in nsARID. Despite the apparent high yield, the causality 
of mutations in many of these genes are not proven beyond doubt given their 
single occurrence in ID. It is also the case with some of the genes that are identified 
earlier. Recently another gene, CRADD has been associated with nsARID.67 So far, 41 
genes have been associated with nsARID. of which, only eight genes are found to 
be recurrently mutated in multiple ARID families (Table 1). The above study with 50 
plausible new genes clearly indicates the power of studying recessive disorders in 
highly consanguineous populations.53 It should be noted that the majority of genes 
implicated in nsARID stems from the extensive genetic study in the Iranian population 
(Table 1), which warrants further studies in other (consanguineous) populations.
17
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Table 1 List of genes implicated in nsARID
No. Gene name MIM # Reference
1 PRSS12* 606709 Molinari, F, et al 2002.
2 CRBN 609262 Higgins JJ, et al. 2004.
3 CC2D1A* 610055 Basel-V L, et al. 2006.
4 GRIK2 138244 Motazacker MM, et al. 2007.
5 TUSC3* 601385 Garshasbi M, et al. 2008.
6 TRAPPC9*# 611966 Mir A, et al. 2009.
7 ST3GAL3* 606494 Hu H, et al. 2011.
8 ZC3H14 613279 Pak C, et al. 2011.
9 TECR 610057 Çalışkan M, et al. 2011.
10 KIAA1033 NA Ropers F, et al. 2011.
11 MED23 605042 Hashimoto S, et al. 2011.
12 ADKa 102750 Najmabadi H, et al. 2011.
13 ADRA2B 104260 Najmabadi H, et al. 2011.
14 ASCC3 614217 Najmabadi H, et al. 2011.
15 ASCL1 100790 Najmabadi H, et al. 2011.
16 C11orf46 612295 Najmabadi H, et al. 2011.
17 C12orf57 NA Najmabadi H, et al. 2011.
18 C8orf41 614426 Najmabadi H, et al. 2011.
19 C9orf86 610615 Najmabadi H, et al. 2011.
20 CASP2 600639 Najmabadi H, et al. 2011.
21 CCNA2 123835 Najmabadi H, et al. 2011.
22 COO5 NA Najmabadi H, et al. 2011.
23 EEF1B2 600655 Najmabadi H, et al. 2011.
24 ELP2* NA Najmabadi H, et al. 2011.
25 ENTPD1 601752 Najmabadi H, et al. 2011.
26 FASN 600212 Najmabadi H, et al. 2011.
27 HIST3H3 602820 Najmabadi H, et al. 2011.
28 INPP4A 600916 Najmabadi H, et al. 2011.
29 MAN1B1*# 604346 Rafique MA, et al. 2011.
30 NDST1 600853 Najmabadi H, et al. 2011.
31 PECRa 605843 Najmabadi H, et al. 2011.
32 PRMT10 307150 Najmabadi H, et al. 2011.
33 PRRT2 614386 Najmabadi H, et al. 2011.
34 RALGDS 601619 Najmabadi H, et al. 2011.
35 RGS7a 602517 Najmabadi H, et al. 2011.
36 SCAPER 611611 Najmabadi H, et al. 2011.
37 TRMT1 611669 Najmabadi H, et al. 2011.
38 UBR7a 613816 Najmabadi H, et al. 2011.
39 ZCCHC8 NA Najmabadi H, et al. 2011.
40 ZNF526* 614387 Najmabadi H, et al. 2011.
41 CRADD 603454 Puffenberger EG, et al. 2012.
aID+ASD
NA= not available
* = recurrence has been identified
# = nsARID/with associated dysmorphic features
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Common molecular pathways in ID
The number of genes involved in the pathology of ID and of other cognitive 
disorders (CD) is increasing with the current advancement in the DNA techniques such 
as massively parallel sequencing.68 Importantly, the rapidly increasing number of ID 
genes allows the identification of common molecular and cellular processes in which 
the corresponding proteins are involved.69 These common processes can be broken 
down into four major categories; 1) Neurogenesis, which ensures and regulates the 
neuronal numbers during development as well as adulthood.70,71 The defects in these 
types of genes (e.g. MCPH1, ASPM, CENPJ, etc) typically give rise to an aberrant head 
size phenotype (i.e. microcephaly/macrocephaly) along with varying levels of ID. 
Genes from this group have crucial role in cell division and cell cycle regulation;72,73 2) 
Neuronal migration. Mutations in genes that are implicated in neuronal migration, 
such as LIS1, ARX, POMT1, and RELN give rise to a heterogeneous group of disorders 
with different types of brain malformations and aberrations of cortical development. 
In most cases these patients have ID and seizures;36,74 3) Synaptic function. Pathogenic 
mutations in the genes involved in synaptic function and plasticity, are mostly 
identified in conditions with ID and/or with other neuropsychiatric disorders such as 
autism spectrum disorder (ASD), schizophrenia (SCZ), Attention-Deficit/Hyperactivity 
Disorder (ADHD) and epilepsy. Disruption of synaptic development and activity might 
reflect a direct synaptic role of the corresponding protein. Examples of such proteins 
are NRXN1, CNTNAP275 and the SHANK proteins, which are all associated with ID, 
SCZ and ASD in various combinations.74,76-78 However, synaptic defects are also seen 
in association with disruption of non-synaptic proteins, such as transcription factors, 
indicating that synaptic deficits can also be an indirect result or an endpoint of a 
disrupted molecular process; 4) Transcriptional and epigenetic mechanisms. The 
genes associated with these mechanisms are regulators of chromatin structure and 
transcriptional regulation.79 Epigenetic modifications are key regulators of expression 
by regulating the accessibility of gene-regulatory elements by the transcription 
machinery. The accessibility is controlled by modulation of the chromatin structure 
through DNA-methylation, histone modifications and non-coding RNAs. Notably, 
mutations in more than 10 genes encoding “writers” (directly involved in chromatin 
remodeling) of the epigenetic code have been identified, which includes EHMT1, 
EP300, NSD1, JARID1C, HDAC4, MLL2, MLL3, and SMARCB1. In addition, more than 20 
“reader” genes (involved recognition and maintenance of the chromatin structure) 
have been identified, such as ATRX, CHD7, MECP2, MED12, RAI1, MBD5, NR1I3, TCF4, 
YY1, ZNF41, and ZNF81. Mutations in epigenetic ID genes have been implicated in a 
broad range of phenotypes from severe sID conditions to mild nsID, ASD and SCZ.26,80 
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Homozygosity mapping and consanguinity
Homozygosity mapping is a powerful tool to map autosomal recessive gene 
defects. It has been proven to be useful in locating the genetic defects in both 
consanguineous and non-consanguineous (unrelated) unions.81 In the latter 
situation, homozygous disease gene mutations may reflect identity-by-descent 
(IBD)/autozygosity, which means that the disease allele derived from a common 
ancestor is segregating through multiple generations to occur homozygously in the 
affected individual. This is also the case in consanguineous families, but there the 
parents are by definition more closely related (second cousins or closer) (Figure 
1).82,83 Homozygosity mapping takes advantage of the fact that not only the mutation 
but also the surrounding region is identical on both chromosomes. These regions 
usually encompassing multiple variable DNA markers such as microsatellite markers 
or single nucleotide polymorphisms (SNPs). By using these DNA markers regions 
of homozygosity (RoH) can be determined. Therefore, this technique is called as 
homozygosity mapping, IBD mapping or autozygosity mapping.84,85
figure 1: A four generation 
consanguineous pedigree presenting 
a disease allele (red bar) and 
surrounding chromosomal region 
(region of homozygosity/colored 
white) transmission from common 
ancestor to the affected individuals. 
The double horizontal line in the 
pedigree represents consanguinity 
and the filled symbols indicate 
affected individuals. This figure is 
adapted from www.autozygosity.org.
The length of RoH is 
determined by the rate of 
recombination events over the 
generations within a family. Thus, 
the RoH will be much shorter in 
distantly related individuals as 
compared to the progeny of first/
second cousins. The average size 
of a homozygous region in a child 
of a first-cousin union is ~26Mb, 
leading up to 11% homozygosity 
genome-wide.86 This percentage 
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of homozygosity decreases after successive recombination events in each generation, 
resulting in a reduced average length of RoH to a few Mb or less.81,86
Consanguinity rate varies among different populations in the World. There are 
few highly consanguineous populations, especially in the areas inhabited by Muslims 
and Jews. From Morocco to China (from North Africa to East Asia), the rate of 
consanguineous marriages is very high in these areas (Figure 2). For example, the 
consanguinity rate in Iran is >40%, and in Pakistan and several Arab countries it is 
above 50%. This high rate of consanguinity has several reasons such as religious, 
socioeconomic cultural, historic background and ethnicity11,87.
Families with members that have ID and consanguineous marriages can 
contribute to the mapping of recessive genetic defects. As compared to the outbred 
(non-related) families, studying consanguineous families is advantageous as they 
often have multiple sibships and large regions of homozygosity. It is well established 
that parental consanguinity is an important risk factor (0.25-20% higher chance)88 for 
ID and other birth defects.89 In humans, the high levels of inbreeding are somehow 
linked to generally reduced cognitive ability.90 Likewise, in mice and Drosophila, it has 
been shown that higher rate of inbreeding have adverse effects on cognitive traits 
along with other fitness-related traits.91,92
Although homozygous mutations are a common cause of disease in consanguineous 
families, it also happens regularly that the consanguinity is unrelated to the disorder. 
Thus, compound heterozygosity can be causative for recessive genetic disorders 
and one should be aware of this, particularly when studying families with only few 
affected individuals residing in a single sibship.93,94
Modern DNa techniques to identify the genetic defects
Several modern DNA techniques that emerged in the last few years have 
accelerated genetic studies, both in the mapping of genetic defect by high resolution 
genotyping as well as in the identification of the causative mutation by next 
generation sequencing.11,26,35
High resolution genotyping techniques
The mapping of genetic defects requires certain markers at the genome level 
to pinpoint the exact position of the defect in the DNA.95 Until a decade ago, the 
use of microsatellite (highly polymorphic with di-, tri- and tetra-nucleotide repeats) 
markers was a standard procedure to genotype the genome. Panels of 300-400 
microsatellites markers equally divided across the genome with a resolution of ~10Mb 
(average spacing) genome-wide were used widely.96 This method has been successful 
in large consanguineous recessive families to identify large homozygous stretches 
21
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figure 2: Global prevalence of consanguineous marriages (www.consang.net, reprinted with 
permission of A.H. Bittles). 
that encompassed respective genetic defect.97 However, the resolution is too low to 
study small non-consanguineous families.97 Mapping of the genetic defect in large 
dominant families was also achieved by this method, but rarely for ID disorders 
because of the paucity of large families.98 only some eight years ago, microsatellite 
genotyping was replaced by high throughput and robust microarray-based SNP 
typing, which have the additional advantage that they are also highly powerful in the 
detection of CNVs. There are several platforms to perform SNP microarrays, offered 
by several companies such as Affymetrix (Santa Clara, CA) and Illumina (San Diego, 
CA) and others. In 1996, Affymetrix released its first platform having about ~1500 
SNPs on a single chip,99,100 which was gradually expanded to include one million SNPs 
(6.0 array) in later generation SNP arrays.95,100 Recently, the CytoScan HD platform 
was released, which comprises 2.6 million probes genome-wide, including ~1/3 
polymorphic SNPs and ~2/3 non-polymorphic probes for the detection of CNVs. This 
is a highly dense array by which we can detect deletions and duplications up to 10 
and 20kb resolution respectively and can also identify RoHs. Similarly, Illumina has 
also increased its capacity with the passage of time by providing several platforms, 
from 6,000 (6k) to 4.3 (Humanomni5-Quad) million markers across the genome.100
There are several benefits to use high resolution genotyping methods. They 
are high throughput, time and cost effective, useful to map both consanguineous 
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and non-consanguineous families, and highly suitable to detect small heterozygous 
and homozygous CNVs.26,95 In addition, these dense SNP arrays are also helpful for 
genome-wide association studies (GWAS) to find the disease predisposition alleles in 
mutifactorial disorders like diabetes and cancer.101,102
Next generation sequencing
For over three decades, Sanger sequencing has been the dominant approach 
for DNA sequencing.103 This classical method is still the gold standard procedure 
in genomic diagnostic laboratories. There are however, several limitations to this 
technique. It has a limited potential, since only a maximum of 1000 nucleotides of 
DNA can be sequenced in a single run. The capacity is relatively low as the latest 
machines (ABI PRISM 3730 DNA Analyzer, Applera Corp, Foster City, CA) can handle 
96 to 384 reactions in parallel. In addition, this technique is labor-intensive and 
expensive (costs $500/Mb of DNA).104,105 In the last few years, conventional Sanger 
sequencing is rapidly being surpassed by massively parallel sequencing (MPS), 
also called next generation sequencing (NGS) or second generation sequencing 
approaches. A considerable amount of new discoveries has been documented in 
the field of genetics because of the robust NGS technologies, which can massively 
generate hundreds of megabases to gigabases of DNA sequence in a single run 
depending on the type of platform.103,105 There are several sequencing platforms 
available, such as Roche/454 GS FLX,106 Illumina Genome analyzer and HiSeq,107,108 
SoLiD and 5500xl from Life technologies.109 All of these platforms have more or less 
similar workflows but they differ in other aspects such as sequencing chemistries 
(Figure 3).110 
 NGS can be used to sequence the entire genome of an individual, referred to as 
“whole genome sequencing” (WGS), as well as only the exons of the genome which 
is referred to as “whole exome sequencing” (WES) or exome sequencing. During the 
last five years, exome sequencing has been the most frequently used tool in research 
and diagnostics, as most of the disease causing mutations reside in the coding part 
and it is cheaper. 
NGS technologies have been very successful in identifying disease causing 
genes regardless of types of DNA variations, phenotypic, genetic heterogeneity and 
inheritance patterns.112 NGS is capable to identify point mutations, small insertions 
or deletions (indels) as well as CNVs.103 Dominant syndromic forms of ID have been 
solved by using exome sequencing, such as Bohring-opitz syndrome that is caused 
by de novo mutations in ASXL1 gene113 and six novel ID genes carrying de novo 
mutations identified by trio-sequencing.48 So far, only few studies have reported the 
identification of novel causes of sARID and nsARID by NGS.9,53,63 
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figure 3: Different sequencing chemistries in next generation sequencers. 
(a) Pyrosequencing approach used by Roche454 technology. The incorporated nucleotides 
are detected by chemiluminescence after the pyrophosphate (PPi)  release. (b) ABI SoLiD 
sequencing-by-ligation method in which labeled degenerate probes are used to sequence the 
templates. (c) Illumina sequencing-by-synthesis. Fluorescently labeled nucleotide analogues 
are used.
The diagrams are derived from Morozova et al. 2009111, and reprinted with permission of 
Marco Marra.
The detection of CNVs by using NGS is still in its early phase, as it critically relies 
on the coverage efficiency (especially in a single mate pair) and there are many 
pitfalls to consider.114 The problem of coverage is less problematic for the detection 
of homozygous deletions, and microdeletions within exons or spanning several exons 
can be successfully identified by (targeted) exome sequencing (Chapter 4.1).12 For 
heterozygous rearrangements the detection problem can be circumvented by the 
use of paired-end/mate pair sequencing, which is not yet commonly used in routine 
laboratory settings (Figure 4a and b), and by increasing the depth-of-coverage of the 
reads.115 Paired-end sequencing can generate sequences of up to 500bp, whereas 
mate-pair sequencing can sequence the ends of 2-5Kb DNA fragments112. These 
strategies are very useful to investigate the chromosomal rearrangements such as 
small CNVs, translocations and inversions. Recently, Talkowski et al. demonstrated 
that mate-pair sequencing can efficiently sequence the breakpoints of balanced 
chromosomal translocations in the patients with neurodevelopment disorders.47
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figure 4: Paired-end and mate-pair sequencing schemes. 
(a) Paired-end sequencing can sequence the both ends of the DNA fragment (0.2-0.5Kb) by 
using adapters. (b) Mate-pair sequencing is able to sequence longer DNA inserts (2-5Kb). Mate-
pair library creates short fragments which consists of two different parts (usually apart from 
each other in the genome), then fragments are end-biotinylated to mate-pair the segments. 
After self-circularization, refragmentation and enrichment of the mate-pair fragments, the 
mate pairs are sequenced by applying adapters on both ends of the fragments. These figures 
are adapted from http://www.illumina.com/technolog.
Despite the successes of exome sequencing, there are also some shortcomings in 
this methodology. In the process of gene identification, exome sequencing cannot be 
the exclusive tool, as not all of the exons are covered. For many if not the majority of 
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genes the first exon is missing because of the high G-C content. In addition, repetitive 
sequences are a big problem in the process of fragment alignments. Thus, alterations 
in repeat sequences such as in the ARX gene, which is a relative frequent (7.5-9.5%) 
cause of XLID,34,116 cannot be detected by exome sequencing. Furthermore, the 
depth of the coverage of all the exons is not uniform across the exomes and non-
coding genes, such as micro-RNAs and other non-coding RNAs, are hardly covered by 
present enrichment kits.112
The development of novel sequencing technologies proceeds at a high pace. 
Most of the problems of NGS that are mentioned in upper paragraphs will be 
circumvented by the implementation of third generation sequencing techniques, 
such as oxford nanopore sequencing, and Pacific biosciences SMRT.117-119 These 
sequencing technologies rely on sequencing of a single molecule of DNA in such a 
way that no synchronization will be required. Such technologies will likely eliminate 
the biases introduced by PCR in the second generation sequencing techniques.120 
Besides this, third generation technologies have several advantages such as, higher 
throughput, longer read length, higher consensus accuracy, small amount of starting 
material, low costs and faster throughput. Having all these advantages in sequencing 
technology, it is anticipated that there will be another rapid boost-up in near future 
in the field of genetics and molecular biology research.121
aim and outline of this thesis
 The aim of this thesis is to elucidate the genetic causes of autosomal recessive 
intellectual disability. The outline is as follows:
• Chapter 2 (Proof-of-concept) describes the use of homozygosity mapping as a 
powerful technique to identify the genetic defects in recessive conditions. In 
this case, homozygosity mapping was conducted in 12 Frank-Ter Haar syndrome 
(FTHS) families which revealed a shared region (5q35.1) of homozygosity in nine 
families. Candidate gene analysis revealed pathogenic mutations of SH3PXD2B 
gene in several families. The pathogenic role of the identified gene was established 
by using an in vivo model system.
• Chapter 3 (overview of aRID studies) reviews all results of a large ID cohort of 
100 mostly consanguineous Pakistani families. The combination of homozygosity 
mapping and NGS in ten families revealed mutations in three known, one novel 
and at least five plausible candidate genes for ARID. The results about known and 
novel ARID genes are described in more detail in Chapters 4 and 5 respectively. 
• Chapter 4 (Novel mutations in known aRID genes) lists the identification of novel 
mutations in two known ARID genes, namely, TPO (chapter 4.1), and DPAGT1 
(chapter 4.2). It also lists the third gene, BBS10 (chapter 4.3), which was identified 
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in another Pakistani family during an independent study. Besides these, chapter 
4 elaborates on the importance of using NGS in those ID families that lack clear 
clinical diagnosis, which also helps to establish the borders of the phenotypic 
spectrum belonging to the respective disorders.
• Chapter 5 (Mutations in a novel aRID gene) describes the identification of a novel 
gene, ANK3. The inactivating mutations have been associated with ID and ADHD 
like phenotype in two independent families. We studied ANK3 in Drosophila to 
establish the pathogenic role of this gene. 
• Chapter 6 (a new candidate gene for aRID) describes the identification 
of a potentially pathogenic missense mutation in SLC6A17 gene in a Dutch 
family. Molecular modeling-based prediction classified this variant as possibly 
pathogenic. 
• Chapter 7 (General discussion and future perspectives) summarizes the results of 
my research and puts these into perspective by discussing the currently available 
knowledge about the genetic causes of ARID and its impact on future diagnostics 
and fundamental research. 
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Chapter 2
Proof-of-concept
Disrupti on of the podosome adaptor protein Tks4 (SH3PXD2B) causes the skeletal 
dysplasia, eye and cardiac abnormaliti es of frank-Ter Haar syndrome
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aBSTRaCT
Frank-Ter Haar syndrome (FTHS), also known as Ter Haar syndrome, is an autosomal 
recessive disorder characterized by skeletal, cardiovascular and eye abnormalities, 
such as increased intraocular pressure, prominent eyes and hypertelorism. We have 
conducted homozygosity mapping on patients representing 12 FTHS families. A locus 
on chromosome 5q35.1 was identified for which patients from nine families shared 
homozygosity. For one family, a homozygous deletion mapped exactly to the smallest 
region of overlapping homozygosity, which contains a single gene, SH3PXD2B. This 
gene encodes the TKS4 protein, a phox homology (PX) and Src homology 3 (SH3) 
domain-containing adaptor protein and Src substrate. This protein was recently shown 
to be involved in the formation of actin rich membrane protrusions called podosomes 
or invadopodia, which coordinate pericellular proteolysis with cell migration. Mice 
lacking Tks4 also show pronounced skeletal, eye and cardiac abnormalities and 
phenocopied the majority of the defects associated with FTHS. These findings 
establish a role for TKS4 in FTHS and embryonic development. Mutation analysis 
revealed five different homozygous mutations in SH3PXD2B in seven FTHS families. 
No SH3PXD2B mutations were detected in six other FTHS families, demonstrating 
the genetic heterogeneity of this condition. Interestingly however, dermal fibroblasts 
from one of the individuals without an SH3PXD2B mutation nevertheless expressed 
lower levels of the TKS4 protein, suggesting a common mechanism underlying 
disease causation. 
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In 1973, Frank et al. described a patient with megalocornea, brachycephaly, large 
anterior fontanels, hypertelorism, anteverted nostrils, thoracolumbar kyphosis, 
prominent coccyx, short hands, flexion deformity of fingers, club feet, and heart 
murmur and suggested this to be a hitherto undescribed entity (Figure 1).1 Later, 
ter Haar et al. described several members of a single family with similar features 
(Supplementary Figure 1).2 This syndrome is now referred to as Frank-Ter Haar 
syndrome (FTHS [MIM 249420]). A small number of additional FTHS families have 
been reported, most within families with consanguineous unions, suggestive of a 
recessive inheritance pattern.3-8 FTHS patients usually die in infancy or in early 
childhood because of the cardiovascular anomalies, respiratory infections, or 
unknown causes. To date the molecular cause of FTHS was not established. 
Here, we performed homozygosity mapping to localize the genetic defect in 
16 patients from 12 apparently unrelated FTHS families with known or suspected 
consanguinity (Supplementary Figure 1 and Table 1). This included the family 
originally described by Ter Haar,2 for which genealogical studies revealed a common 
ancestor for the parents of some of the patients eight to ten generations back 
(Supplementary Figure 1). Written informed consent was obtained for all patients, 
and research was approved by the local ethics committee of the Radboud University 
Nijmegen Medical Centre. Genome-wide homozygosity mapping was carried out 
with the Affymetrix mapping 250K SNP array, on DNA fragments in the 200 to 
1100 bp size range amplified from 250 ng genomic DNA. The data were analyzed 
by genotyping console. The mapping revealed a region on chromosome 5q35.1 
for which 12 out of 16 patients had overlapping regions of homozygosity (Figure 
1). To confirm the homozygosity, we used microsatellite markers on chromosome 
5q35.1 region. Families 1 and 2, both of Dutch origin, shared the same haplotype, 
suggesting a founder effect. The common region of homozygosity spanned only 0.27 
Mb, and comprised the NEURL1B gene and part of the SH3PXD2B gene. Interestingly, 
analysis of the SNP array data for copy number variation with copy number analyzer 
for GeneChip (CNAG)9 revealed a homozygous deletion in the patients of family 7, 
who manifested the typical FTHS phenotype (Table 1)5 Genomic quantitative PCR 
analysis confirmed the homozygous deletion and mapped the endpoints between 
STK10 (MIM 603919) and AK026748 (Supplementary Figure 1). This deletion harbors 
the UBTD2 (MIM 610174) and SH3PXD2B genes. Thus, the cumulative results of 
homozygosity mapping and copy number analysis identified SH3PXD2B as the most 
plausible FTHS candidate gene (Figure 1). 
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figure 1: Clinical features of FTHS, homozygosity mapping and analysis of SH3PXD2B. 
(a) Left: girl from family 1 showing broad face, megalocornea, low nasal bridge, upturned nares, 
open mouth appearance, full cheeks, and small chin. Right. The same girl at a later age showing 
sustained facial features. (b) Facial feature of patient 9.1 at age 3.5 years, demonstrating 
hypertelorism, large eyes, full cheeks, wide mouth, microretrognathia and large ears. (c) Patient 
9.2 showing brachycephaly, high forehead, hypertelorism, large eyes, megalocornea, broad 
mouth and small chin. (d) Caudal appendage at coccyx with prominent skin fold. (Family 6). 
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(e) Left: hand of patient 9.1 showing short fingers with short and broad terminal phalanges. 
Camptodactyly was seen only after birth. Right. X-rays showing generalized osteopenia, short 
tubular bones of the hand. (f) Increased lower thoracolumbar kyphosis and brachycephaly in 
patient 9.1. (g) Poor modelling of long bones including the distal radius and ulna in patient 
1. (h) Schematic representation of the 5q35.1 region that is homozygous in 12 patients and 
homozygously deleted in family 7. The deletion was identified upon analysis of the 250K SNP 
array data using the CNAG algorithm, as visualized by the bottom diagram in which the deletion 
is encircled in blue. The overlap between the deletion and the smallest region of homozygosity 
harbors only a single gene, SH3PXD2B (gray). An asterisk indicates patients in whom a mutation 
has been identified. The hg18 UCSC genome build (version 2006) was used for the coordinates 
in the genetic map. (i) Schematic representation of TKS4 protein structure with an N-terminal 
PX domain and four SH3 domains. The position of the mutations is indicated. (j) Position of the 
amino acid substitution R43W at a highly conserved region within the PX domain predicts a 
disruptive effect on its normal function in phosphoinositide binding and membrane association. 
(k) Immunoblot analysis with a TKS4-specific antibody detects a 120 kDa band in mouse 
fibroblasts (3T3), mouse fibroblasts transformed with Src (Src-3T3) and in fibroblasts from 
control individuals (control). No such product is seen in fibroblasts from three different patients 
from families 1 and 2 with a SH3PXD2B mutation. The TKS4 band was also present but at clearly 
reduced levels in cells from another FTHS patient from family 3 without an SH3PXD2B mutation 
(unsolved). Tubulin was used as a loading control.
Next, we screened the SH3PXD2B gene in probands representing 13 FTHS families 
from our cohort by direct DNA sequencing. Intron specific primers were designed for 
the amplification of the exons 1-13 of the SH3PXD2B gene (Supplementary Table 1; 
data not shown). The segregation of DNA variants was verified in the corresponding 
families. In addition, we analyzed all variants in 50 unrelated control individuals to 
exclude benign polymorphisms. A total of four additional homozygous mutations 
were identified in 6 families (Figure 1). In families 1 and 2, a homozygous insertion 
c.147insT was detected, which predicted the creation of an immediate stop in 
the same codon (p.F49X), in all three affected individuals available for testing. In 
families 6 and 9, which are of unrelated ethnicity, we detected a homozygous 1 bp 
deletion c.969delG, which predicts a frameshift followed by a premature stop codon 
(p.G323fsX19; Figure 1 and Supplementary Figure 1). In family 12, we identified a 
substitution c.129C>T (p.R43W), which disrupts a highly conserved amino acid within 
the phox homology (PX) domain of the protein (Figure 1), and which is predicted to 
abolish binding to phosphoinositides.10,11 Finally, a c.76-2A>C splice site mutation was 
identified in an additional patient who was not included for homozygosity mapping 
(family 13), which disrupts the strictly conserved adenosine of the splice acceptor site. 
All mutations segregated within the respective families in a pattern compatible with 
autosomal recessive inheritance (Supplementary Figure 1). None of the truncating 
mutations were detected in a minimum of 50 control individuals. In addition, none of 
210 control chromosomes contained the nontruncating mutations. Together, these 
data establish that SH3PXD2B gene mutations are causative for a subset (7 of 13) 
of FTHS families. The phenotype of patients with an intragenic SH3PXD2B mutation 
does not appear notably different from that of the patients of family 7, who carry a 
deletion that also disrupts UBTD2 (Table 1). 
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Table 1 Clinical features of FTHS patients in this study
Family 1 2 3 4 5 6 7 8 9 10 11 12 13
Patient 1 1 2 1 1 1 1 1 2 1 1 2 1 2 1 1 1
Gender M M M M M F F M F F M M M F F M M
Consanguinity - + + + + + + + + + + + + + - + +
Motor retardation + + + + + + + + + + - + +
Craniofacial abnormalities
Prominent 
forehead
+ + + + + + + + + + + + - - + + +
Brachycephaly + + + + + + + + + - + + - - - + +
Wide anterior 
fontanel
+ + + + + + + + + + + + + + + +
Hypertelorism + + + + + + + + + + + + + + +
Congenital 
glaucoma
+ + + - + - + + -a - - - - + -b -
Large cornea + + + + + + + + - + + + + + + +
Prominent eyes + + + + + + + + + + + + + + + + +
Full cheeks + + + + + + + + + + + + + + + +
Anteverted 
nostrils
+ + + + - + + - - - + + + + +
Broad mouth + + + + + + + + + + + + + + + +
Broad alveolar 
ridges
+ + - + + + - - - + + + +
Micrognathia + + + + + + - + + + + + + + - + +
Protruding ears + + + + + - - - + + - +
Skeletal abnormalities
Kyphosis + + - + + + - - + - - - - + +
Prominent 
coccyx
+ + + + + + + + - - + + - + +
Bowing of long 
bones
+ + + - + - + + - - - - - - +c +
Short hands + + + - + + + + - + + - - - + +
Flexion 
deformity of 
fingers
+ - - + + + + - - + - - + + - - +
Club feet + + - + - - PA + + - - - + -d +
Cardiac manifestations
Mitral valve
anomaly
+ + MVP + - - - - - - +e -
Double right
outlet
+ + - - - - - -
Ventricular
septal defect
- + + - + - - + HCM ASD + +f
other abnormalities gall 
stones
brain 
MRIg
auri-
cular 
pits
SH3PXD2B mutation + + + - - - + + + - + + - - - + +
a: bilateral iris and retinal coloboma; b: retinal detachment, sudden vision loss at age 7 years; c: severe genu 
valgum, dislocated left knee, bilateral hips, both elbows; d: pes valgus; e: cardiomegaly, severe mitral and 
aortic valve prolapsed; f: VSD, ASD and patent ductus arteriosis; g: slightly prominent ventricles on MRI. ASD: 
atrial septal defect; VSD: ventricular septal defect; MVP: mitral valve prolapsed; PA: pes adductus; HCM: 
hypertrophic cardiomyopathy. Family 2 was described by ter-Haar et al. 1982 (ref 2) and Hamel et al. 1995 
(ref 3), family 3 by Wallerstein et al. 1997 (ref 7), families 4 and 6 by Maas et al. 2004 (ref 4) and family 7 by 
Megarbane et al. 1997 (ref 5).
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Apparently, the function of UBTD2 is at least partially redundant in humans. 
The clinical features in FTHS patients in whom no mutations were detected are 
highly similar to those of patients with SH3PXD2B mutations, indicating genetic 
heterogeneity in FTHS. Indeed, the result of homozygosity mapping analysis excludes 
the 5q35.1 locus in four families and supports the involvement of multiple other loci. 
The protein product of the SH3PXD2B gene is known as TKS4 (tyrosine kinase 
substrate with four Src homology 3 [SH3] domains). It is an adaptor protein with a 
PX domain, four SH3, and a substrate of the tyrosine kinase Src.10 In Src-transformed 
murine fibroblasts, Tks4 is required for the formation of podosomes/invadopodia, 
which are dynamic, actin-rich plasma membrane protrusions involved in cell adhesion, 
migration, and matrix degradation.12 In these cells, Tks4 recruits to podosomes the 
membrane type-1 matrix metalloprotease10 (MT1-MMP), an obligate podosome/
invadopodia protein involved in pericellular proteolysis of extracellular matrix.13 A 
paralog of Tks4, Tks5, encoded by SH3PXD2A on chromosome 10, is also an adaptor 
protein involved in podosome/invadopodia formation14, but none of the unexplained 
FTHS patients showed homozygosity at this locus (data not shown). Podosomes 
are necessary for the adhesion and migration of a variety of cell types, including 
macrophages, dendritic cells, osteoclasts, vascular smooth muscle and endothelial 
cells12,13,15, several of which may be relevant to the FTHS phenotype. 
The TKS4 protein levels in human primary dermal fibroblasts were analyzed by 
immunoblot of total cell lysates as previously described.10 A Tks4 signal was observed 
in control fibroblasts, whereas no signal could be detected in cells from patients of 
families 1 and 2 with an SH3PXD2B mutation, demonstrating that FTHS can be caused 
by homozygous loss-of-function mutation of SH3PXD2B (Figure 1). Quantitative RT-
PCR analysis was conducted to analyze the SH3PXD2B transcript in these fibroblasts. 
Normal levels of SH3PXD2B transcript were detected for three affected individuals 
with the c.147InsT (F49X) mutation, even though no TKS4 protein was detected. This 
indicates that the premature stop codon introduced by this mutation does not result 
in nonsense-mediated RNA decay, and likely results instead in a truncated unstable 
protein. Fibroblasts from other affected individuals with SH3PXD2B mutations were 
not available, precluding a more detailed analysis. 
No SH3PXD2B mutations were identified in six FTHS families, including families 3, 
4 and 5 for which patients showed homozygosity at the 5q35.1 locus. It is possible 
that mutations in cis-regulatory elements have been missed in these three families. 
In keeping with this hypothesis, while fibroblasts derived from the patient from 
family 37 with no mutation in the SH3PXD2B coding sequence did contain detectable 
Tks4 protein, its abundance was sharply reduced compared to wild-type cells. 
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figure 2: Developmental defects due to Sh3pxd2b  inactivation in the mouse. 
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(a) Mice in which the Sh3pxd2b gene is inactivated due to a gene trap insertion have increased 
mortality during the first three weeks of life. (b) Sh3pxd2b null (-/-) mice experience severe 
growth retardation as compared to wild type and heterozygous mutants. The image shown 
is of mice at 3 months of age. (c) Lateral and dorsal view of wt and Sh3pxd2b -/- mouse heads 
from 10 week old mice. Sh3pxd2b -/- mice have craniofacial defects characterized by a shorter 
distance between nose and forehead and hypertelorism. A depressed nasal bridge and small 
chin can also be seen. (d) Alizarin red stained skulls of 5-month old wt and Sh3pxd2b -/- mice. 
Mutants have open sagittal sutures, as well as wormian bones (*). ls, lambdoid suture; ss, 
sagittal suture; cs, coronal suture. (e). other skeletal defects in Sh3pxd2b -/- adult (2 month 
old) mice visible by X-ray imaging include the teeth (reduced size), neurocranium (decreased 
anterior-posterior diameter), viscerocranium (short maxilla, short mandibula and more 
vertical orientation of skull base). (f) View of the iliac crest showing shortening and widening 
with decreased flaring of iliac wings in the null mice at 2 months of age. (g) Prominence of the 
xyphoid part of the sternum is noted in the null mice at 2 months of age. (h) The vertebral 
column, showing marked thoracic kyphosis and mild lumbosacral lordosis in null mice at 2 
months of age.
(E-H: Defects indicated by arrowheads and square). (i) H&E stained coronal heart sections from 
4 month old wt and old Sh3pxd2b -/- mice. The ventricular septum thickness is indicated with 
a black line. The asterix indicate apical indentation. Carats mark the dysmorphic chambers, 
and the blue line shows the ventricular wall thickness. RV, right ventricle; LV, left ventricle. 
(j) Coronal H&E sections of 4 month old wt and Sh3pxd2b-/- mice to show the mitral valves, 
which are indicated by the black arrowheads. (k) Echocardiogram of 2.5-month old wt and 
Sh3pxd2b -/- mouse. Sh3pxd2b -/- mice were bradycardic as shown by the longer interval (red 
line) between two consecutive systoles. (l) Intraocular pressure (IoP) measurements of eyes 
from wt and Sh3pxd2b -/- eyes. The ages ranged from 4-16 months in both groups. (m)  H&E 
staining of anterior segments of eyes from wt and Sh3pxd2b -/- mice, to reveal the structure of 
the cornea and iris. Note that the angle between the cornea (C) and the iris (Ir) extends back 
to the ciliary body (CB) in the wild type eye. In contrast, homozygous null mice had apposition 
of the peripheral iris to the corneal endothelium (between arrows). In the homozygous null 
mice the cornea bulges anteriorly. Bar=300 µm.
Quantitative PCR did not reveal any differences at the mRNA level (data not 
shown), so it is possible that a mutation affecting TKS4 protein synthesis or stability 
has been missed. Alternatively, this patient carries a mutation in another gene which 
regulates TKS4 protein homeostasis. Genetic heterogeneity of FTHS would also be 
consistent with the observation that there are several other homozygous regions in 
patients from each of six unsolved families. The results of homozygosity mapping 
also support the involvement of multiple other loci.
Murine Tks4 is 87% identical to the human paralog and has a similar domain 
structure. To gain more insight into where Tks4 may play a role during development, 
we performed cRNA in situ hybridization analysis of embryonic mouse cryosections 
with probes specific for Sh3pxd2b. Spatiotemporally restricted Sh3pxd2b expression 
was observed at various embryonic development stages in tissues that are affected 
in FTHS patients: heart, bone, and eye (Supplementary Figure 2). At embryonic day 
(E) 10.5, a speckled expression of Sh3pxd2b was observed in heart and hindbrain, 
which appeared to have increased at E12.5, and involved a subset of cells on the 
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luminal side of the left ventricular wall in the case of the heart and neuroepithelium 
in the case of the brain. At E14.5 expression was present in developing bones (e.g., 
the proximal ribs, lower jaw, clavicle), but the expression in the heart was no longer 
detectable. At stages E16.5 and E18.5, strong expression was seen in the long bones 
of the limbs, particularly in the growth plates, as well as in the facial and cranial bones 
and the primordial incisor. Expression in the ribs was seen in the proximal regions, 
in those areas where the transition from cartilage to bone is expected to occur. 
Disruption of expression during rib and vertebral bone development could explain 
the chest deformities and kyphosis observed in FTHS. Expression in the eye at E16.5 
was highly specific for the ganglion cell layer. The significance of this observation for 
the occurrence of glaucoma in FTHS patients and in Sh3pxd2b mice (see below) is 
presently not clear. overall, the fact that Sh3pxd2b expression can be found in tissues 
that are affected in FTHS suggests that it is required for the correct patterning and 
development of these organs. However, expression is also observed in areas that do 
not directly relate to the FTHS phenotype, for example the hindbrain. In the future it 
will be interesting to determine if this is relevant to the motor retardation frequently 
observed in affected individuals (Table 1).
To investigate the function of Tks4 in vivo, we analyzed Sh3pxd2b mutant mice 
that were generated using via a gene-trap strategy by Lexicon Pharmaceuticals (ES 
clone ID GST_1527_E5). Inactivation of Sh3pxd2b in these mice is caused by insertion 
of the gene-trap vector VICTR 48 between exons 3 and 4 of the Sh3pxd2b gene on 
chromosome 11. Mice were kept in a mixed genetic background (C57BL6/a129SvJ). 
All animal experiments were approved by the Burnham Institute’s Institutional Animal 
Research Committee. Disruption of the Sh3pxd2b gene was assessed by PCR of 
genomic DNA and immunoblot on total lysates from murine embryonic fibroblasts.10 
No Tks4 protein was detected in fibroblasts derived from E12.5 homozygous mutant 
embryos, suggesting that the gene trap caused a complete loss of gene expression 
from this locus; therefore these mice will be referred to as Sh3pxd2b null. We noted 
that Sh3pxd2b null mice were born at Mendelian ratios, but approximately 20% of 
the null mice died in the first weeks of life of undetermined causes. For those that 
survived, lifespan did not appear to be compromised (Figure 2). At birth, Sh3pxd2b null 
mice were on average the same size as their wild type and heterozygous littermates. 
However, the null mice were markedly smaller by weaning, and this growth retardation 
was maintained during their lives (Figure 2 and Supplementary Figure 3). 
Alizarin red staining of Sh3pxd2b null skulls demonstrated severe craniofacial 
defects characterized by a shorter nasal bone, micrognathia, hypertelorism, sagittal 
suture agenesis, and the presence of wormian bones (Figure 2 and Supplementary 
Figure 4). Mouse skeletons were also analyzed by X-ray with a FAXITRoN MX-20 
machine. Mutant mice displayed marked kyphosis, poorly aligned teeth, as well 
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as anomalies in the iliac crest and a prominent xiphisternum, when compared to 
heterozygotes and wild types (Figure 2). Most of these developmental abnormalities 
bear a remarkable similarity to the skeletal defects of FTHS patients (Table 2). 
Table 2 Comparison of features present in FTHS patients and Tks4-/- mice. 
FTHS patients Tks4-/- mouse
Craniofacial
Brachycephaly + -
Suture agenesis            + +
Wormian bones + +
Prominent forehead + +
Hypertelorism + +
High palate + +
Dentition abnormalities  +a +
Micrognathia + +
Skeletal
Prominent sternum/xyphoid - +
Pectus excavatum + -
Increased thoracic kyphosis + +
Pelvic anomalies  +b +
Bowing of long bones + -
Extremity abnormalities  +c ND
Prominent coccyx + NA
Eye
Glaucoma + +
Megalocornea + +d
Buphthalmos + +
Cardiac
Ventricular defectse + +
other Growth retardationf + +
Adiposity  ? g +
a Patients present broad alveolar ridges.
b Patients present hip dysplasia, while mice have malformation of iliac crest.
c Patients present short hands, flexion deformity of hands, and club feet.
d Unlike megalocornea in humans, the enlargement of the cornea increases with age.
e Defects in patients include mitral valve anomalies, double-outlet right ventricle and ventricular septal 
defects. In the mice, dysmorphia of the septal anterior wall, ventricles and mitral valve have been observed.
f Patients have been described to be in the lower weight and height centiles as they grow.
g one patient reported to have “little or no subcutaneous fat”.
ND: Not Determined; NA: Not Applicable.
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Many FTHS patients have cardiac deficiencies. To investigate possible heart 
defects in the Sh3pxd2b null mice, we dissected, fixed, embedded, and sectioned 
hearts at 5 mm for hematoxylin and eosin (H&E) staining. Coronal sectioning of 
hearts showed that all Sh3pxd2b null mice examined had cardiac abnormalities (8 
of 8), although there was variability in the range of phenotypes seen.  Anomalies 
included dysmorphic ventricular chambers (8 of 8), thin mitral valves (4 of 8) that 
may be causative of prolapse, and immature and disarrayed trabeculae (6 of 8) with 
frequent apical indentation (5 of 8) (Figure 2). Echocardiographic analyses were 
also performed in male mice using a Visual Sonic Vevo 770 fitted with an 8-15 MHz 
linear array transducer as previously described.16,17 This analysis revealed reduced 
thickness of the septal anterior wall and bradycardia (300-400 bpm compared to 
>500 for wild-types) (3 of 3) (Figure 2). It is of interest to note that FTHS individuals 
also show septal, ventricular and mitral valves defects (Table 2). Further analysis will 
be required to determine the molecular basis for these observations.
Because one of the most highly penetrant features of the FTHS patients involves 
the eye, we also looked for eye phenotypes in the mice. Intraocular pressure (IoP) 
was directly measured in both eyes within the first 7 minutes after injecting ketamine/
xylazine anesthesia as previously described.18 Data were analyzed using Student’s 
t-test. This analysis demonstrated that the Sh3pxd2b null mice had glaucoma, 
which was not detected in either wild-type or heterozygous littermates (Figure 2). 
Analysis of H&E stained fixed sections of eyes revealed substantial variability in 
the structure of Sh3pxd2b null mouse eyes. Apposition of the peripheral iris to the 
corneal endothelium and enlargement of the cornea was generally noted (Figure 
2). The corneal enlargement was similar to human megalocornea except that in the 
mice the cornea was largest in older animals, suggesting continued enlargement with 
increasing age. Aqueous humor drains from the anterior chamber of the mouse eye 
via trabecular outflow and uveoscleral outflow, which both originate between the 
iris and cornea adjacent to the ciliary body.19,20 Hence the peripheral apposition of 
the iris and cornea in the Sh3pxd2b null eyes likely obstructed outflow and induced 
elevated intraocular pressure in a manner analogous to closed angle glaucoma.21,22 
Furthermore, corneal thickening and increased opacity, and phtisis bulbi with partial 
exudation of the lens through a central corneal perforation were sometimes noted. 
Taken together, many of the abnormalities we observed in the Sh3pxd2b null mice 
are highly reminiscent of phenotypes characteristic of FTHS patients, particularly the 
skeletal, cardiac and eye phenotypes, and confirm a role for the TKS4 protein in the 
generation of FTHS (Table 2). Two other striking features of the Sh3pxd2b null mice 
are their decreased size and marked loss of adipose tissue (Figures 2, Supplementary 
Figure 3 and 5). While these features are not currently part of a FTHS diagnosis, 
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we note that many affected individuals are of short stature,2,4,7 and lack of adiposity 
has been noted in at least one case.7 Very recently, a mutant mouse with skeletal, 
eye and adipose abnormalities was shown to express a truncated form of Tks4:23 
glaucoma and cardiac defects were not noted, suggesting that complete loss of Tks4 
may give rise to different phenotypes than truncation of the protein product. 
our results establish a crucial role for Tks4 in bone, heart and eye development, 
as well as a variety of other tissues. To date, the only known function of Tks4 is in 
podosome formation,10 leading us to speculate that defective podosome formation 
may contribute to a human developmental disorder. FTHS was originally reported 
as an atypical form of Melnick-Needles syndrome, which is usually caused by 
mutation of the FLNA gene (MIM 300017).24 In osteoclasts, filamin A is present in the 
podosome belt, and its cleavage by calpain is necessary for osteoclast spreading and 
motility during bone development and homeostasis.25 Given the apparent genetic 
heterogeneity of FTHS, it is likely that other FTHS cases and related disorders such as 
megalocornea-mental retardation syndrome (MIM 249310) and serpentine fibula-
polycystic kidney syndrome (MIM 600330) have defects in genes that might interact 
with TKS4 and/or in genes involved in podosome formation or function, which may 
facilitate the identification of causative genes for these conditions. 
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Supplementary figure 1: Pedigree structures from patients used in this study and mutation 
analysis. 
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(a) Family 07 is a Lebanese family described by Megarbane et al5. Confirmation of a 
microdeletion was by genomic qPCR, which revealed that the two patients have a homozygous 
deletion of exons from the SH3PXD2B and UBTD2 genes but not of flanking genes. The parents 
are clearly heterozygous for this deletion. (b,c) Family 01 is from an apparently isolated Dutch 
patient who turned out to carry the same mutation as the one in the family originally reported 
by ter-Haar et al. (family 02)2 having mutation c.147 ins T (p.F49X). Parents are carriers for this 
mutation. 
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Supplementary figure 1 (Continued)
(d,e)  Family 06 is from Turkey and described by Maas et al4. The patient is homozygous for 
the same mutation c.969 del G (p.G323fsX19) as seen in the patients from Family 09, who are 
of Arabic origin. Parents are heterozygous for this mutation. (f)  Family 12 is an unpublished 
patient from Turkey carrying a c.129C>T (p.R43W) mutation and the parents are heterozygous 
for this mutation. (g) Family 13 is an unpublished patient from Israel carrying a c.76-2A>C 
mutation. The father was found to be heterozygous for this mutation.
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Supplementary figure 2: Localization of Sh3pxd2b expression by cRNA in situ hybridization at 
various murine embryonal developmental stages. Mouse embryos were collected at various 
embryonic stages (10.5 to 18.5 dpc), embedded in Tissue-Tek oCT compound and sagittal 
sections hybridized with digoxigenin-labeled cRNA probes. 
(a) overview of an E10.5 embryo showing staining in the ventral hindbrain neuroepithelium (box 
b) and the heart (box c). (b) Higher magnification of the hindbrain in box b, showing dark blue 
staining in a subset of cells in the ventral hindbrain neuroepithelium. (c). Higher magnification 
of the heart region in box c, showing a signal in a subset of cells in the heart wall. (d) E12.5 
overview of the heart region, showing a signal in a subset of cells at the luminal side of the left 
ventricular heartwall. (e) At E14.5, intense staining, indicative of high expression, was observed 
in the lower jaw, the primordium of the clavicle, and the proximal region of the ribs. The intensity 
of the staining in the heart has diminished to background levels, indicating a marked decrease in 
Sh3pxd2b expression in the heart. (f-h) At E16.5, intense staining was observed in the long bones 
of the upperlimb (F), in the developing facial and skull bones (G, H), and in the ganglion cell layer 
(gcl) of the developing retina (H). 
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I. E18.5 Strong staining is seen in the primordium of left incisor, upper jaw, left clavicle and 
trigeminal ganglion. Aa: ascending aorta; aw: atrial wall; bb: Basioccipital bone; bct: left atrio-
ventricular bulbar cushion tissue; cb: cheekbone; cla: clavicle; dia: diaphragm; drg: dorsal 
root ganglia; gcl: ganglion cell layer; hp: hard palate; hum: humerus; hyp: hypothalamus; 
inc: primordium of left incisor; le: lens; li: liver; lj: lower jaw; lu: lumen; lvw: wall of left 
ventricle; mf: mesencephalic flexure; mol: molars; nb: top of nasal bridge; ns: nasal septum; 
oe: olfactory epithelium; pr: proximal rib; rad: radius; tb: temporal bone; ton: tongue; tri: 
trigeminal ganglion; uj: upper jaw; v4: fourth ventricle; vw: ventricle wall. Scale bar = 500μm.
Supplementary figure 3: Growth rates of Sh3pxd2b null mice. 
Mice were weighed weekly starting at weaning at 3 weeks of age.  = wt. § = het. p = null.
Time points show mean values +/- standard error of the mean.
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Supplementary figure 4: Morphometry of Sh3pxd2b null mouse skulls. 
Top. Alizarin red-stained skulls from 10 week old mice were measured using calipers to 
determine length (α), nasal bone length (β) width (γ) and distance between the eyes (δ). In 
addition the sutures are visualized.
Bottom. Quantitation of the morphometric analysis. The mean +/- SEM (in mm) were 
calculated for 6 mice in each group and analyzed by Student’s t test.
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Supplementary figure 5: Adiposity in Sh3pxd2b mice. 
                                 
Relative weight of left epididymal (visceral) and left inguinal (subcutaneous) white adipose 
fat pads (WAT) and interscapular brown adipose fat pad (BAT) in 5-7 month old mice is 
shown. Mean values and SEM were calculated and analyzed by Student’s t test. n=6. ns = non 
significant. 
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Supplementary Table 1 Sequences of oligonucleotides used for mutation analysis of the 
SH3PXD2B gene
Primer ID Sequence Product size GC %
SH3_EX1_F GATTGCGCTCAGCTCCAG 275 75
sH3_EX1_R GCTGGAGGCAGAAGTTTTCC   
SH3_EX2_F GTCATTGGCAGAGCTAAGGC 397 52
SH3_EX2_R CTCGAGTGATCCACCCAC   
SH3_EX3_F TTTGGGTTTCTGGAAAGCTG 316 45
SH3_EX3_R TCCCCTGATAAAGGAAGACAAG   
SH3_EX4_F GGAATTTTGGCACCACTCAG 310 46
SH3_EX4_R TCTTTACATTCCTTTGAATTGCAC   
SH3_EX5_F TGGGTTTGCTTTTGTGTTTG 514 56
SH3_EX5_R CTCAGCCAGTTTCCTTCACC   
SH3_EX6_F TCACTGATGATGTTGTGGGG 240 47
SH3_EX6_R GTATCCTCAGCATGGAACCC   
SH3_EX7_F TTTGGAACGTCCTCTTGACC 366 55
SH3_EX7_R TCTAGGAGACCCTCAGCAGG   
SH3_EX8_F TTAGCCTTACCCTGTGCATTC 342 55
SH3_EX8_R AGCCAGTGAGCTGCTGAGAC   
SH3_EX9_F CTGAAGGAAATCCTCCCTCC 319 59
SH3_EX9_R CTTACCGACCTCTGTGAGGC   
SH3_EX10_F TGGGACCTGTCATGTGATTC 444 63
SH3_EX10_R TTCTTATCTGGAGGATGGGG   
SH3_EX11_F GCCTGTGTTCAATCTTCTGC 278 54
SH3_EX11_R CAAGGCTGTTGTGTGGACAG   
SH3_EX12_F AATCCAACTAGGTCCCCAGC 351 58
SH3_EX12_R CCACCCACCCAGTGAAGTAG   
SH3_EX13_F AACATCTCCATTGGTGGTCC 677 59
SH3_EX13_R GATGTGTTTGGCTGGCATC   
All oligonucleotides were designed using the program Primer 3 (http://fokker.wi.mit.edu/primer3/).
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aBSTRaCT
Robust methodologies for genome-wide analyses, such as microarray-
based genotyping and next generation sequencing (NGS), have revolutionized 
the identification of genetic and genomic defects in genetically heterogeneous 
conditions, such as intellectual disability (ID). Due to the limited availability of 
large families and the extreme heterogeneity of the condition, gene identification 
for autosomal recessive ID (ARID) has been particularly challenging. Here, we have 
collected families with multiplex ID cases from the Pakistani population, which shows 
a general consanguinity rate of >60%. In total, we have ascertained 100 ID families, 
including 66 families with apparent autosomal recessive pattern and 34 families with 
either X-linked or autosomal recessive inheritance. About one-fourth of families 
has ≥4 affected individuals and 81 families presented with consanguineous unions. 
Homozygosity mapping and NGS were used to identify the genetic defects in ten 
families. This approach revealed three novel mutations in known ID genes, TPO, 
DPAGT1, and AIMP1, one mutation in a novel gene, ANK3, and at least three single 
plausible candidate genes, FAIM2, THUMPD1, and ZNF498. In two families, we have 
identified two plausible candidate genes each, TMEM132E and MYO1D in one family 
and CCDC23 and KLHL21 in another. one family remained without an obvious genetic 
defect. our results support the usefulness of consanguineous families in order to 
identify recessive genetic defects.
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INTRoDuCTIoN
Intellectual disability (ID) is a common disorder which greatly impacts the 
quality of life of patients and families confronted with the disorder. Due to its high 
prevalence rate of 2-3% and the life-long care that is often needed, ID is the leading 
category in health care expenditure in Western countries, surpassing cancer and 
dementia together.1,2 Among monogenic causes of ID, X-linked ID (XLID) has been 
studied more extensively as compared to the autosomal forms of ID.2 Due to reduced 
fecundity in ID, autosomal dominant ID (ADID) families with multiple patients are 
rarely seen.3 Indeed, the most common cause of ADID are de novo copy number 
variations (CNV) resulting in dosage effects of specific genes.4 Moreover, there is 
growing evidence that a high number of sporadic/isolated cases in the Western 
countries contain de novo point mutations.3,5-7 Research into autosomal recessive 
ID (ARID) is still in its infancy. Most of the genes implicated so far are involved in 
syndromic forms of ARID, because these were relatively easy to solve as patients with 
such defects exhibit prominent phenotypic features in addition to the ID, enabling 
clustering of phenotypically similar patients and families. Moreover, syndromic ARID 
is often caused by metabolic defects, which can provide a lead for elucidation of the 
genetic defect.8 In contrast, the identification of genetic defects in non-syndromic 
ARID is limited by the absence of patients with a similar etiology, the paucity of 
large families and the extreme heterogeneity of the condition7. Recently, access 
to the consanguineous families combined with next generation sequencing (NGS) 
technology improved the identification of ARID genetic causes considerably.9
This study is designed to exploit the consanguineous marriages in the highly 
inbred Pakistani population (consanguinity rate of >60%),10 in order to identify the 
causal genes responsible for ARID. Following the ascertainment of an ID family on 
the basis of mode of inheritance, we have devised the following strategy. In all the 
families with possible X-linked and X-linked/ARID inheritance patterns, Fragile X 
syndrome (FXS) screening was performed. Next, FXS negative families were selected 
for X-exome sequencing in order to identify the possible variants in the coding 
regions of the X chromosome. Families with no mutations on the X chromosome and 
the ARID families were selected for genotyping, in order to perform CNV analysis 
and homozygosity mapping. After the genotyping process, one of the affected 
individuals was selected for targeted NGS or exome sequencing. In addition, in a 
subset of families we have genotyped one affected individual on a high resolution 
array to detect possible CNVs followed by exome sequencing of one/two affected 
individuals per family - no prior mapping was performed in this case. Finally, all 
the data obtained from CNV analysis, mapping and NGS were used to identify ID 
candidate genes (Figure 1). 
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figure 1: Flow diagram, illustrating the strategy to identify the candidate genes in Pakistani 
families with ID.
 
Abbreviations; intellectual disability (ID); X-linked intellectual disability (XLID); autosomal 
recessive intellectual disability (ARID); copy number variation (CNV); single nucleotide 
polymorphism (SNP). The + sign indicates “YES” and – sign indicates “No” throughout the flow 
diagram. The intersecting lines are indicated in a stippled style.
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For this study, we have collected 100 ID families, including six XLID, 28 XLID/
ARID and 66 ARID families. Consanguinity was observed in six out of six XLID, 23 
out of 28 XLID/ARID and 52 out of 66 ARID families. We performed FXS screening, 
which revealed six families with positive diagnosis. In total, 54 families have been 
selected for targeted NGS and exome sequencing (Table 1). So far, ten families were 
sequenced, which revealed several potential candidate genes (Table 3). This chapter 
only elaborates on the NGS results of five families in which one or two plausible 
candidate genes per family are identified.
Table 1 Summary of Pakistani cohort of intellectual disability
No. Category No. of 
families
No. of affected 
members in 
family
1-2        3        ≥4 
Consan-
guineous 
families
Families 
used for 
mapping
Families 
used for 
X-exome 
sequencing
Families 
used for NGS 
(Targeted/
exome)
Fragile X 
positive 
families
1 XLID 06 03 01 02 06 06 04 - 02
2 XLID/ARID 
families 
28 16 09 03 23 17 17 01 03
3 ARID 
families
66 24 20 22 52 37 - 53 01
4 Total 100 43 30 27 81 60 21 54 06
PaTIeNTS aND MeTHoDS
Families
 The families of our cohort were ascertained from four provinces in Pakistan, 
Punjab, Sindh, Khyberpakhtoonkhwa and Balochistan. A standard form was used 
to record the family history and ID related phenotypic features of the patients.11 
Families with at least two affected individuals were enrolled and collected, except 
two families with single affected member. We have classified our collected families 
into three categories: 1) XLID, when there are only males affected and who are 
divided over different sibships separated by unaffected females; 2) XLID/ARID, when 
only affected males are found in the family; and 3) ARID, when affected males and 
females are found in the family and the pedigree structure suggests an autosomal 
recessive pattern of inheritance. We have ascertained 100 ID families comprising six 
XLID, 28 XLID/ARID and 66 ARID families. out of the six XLID families, two families had 
≥4 affected individuals and all six families presented with consanguineous marriages. 
The 28 XLID/ARID families comprised three families with ≥4 affected individuals 
and 23 consanguineous families. out of the 66 ARID families, 22 had ≥4 affected 
individuals and 52 consanguineous families (Table 1). Informed consents were 
obtained from all the participating subjects of each family and/or their caretakers. 
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This large scale study was approved by the Institutional Review Board (IRB) of the 
Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore, 
Pakistan and the ethics committee of the Radboud University Nijmegen Medical 
Centre, Nijmegen, and The Netherlands. DNA isolation was performed at CEMB 
following standard procedures.12
FXS screening
Two different methods were used for the FXS screening. In the first method, 
the CGG repeat in the FMR1 promoter was amplified as described by Fu et al.13 
Fragment length analysis was carried out on an ABI Prism 3730 DNA Analyzer (Life 
Technologies, Foster City) and the Genemapper software (version 4.0, Apache) was 
used to determine the exact length of the CGG repeat. Southern blot analysis of 
the FMR1 CGG(n) repeat was performed as described previously.13 In the second 
method, the analysis of the repeat length was performed by using a three-primer 
CGG repeat primed FMR1 PCR method (Asuragen Inc, Austin, CA), according to the 
manufacturer’s protocol.14 
Genotyping, CNV analysis and homozygosity mapping
 CNV analysis was performed by genotyping patients with high resolution 
genotyping techniques using 250k, 6.0 and Cytoscan HD arrays (Affymetrix, Santa 
Clara, CA). For CNV detection the SNP array data were analyzed by using Copy Number 
Analyzer for GeneChip (CNAG)15 (Affymetrix, Santa Clara, CA). For the purpose of 
homozygosity mapping, individuals were genotyped using Illumina 6k and Illumina 
HumanomniExpress BeadChip array (700k array) (Illumina, Inc., San Diego, CA). 
To generate the genotype calls, we have used the Illumina BeadStudio genotyping 
module software (Illumina, Inc., San Diego, CA). The regions of homozygosity of at least 
1Mb were determined either by visual inspection or by using HomozygosityMapper 
(http://www.homozygositymapper.org/).
Next generation sequencing (NGS)
 We used three types of NGS techniques: targeted NGS, exome sequencing and 
X-exome sequencing. Targeted NGS was used to sequence the complete homozygous 
regions on one-quarter plate of a Roche 454 as described before11 (Chapter 4.1). In 
brief, all coding and non-coding exons of respective homozygous regions including 
surrounding sequences to cover the splice sites and untranslated regions were targeted 
on a 385K sequence capture array (Roche NimbleGen, Madison, WI). Sequence 
capture, amplification of captured DNA, sequencing and data analysis were done as 
described before.11,16 Variant prioritization was performed as described previously.16 
The exome sequencing, exome enrichment was carried out by using the SureSelect 
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Human All Exon 50 Mb Kit (Agilent, Santa Clara, CA), with coverage of ~21,000 genes, 
and multiplexed analysis on a SoLiD 4 System sequencing slide (Life Technologies, 
Carlsbad, CA). Color space reads were mapped to the hg19 reference genome with 
the SoLiD BioScope version 1.3, which utilizes an iterative mapping approach. The 
prioritization of the variants was performed as described earlier.16,17 In X-exome 
sequencing, targeted sequencing of the coding parts of X chromosome was performed 
by using Agilent SureSelect (Agilent, Santa Clara, CA) Human X chromosome Kit with 
single-read 76nt NGS on the Illumina GAII sequencer (Illumina, Inc., San Diego, CA). 
The prioritization of the variants was performed as described before.18,19
Sanger sequencing
 The NGS results were validated and confirmed by using Sanger sequencing. 
Primers for the amplification of the exons carrying variants were designed by using 
Primer3.20 PCR reactions were performed on 50ng of genomic DNA with Taq DNA 
polymerase (Invitrogen, Carlsbad, CA). PCR amplicons were purified with NucleoFast 
96 PCR plates (Clontech Lab, Mountain View, CA), according to the manufacturer’s 
protocol. We used the ABI PRISM Big Dye Terminator Cycle Sequencing V3.1 Ready 
Reaction Kit and the ABI PRISM 3730 DNA Analyzer to perform sequencing (Applera 
Corp, Foster City, CA). 
Drosophila genes and lines
RNAi lines of the Drosophila orthologs of TMEM132E (CG14446) and MYO1D 
(CG7438), were obtained from the Vienna Drosophila Research Center (VDRC) 
[VDRC10274, VDRC12558] and Transgenic RNAi Project (TRiP) available at 
Bloomington [BL32487, BL33971]. The Drosophila lines, VDRC60000 and BL36303 
were used as controls, representing the same genetic background as the RNAi lines. 
RNA interference was induced with the UAS-Gal4 system21. Flies were maintained at 
28°C, ensuring maximal RNAi efficiency.
Immunostaining and data acquisition
Drosophila Type 1b neuromuscular junctions (NMJs) of muscle 4 were analyzed 
after dissection of L3 larvae and fixation in 3.7% PFA for 30 min at room temperature. 
Discs large 1 and Bruchpilot were co stained using the Zenon Alexa Fluor 568 Mouse 
IgG1 labeling kit (Invitrogen, Carlsbad, CA) and the primary antibody nc82 (1:125) 
(DSHB), applied overnight at 4°C. The Alexa 488-labeled antibody goat-anti-mouse 
was used as a secondary antibody (1:500) (Invitrogen, Carlsbad, CA). NMJ pictures 
were obtained using a Leica automated bright field multi-color epifluorescent 
microscope. NMJ area, perimeter, length and the branching pattern were quantified 
by a validated, self-made Fiji macro.
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ReSuLTS 
Overview
our cohort of 100 ID families comprises of 34 XLID and XLID/ARID, and 66 ARID 
families. of these, 60 families were genotyped including six XLID, 17 XLID/ARID and 
37 ARID families for the purpose of X-chromosomal mapping/homozygosity mapping. 
As FXS is the most frequent cause of XLID with a prevalence rate of 1/5,000-6,000,22 
we performed FXS screening in 31 families, including 30 XLID and XLID/ARID and one 
family from ARID group. This latter family was included, because consanguinity was 
not reported and there was only one affected female and three affected males in 
consecutive generations separated by a non-affected female. This analysis revealed 
six families (19%) with a full expansion of CGG repeats in the promoter region of the 
FMR1 gene (Table 1). These fragile X-positive families, included the family harboring 
the affected female. Due to the unavailability of DNA samples, the remaining four 
families from XLID and XLID/ARID categories were not screened for FXS. So far, six 
families are fully analyzed by X-exome sequencing, which revealed no potential 
pathogenic variants. Ten ARID families out of the 54 selected have been sequenced 
by using targeted NGS and exome sequencing (Table 1). NGS data revealed three 
novel mutations in known ARID genes, TPO (for details, see chapter 4.1), DPAGT1 (for 
details, see chapter 4.2), and AIMP1. one novel gene, ANK3 was identified in PKMR14 
(for details, see chapter 5). Several plausible candidate genes were identified in each 
of five families, FAIM2 (PKMR11), TMEM132E and MYO1D (PKMR15), THUMPD1 
(PKMR16), CCDC23 and KLHL21 (PKMR17), and ZNF498 (PKMR24). one family, 
PKMR95 (Table 3) remained inconclusive after the validation and confirmation 
process of NGS data. The results of the five families with plausible candidate genes 
are elaborated below. 
Families
Family PKMR11
PKMR11 is a consanguineous family with three affected individuals, of which DNA 
samples and clinical data was available of two individuals (Figure 2a). The affected 
individuals, IV:4 and IV:7, presented with moderate ID. No additional dysmorphic 
features were observed. Homozygosity mapping was performed by genotyping the 
individuals, III:1, III:2, IV:1, IV:2, IV:3 and IV:4 with the Illumina 6k SNP array platform. 
To perform CNV analysis as well as additional homozygosity mapping, one patient, 
IV:7 was genotyped by Affymetrix 250k array (high resolution array). No pathogenic 
CNVs were detected. Homozygosity mapping data revealed three homozygous regions 
on chromosomes 2, 11 and 12 with sizes of 7.5, 1.8 and 15Mb respectively (Table 
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2). To identify the causative variant in this family, we used targeted NGS to analyze 
all exons in the three identified homozygous regions. The generated NGS data was 
filtered according to a recessive model of inheritance (>70% variant reads, at least 
≥2 reads with the variation). After all the selection steps, two potential pathogenic 
missense variants were found: c.325A>G (p.Ileu109Val) in FAIM2 (NM_012306.3) and 
c.5387C>T (p.Pro1796Lue) in NACA (NM_001113203) (Table 3). Both are located on 
chromosome 12q13, in the largest identified homozygous region. Sanger sequencing 
confirmed the segregation of both variants with the phenotype (Figure 2a). The 
phyloP score of both changes was 3.8 and 1.6, respectively (Table 3). The mutated 
amino acid in FAIM2 is located at the UPF0005 domain, and is conserved among 
several animal species (Figure 3a). We have used two bioinformatics-based programs, 
SIFT23 and polyPhen224, to predict the possible pathogenicity of the variants. The 
change c.325A>G (FAIM2) is predicted to be tolerated by SIFT but probably damaging 
by polyPhen2, whereas the change c.5387C>T (NACA) is predicted to be deleterious 
by SIFT but benign by polyPhen2. The FAIM2 variant was absent in dbSNP (v137), 
1000 genomes, but was present in 1/10757 (0.009%) alleles in Exome Variant Server 
(EVS), NHLBI Exome Project (ESP) (http://evs.gs.washington.edu/EVS/), whereas, 
the variant (c.5387C>T) of NACA gene was absent from all databases mentioned 
above. Besides this, we have searched all publically available databases, whether any 
frequent truncating mutations are known in the general population. But we did not 
find any such polymorphisms, which suggests that these genes are not redundant at 
the functional level.
FAIM2 codes for the Lifeguard (LG) protein, which is an anti-apoptotic protein 
and antagonizes the Fas pathway.25 It is highly expressed in brain and remarkably 
enriched in hippocampus of the mouse brain at postnatal day 56 (Allen Brain Atlas, 
http://www.brain-map.org). Apoptosis plays an important role in the brain as well 
as plasticity, as the expression levels of the apoptotic proteins were found to be 
deregulated in the subjects of mild cognitive impairment and Alzheimer’s disease.26 
In several independent genome wide association studies (GWAS), FAIM2 has been 
associated with obesity together with other obesity-related genes. Recently, Boender 
et al.27 observed that the nutritional state affects the expression of obesity related 
genes including Faim2, and they studied two brain (ventro-medial hypothalamus and 
substantia nigra) areas that are involved in regulation of cognition, energy intake and 
expenditure. This study reflects an important role of FAIM2 gene in the brain27 as most 
of the obesity-related genes are involved in neuronal signaling in the central nervous 
system (CNS). No obese appearance was noticed in patients of family PKMR11. 
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figure 2: Pedigree structures and mutation segregation pattern of five families (a-e). 
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Asterisks represent the individuals genotyped by using Illumina 6k array. The arrow symbol 
indicates the individuals analyzed by Affymetrix 250k array in PKMR11, PKMR15, PKMR16, and 
by Affymetrix 6.0 array in PKMR17 and PKMR24.
NACA encodes a nascent-polypeptide associated complex alpha protein which 
binds to polypeptides as they emerge from ribosomes and prevent them to be 
mistranslocated to endoplasmic reticulum (ER)28,29. NACA has two isoforms, a short 
isoform (~1kb) and a long isoform (7kb). The short isoform is ubiquitously expressed, 
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whereas the longer isoform is heart and muscle specific.30 The identified mutation, 
c.5387C>T is located in exon 3 that is only present in the longer isoform of NACA. 
Based on the expression pattern of this isoform it appears that the variant in the 
NACA gene is unlikely to be causative for the brain phenotype. 
Family PKMR15
PKMR15 is a large consanguineous family with six affected individuals in two 
sibships (Figure 2b). Patients VI:2, VI:3, VI:4, VI:5, VI:8 and VI:9, presented with 
mild to moderate ID and all of the patients showed aggressive behavior. No other 
phenotypic features were observed in the family. Computed tomography (CT) scans 
of two patients, VI:3 and VI:5, showed no structural brain anomalies. Individuals 
V:1, V:2, V:7, VI:1, VI:3, VI:4, VI:5, VI:8 and VI:9 were genotyped on Illumina 6k 
array for homozygosity mapping. Patient VI:2 was used to genotype on Affymetrix 
250k array for CNV analysis and homozygosity mapping (Figure 2b). No pathogenic 
CNVs were detected. Homozygosity mapping revealed a single large homozygous 
region of 18.4Mb on chromosome 17 (Table 2). To identify the underlying genetic 
defect, this homozygous region was sequenced using one-quarter Roche 454 plate 
as described.11 Variant prioritization was performed as described previously.5 After 
applying filtering criteria, we found 11 homozygous variants, of which only two were 
highly conserved, having a phyloP value greater than 2.5.5 These two changes were 
in TMEM132E, NM_207313.1 (c.2728G>A, p.Glu910Lys, phyloP 6.4) and in MYO1D, 
NM_015194.1 (c.2585A>T, p. His862Leu, phyloP 4.5) genes (Table 3). Both changes 
affect highly conserved amino acids (Figure 3b, and c). The variant c.2728G>A 
(TMEM132E) was classified as benign by SIFT23 and polyPhen224, whereas the 
variant c.2585A>T (MYO1D) was classified as possibly damaging by SIFT but benign 
by polyPhen2. Sanger sequencing revealed complete segregation of both variants 
with the phenotype (Figure 2b). The mutated amino acid residue in TMEM132E is 
not present in any of the protein domains, whereas the variant in MYoID is located 
in myosin_TH1 domain of the protein (Figure 3b and c). The TMEM132E variant 
(c.2728G>A) was not present in dbSNP (v137), 180 ethnically matched chromosomes, 
1000 genomes data, nor in the EVS. The MYO1D variant (c.2585A>T) was not found 
in 1000 genomes data set, but identified once out of 180 (0.5%) ethnically-matched 
chromosomes, and was also present in 25/10733 (0.2%) alleles in EVS. Although it is 
not a common polymorphism (>1%), the allele frequency indicates that it is less likely 
to be pathogenic. No frequent truncating mutations were observed in these genes in 
all available public databases. In addition, to identify additional mutations in these 
two candidate genes, we selected patients from a cohort of >5000 idiopathic ID cases 
from the Nijmegen Clinical Genetics Center on the basis of overlapping homozygosity 
(homozygous region >5Mb) encompassing the gene of interest. 
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We selected four additional patients to screen TMEM132E and MYO1D genes, 
but did not find any potentially pathogenic mutations in these genes. 
TMEM132E encodes an uncharacterized transmembrane protein. ISH data shows 
pronounced expression of TMEM132E in cortical areas of the mouse brain at postnatal 
day 56 (Allen Brain Atlas, http://www.brain-map.org).  The ortholog of TMEM132E in 
Drosophila (CG14446) is preferentially expressed in the mushroom body, the learning 
and memory center of Drosophila.31 We used the SMART database (http://smart.
embl-heidelberg.de/)32 to predict the protein structure, which revealed a signal 
peptide (amino acids 1-25) and a transmembrane domain (amino acids 802-824) in 
the protein. More in-depth bioinformatics-based phylogenetic investigations showed 
that TMEM132E is conserved down to Monosiga brevicollus (choanoflagellate). It 
has a central region with low homology to the bacterial cell-adhesion intimin that 
mediates bacterial host-cell interaction (Prof. M. Huynen, CMBI Nijmegen, personal 
communication). on the basis of these predictions, TMEM132E may play a role in cell 
adhesion processes. Interestingly, mutations in adhesion molecules such as NRXN1, 
NLGN1, NLGN3 and NLGN4 have been implicated in ID, autism and schizophrenia.33-35 
In addition, synaptic adhesion molecules are crucial for correct development of 
synapse formation and function.35 The TMEM132 gene family has five paralogs; 
TMEM132A, TMEM132B, TMEM132C, TMEM132D and TMEM132E. TMEM132A 
has a vital role in cell survival and regulating ER stress-related gene expressions in 
neuronal cells.36 Recently, Mick et al.37 conducted a GWAS on a cohort affected with 
Attention-Deficit-Hyperactivity-Disorder (ADHD), which revealed that TEME132A 
is a plausible candidate gene to contribute to ADHD.37 In another, independent 
association study, TMEM132D has been associated with panic disorder.38 These 
associations point towards an important role of the TMEM132 gene family in the 
development of the brain. 
MYo1D is a member of unconventional type of myosin class I proteins. It is 
an actin-based motor molecule that is involved in intracellular trafficking.39 It is a 
ubiquitously expressed protein with highest expression levels in the brain, especially 
in the hippocampus and the cortex region.40 Recently, Myo1d has been studied in the 
developing nervous system in mice, which revealed that it is abundantly expressed 
in myelinating cells as well as in cell bodies and axons.41 In addition, Myo1d interacts 
with aspartoacylase, which is involved in the catabolism of N-acetyl-L-aspartic acid 
(NAA) in the CNS,41 which is considered to be critical for maintaining the correct 
neuronal populations. Some neuropathies such as schizophrenia, epilepsy, ADHD 
and multiple sclerosis, are associated with the deregulated levels of NAA in the 
CNS.42,43. Moreover, mutations in aspartoacylase can lead to the higher levels of NAA 
in the brain which eventually causes Canavan disease, a leukodystrophy causing ID.44 
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There is evidence that MYO1D plays a role in the development of CNS, as Stone et 
al.45 have shown a strong association of autism with MYO1D.45 However, we did not 
observe any altered levels of NAA in the CNS of two investigated patients (VI:3 and 
VI:5) of PKMR15 on CT scan, but may be detailed MRI scan is warranted to fully rule 
out the possibility. In addition, MYO1D has an ortholog (Myo31DF) in Drosophila, and 
two independent studies have shown that dysfunction of this gene causes left-right 
asymmetry in Drosophila.46,47 Therefore, we re-investigated patients VI:3 and VI:5 of 
family PKMR15, but no left-right asymmetry was noticed. 
To address the role of TMEM132E and MYo1D in the nervous system, and thus 
to assess their potential contribution to the human phenotype, we used Drosophila 
as a model system. We performed inducible RNA interference to knockdown the 
genes in fly neurons and focused our analysis on the larval Neuromuscular Junction 
(NMJ). The NMJ is a well-characterized synapse that shares major features with 
central excitatory synapses of the mammalian brain,48 and has already provided 
fundamental insights into the molecular basis of ID.49 Knockdown of either gene 
showed a significant increase in synaptic branching of NMJ terminals. TMEM132E 
knockdown synapses also showed a mild increase (12%) in synapse area (P=0.006) 
(Figure 4a and b). This raises the possibility that both genes may contribute to the 
phenotype as seen in our family. 
Family PKMR16
 PKMR16 is a consanguineous family presenting with three (V:2, V:3, V:4) affected 
boys in one generation (Figure 2c). The affected individuals show mild ID without 
any additional phenotypic features. As the family comprises only affected boys, 
this family was classified as XLID/ARID family. Therefore, by following the first line 
of our strategy (Figure 1), we excluded a CGG repeat expansion of FMR1. X-exome 
sequencing of individual V:2 revealed four private variants, none of which was 
segregating with the phenotype. Next, we performed homozygosity mapping by 
genotyping all the available individuals IV:1, V:1, V:2, V:3, V:4 and V:5, on the Illumina 
6k SNP array. Individual V:2 was also genotyped by the Affymetrix 250k SNP array, in 
order to perform CNV analysis and homozygosity mapping (Figure 2c). No pathogenic 
CNVs were detected. Homozygosity mapping data revealed two homozygous regions 
located on chromosomes 13 and 16 with  sizes of 5.6 and 3.8Mb, respectively (Table 2). 
Targeted NGS identified one variant in SMG1, c.10691_10692insC, p.Gln3564Hisfs*9 
and one in THUMPD1 (NM_017736.3), c.133G>A, p.Gly45Ser (Table 3). Conventional 
Sanger sequencing could not confirm the variant in SMG1 but c.133G>A in THUMPD1 
segregated with the phenotype (Figure 2c). The position c.133G has a phyloP score of 
4.9 (Table 3). The affected amino acid residue Gly45 is conserved down to Drosophila. 
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figure 3: Illustration of the protein structures as well as conservation of mutated amino acids 
among most commonly used model systems.  
(a) Protein structure of FAIM2. The mutated amino acid is located at UPF0005 domain which is 
a transmembrane domain; (b) The mutated amino acid is not located in any of the domains of 
the TMEM132E. SP and TM indicate signal peptide and transmembrane domains respectively; 
(c) The MYo1D protein contains three domains; MYSc (motor molecule), IQ (calmodulin-
binding), and Myosin_TH1 (tail) domains. The mutated amino acid is located at tail domain; 
(d) The mutated amino acid is not present in the only domain (THUMP, RNA binding domain) 
of THUMPD1 protein; (e) KLHL21 has one BTB (protein-protein interaction), one Back (BTB and 
C-terminal kelch) and five kelch domains. The mutated amino acid is not located in any of the 
domains; (f) ZNF498 contains one SCAN, one KRAB (Krueppel-associated box) and seven C2H2 
domains. The identified mutated amino acid is not located in any of these domains. All protein 
structures are derived and adapted from SMART database (http://smart.embl-heidelberg.
de/).
The identified mutation is not located in a recognizable protein domain (Figure 3d). 
Both SIFT23 and polyPhen224 classified this change as pathogenic. We did not find 
this variant in 200 ethnically-matched chromosomes, dbSNP (v137), 1000 genomes 
data, or in EVS. No frequent truncating variants in THUMPD1 were identified in public 
databases. We selected three additional ID cases to sequence THUMPD1 gene and 
did not find any pathogenic mutations.
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figure 4: Increased synaptic branching upon knockdown of Tmem132e or Myo1d in type 1b 
NMJs of muscle 4. 
NMJs are visualized by immunostaining of scaffolding protein Discs large 1 (dlg), member of 
the membrane-associated guanylate kinase (MAGUK) subfamily. (a) Synaptic terminals show 
an increased amount of branches and branching points upon knockdown of either Tmem132e 
and Myo1d versus wild type pattern; (b) Quantification of the amount of branches and 
branching points. Bars indicate the average amount per NMJ for wild type (n=28) and upon 
knockdown of Tmem132e (n=26) and Myo1d (n=25). Error bars indicate the S.E.M., *P<0.05; 
**P≤0.01 as compared to wild type.
THUMPD1 is an uncharacterized protein. ISH data shows THUMPD1 expression in 
hippocampus and the cortex region of the mouse brain at postnatal day 56 (Allen 
Brain Atlas, http://www.brain-map.org), which indicates that this gene might have 
an important role in the brain. THUMPD1 has only a single domain, called “THUMP” 
domain (amino acids 161-254) (http://smart.embl-heidelberg.de/).32 No signal 
peptide was observed (http://www.predisi.de/). The THUMP (thiouridine synthases, 
methylases and pseudouridine synthases) domain is an RNA binding domain, which is 
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present in various enzymes that are involved in delivering different RNA-modifications 
to target non-coding RNAs such as tRNA, rRNA and small nuclear RNAs.50 The tRNAs 
are the most extensively modified RNAs.51 These modifications are essential for 
stabilization, structural folding and molecular recognition of the functional RNAs. For 
example, the THUMP-domain containing Thil protein is vital for 4-thiouridine formation 
of some bacterial tRNAs. Likewise, the Tan1 protein of yeast, which also contains 
THUMP domain and is involved in N4-acetylcytidine formation in tRNAs which is very 
important for tRNAs stability.52 Furthermore, there is growing evidence that defects in 
the genes that are involved in the modifications of non-coding RNAs, are implicated in 
ID in humans. Mutations in FTSJ1, encoding an rRNA-methyltransferase,53 cause non-
syndromic XLID and TRMT1 (tRNA-methyltransferase)9 has been implicated in non-
syndromic ARID. Finally, homozygous defects in NSUN2 (tRNA-methyltransferase)54 
were recently shown to cause ARID. 
Family PKMR17
 PKMR17 is a family consisting of two affected girls (IV:1 and IV:2) and two non-
affected siblings (IV:3 and IV:4) of first-cousin parents (Figure 2d). Patient IV:1 
presented with moderate ID and aggressive behavior. Patient IV:2 presented with 
moderate to severe ID, and fatigue. CT scan of both affected individuals showed a 
normal brain structure. Genotyping and homozygosity mapping was carried out in 
individuals III:1, IV:1, IV:2, IV:3 and IV:4 using the Illumina 6k array. Individual IV:1 
was also genotyped on an Affymetrix 6.0 array (Figure 2d). No pathogenic CNVs were 
observed. Three homozygous regions on chromosomes 1 (7.7Mb), 1 (29Mb) and 
5 (26.8Mb), were identified by homozygosity mapping (Table 2). Targeted NGS as 
described above revealed ten homozygous variants. on the basis of mutation type, 
gene function and nucleotide conservation with a phyloP score >2.5,5 we selected two 
variants: c.82C>T (p.Gln28*) in CCDC23 (NM_199342.3) and c.1762C>T (p.Arg588Trp) 
in KLHL21 (NM_014851.2) (Table 3). The nonsense change in CCDC23 has a phyloP 
score of 4.8 and creates a premature stop codon. The missense change in KLHL21 has 
a phyloP score of 3.2. The mutated arginine is conserved down to the frog (Xenopus). 
The identified mutation is not located in any of the domains of the protein  (Figure 3e, 
Table 3). This change is predicted to be likely pathogenic by SIFT23 and polyPhen2.24 
Both changes segregated with the phenotype (Figure 2d). The KLHL21 variant was 
found once in 240 (0.4%) ethnically-matched chromosomes, but not in any publically 
available databases such as dbSNP (v137), 1000 genomes data and EVS. The CCDC23 
variant (c.82C>T) was not present in 240 ethnically-matched chromosomes nor in any 
of the mentioned databases. No frequent truncating mutations were noticed in public 
databases in either of these two genes. We sequenced six additional ID cases with 
regions of homozygosity overlapping CCDC23 and four for KLHL21, but did not find 
any pathogenic mutations.
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 The DNA sequence of CCDC23 is almost completely conserved among mammals. 
It contains one coiled-coil domain (amino acids 32-52) and is abundantly present 
in testis, spleen and bone marrow, but also at lower levels in various other organs 
including the brain.55 CCDC23 is a small vasohibin-binding protein (SVBP). SVBP 
interacts with vasohibin-1 (VASH1), which is produced and secreted by endothelial 
cells upon stimulation by vascular endothelial growth factor (VEGF) and fibroblast 
growth factor-2 (FGF-2). VEGF and FGF2 are main stimulators of angiogenesis.56 
VASH1 regulates endothelial cell proliferation and migration, and acts as a negative 
feedback regulator.57 Recently, Suzuki et al,55 demonstrated that SVBP is a secretory 
chaperon for VASH1, and plays an important role in establishing the anti-angiogenic 
activity of VASH1. SVBP might not only be an interactor of VASH1, but it may also 
have additional roles.55 A number of studies show that dysfunction of proteins 
involved in vasularization/angiogenesis may give rise to different pathogenic 
conditions including ID. For example, defects in ELN are associated with Williams 
syndrome58 and dysfunction of SRPX2 is implicated in disorders of language cortex 
and cognition.59 Along these lines, it is possible that CCDC23 might also contribute to 
the development of ID.
  KLHL21 is expressed in several tissues including brain60. ISH images show 
specifically high expression in hippocampus of the mouse brain at postnatal day 56 
(Allen Brain Atlas, http://www.brain-map.org). Recently, Maerki et al.60 showed that 
KLHL21 interacts with Cullin3-based E3 ubiquitin ligase and is involved in efficient 
chromosomal alignment and regulation of cytokinesis during cell division.60 Cell cycle 
regulation and cell division has been previously implicated in ID and microcephaly. 
Mutations in CUL4B have been implicated in syndromic form of XLID.61 Several 
cell cycle related genes including MCPH1 and ASPM are involved in development 
of ID and microcephaly.62,63 We did not find an abnormal head size of the affected 
individuals of the PKMR17 family.
 
Family PKMR24
PKMR24 is a consanguineous family with three affected individuals IV:2, IV:3 and 
IV:4 in one generation (Figure 2e). The three affected individuals show moderate ID, 
without additional defining characteristics. Individuals III:2, IV:1, IV:2, IV:3, IV:4 and 
IV:5 were used for homozygosity mapping, by the Illumina 6k array and individual 
IV:2 was also analyzed by using the Affymetrix 6.0 array. No pathogenic CNVs were 
observed. Homozygosity mapping revealed a single large homozygous region of 
21.6Mb on chromosome 7 (Table 2). The exome of patient IV:3 was sequenced using 
the 50 Mb SureSelect human exome kit (Agilent Santa Clara, CA), with a SoLiD 4 System 
sequencing slide (Life Technologies, Carlsbad, CA). We filtered variants according 
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to a recessive mode of inheritance as described above. In the homozygous region 
on chromosome 7q21.12-q31.1, we detected a single non-synonymous missense 
variant in ZNF498 (NM_145115.2), c.506A>G (p.Glu169Gly) (Table 3). This variant has 
a phyloP score of 1.3 and the mutated amino acid is conserved down to the dog. The 
identified mutation is not located in any of the protein domains (Figure 3f, Table 3). 
It is predicted to be damaging by both SIFT23 and polyPhen2.24 The c.506A>G change 
was not present in any databases such as, dbSNP (v137), 1000 genomes project, 
and EVS. In addition, no frequent truncating mutations were found in ZNF498 in 
these databases. This variant segregated with the phenotype in the family as shown 
by Sanger sequencing (Figure 2e). In the remaining part of the exome, one other 
homozygous missense variant (c.578C>T, p.Thr193Ile) was found in a known non-
syndromic ARID gene, TRAPPC9. However, subsequent Sanger sequencing showed 
that this missense mutation does not co-segregate with the phenotype in PKMR24. 
Moreover, the introduced amino acid (Ile) was found in other mammalian species at 
the position corresponding to Thr193 in humans.
ZNF498 is a transcription factor, containing one SCAN (leucine-rich domain) 
domain, one krüppel-associated box (KRAB) domain and seven C2H2-type Zinc finger 
domains (http://smart.embl-heidelberg.de/). The identified missense variant is not 
located in any of the predicted domains of ZNF498. No expression data is present 
in the Allen Brain Atlas database. ZNF498 is similar to other KRAB C2H2-type ZNF 
proteins. This group of zinc finger proteins is the most enriched class of proteins in 
human proteome.64 KRAB containing C2H2-type zinc finger proteins are involved in 
transcriptional repression as well as RNA processing, illustrating a diverse role of such 
proteins during development.65 During past few years, it has been demonstrated that 
several zinc finger genes play a crucial role in the development of brain. Until now, 
mutations in ZNF41, ZNF81, ZNF674 and ZNF526, KRAB box containing zinc finger 
genes have been associated with non-syndromic ID.9,66 
DISCuSSIoN
 To elucidate the genetic causes of ID in an inbred population, we have ascertained 
100 ID families from Pakistan, comprising six XLID, 28 XLID/ARID and 66 ARID families. 
In total, we have collected 43 families with 1-2 affected individuals, 30 families with 
three affected individuals, 27 families with ≥4 affected individuals. Consanguinity was 
observed in 81 families. FXS screening was performed in 31 families, which revealed 
six families (19%) with positive diagnosis. The prevalence of FXS is in accordance with 
the reported figure of 15-25% for all the patients with possible XLID inheritance.22 
We selected 21 families for X-exome sequencing and 54 families for NGS (targeted 
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exome/whole exome). X-exome sequencing of six XLID and XLID/ARID families 
revealed no pathogenic variants. NGS data of the ten analyzed ARID families revealed 
mutations in three known genes in respective families, one truncating mutation in 
a novel gene, and potential pathogenic variants in FAIM2, TMEM132E, MYO1D, 
THUMPD1, KLHL21, CCDC23 and ZNF498 in five families. 
To prove that the latter genes are involved in ARID, it is essential to obtain one or 
more lines of complementary support. 1) The identification of additional mutations 
in the respective candidate genes would provide the strongest evidence of causality, 
especially if the corresponding phenotypes overlap. For such genetic investigations 
we have access to the large cohort of >5000 patients of idiopathic ID cases.  Until 
now, we have analyzed multiple patients to identify possible second mutations 
in all of the above mentioned candidate genes except FAIM2 and ZNF498, but no 
pathogenic mutations were identified. We are currently expanding the search for 
additional mutations to the international level. As being the partner of the GENCoDYS 
(http://www.gencodys.eu/) consortium, we share data amongst groups carrying out 
similar studies, which will hopefully expedite the finding additional mutations in the 
respective genes. Previously, a similar collaboration within the EURo-MRX consortium 
has been very helpful for the identification of genes for XLID; 2) characterize the 
effect of the variant on mRNA and protein level. And, in vitro testing of the identified 
variants in cellular models; 3) establish relevant animal models (mouse, Drosophila 
or other) to study learning and memory, and assess the specific identified variants in 
vivo. In this study, we have used Drosophila as a model to study the functional role of 
two genes, TMEM132E and MYO1D, and found an NMJ phenotype at morphological 
level for both genes. We are expanding the characterization of these fly mutants by 
applying them to tests for learning and memory, in order to gain more information 
on the function of these genes. For other cases where multiple candidate ID genes 
will be identified, using Drosophila knockdown models may provide a powerful tool 
to assign causality to a single gene. Proof-of-concept has been provided by studying 
the orthologs of two different genes in which mutations had been identified by 
exome sequencing in an individual with Kleefstra syndrome phenotype.67 Drosophila 
modeling has also been instrumental in establishing the pathogenic role of ANK3 in 
ARID (Chapter 5).
out of ten families, one family (PKMR95) remained unsolved (Table 3). The causal 
variant in PKMR95 might have been missed as not all of the exons of the genome are 
covered by exome sequencing. Alternatively, the causal variant could reside in non-
coding regions of the genome. Finally, it cannot be excluded that there is more than 
one genetic mutation within this family, resulting in a phenocopy. Such phenocopies 
can mask causative variants due to apparent non-segregation of any single variant 
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within such families. Therefore, to solve the genetic defect(s) in families like PKMR95, 
future whole-genome sequencing of multiple individuals should be considered. In 
conclusion, by studying ten ARID families we found novel mutations in three known 
ARID genes, one novel gene and several plausible candidate genes. 
Most recently, NGS has been performed for the remaining 44 ARID families. 
Following homozygosity mapping, a single patient was selected from 16 families for 
exome sequencing. For the other 28 families either one (n=15 families) or two (n=13 
families) affected individuals were used for exome sequencing without performing 
any prior mapping (Figure 1). So far, we have analyzed the exome sequencing results 
of 31 families, which revealed recessive mutations in known ARID genes in nine 
families. In another eight families we identified segregating recessive mutations in a 
single gene not previously linked to ID, indicating that possible novel ARID genes may 
have uncovered. In nine families multiple segregating rare variants are identified. 
Three families remained inconclusive, and the results of two families are in progress. 
We will follow the same strategy as described above, in order to find the recurrence 
and establish the pathogenicity of the identified candidate genes. The yield of latter 
investigated group of families (31/44) is comparable with previously studied ten 
ARID families. These data demonstrate that NGS is a powerful tool to investigate 
the genetic defects of extremely heterogeneous disorders as ID. our results clearly 
show the power of devised strategy as well as the use of consanguineous families to 
elucidate the autosomal recessive genetic defects. 
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aBSTRaCT
Backgrounds and Aims. Next generation sequencing (NGS) approaches have 
revolutionized the identification of mutations underlying genetic disorders. This 
technology is particularly useful for the identification of mutations in known and new 
genes for conditions with extensive genetic heterogeneity. In the present study we 
investigated a consanguineous Pakistani family with intellectual disability (ID). 
Methods. Genotyping was carried out by using 250k and 6k SNP microarrays in 
order to perform homozygosity mapping and copy number variation (CNV) analysis. 
Targeted NGS was performed to identify the genetic defect in this family. qPCR was 
performed to validate and confirm the NGS result.
Results. Homozygosity mapping positioned the causative defect on chromosome 
2p25.3-p25.2. Subsequent targeted NGS revealed an intragenic deletion of five exons 
of the gene TPO. 
Conclusions. NGS is a powerful method to uncover submicroscopic structural 
variations. This result demonstrates that an unbiased screening approach such as 
NGS can help to identify even unexpected disease-causing mutations. 
91
NoVEL MUTATIoNS IN KNoWN AUToSoMAL RECESSIVE INTELLECTUAL DISABILITY GENES | 
INTRoDuCTIoN
Due to the high consanguinity rate, genetic disorders are a major cause of infant 
mortality, morbidity and handicap in countries of the greater Middle East.1 Congenital 
disorders with intellectual disability (ID) constitute a particularly important medical 
problem because of the high prevalence and life-long care that patients will need. 
The extreme genetic heterogeneity of ID is a major problem for pre- and postnatal 
diagnostics. In some cases, however, early detection of a mutation may be important 
to prevent the manifestation of the handicap. Congenital hypothyroidism (CH) is one 
of the most frequent causes of preventable ID, which can be averted by administering 
the thyroid hormone in the early postnatal life. The worldwide prevalence of this 
condition is 1/4000 live births.2 Many defects in thyroid hormone biosynthesis have 
been elucidated, of which thyroid peroxidase deficiency (oMIM 606765) caused by 
TPO gene mutations is the most common defect, accounting for more than half of 
the cases.3 
Identification of mutations in conditions with extensive genetic heterogeneity 
has been proven difficult with conventional diagnostic approaches. NGS, however, 
has recently been shown to be an extremely powerful method for solving such 
diseases.4,5 In this study we report a consanguineous Pakistani family presenting 
moderate to severe ID but no obvious signs of CH. Using NGS, we were able to 
identify a homozygous intragenic deletion of five exons in the gene TPO, leading to 
the conclusion that this family is suffering from CH rather than a new nonsyndromic 
form of ID. 
MaTeRIaLS aND MeTHoDS
Patient material
A consanguineous Pakistani family (PKMR07) was ascertained from the southern 
part of the Punjab province (Figure 1a). Affected family members were originally 
diagnosed with an unexplained nonsyndromic form of autosomal recessive ID. 
Informed consent was obtained from all the participating subjects. This study was 
approved by the Institutional Review Board (IRB) of the Centre of Excellence in 
Molecular Biology (CEMB), University of the Punjab, Lahore, Pakistan and the local 
ethics committee of the Radboud University Nijmegen Medical Centre, Nijmegen, the 
Netherlands. DNA was isolated from peripheral blood using standard procedures.6
Homozygosity mapping and CNV analysis
Individuals 44571, 44572, 44573, 44574, 44575 and 44576 of PKMR07 were 
genotyped on an Illumina 6k SNP array platform. To investigate the CNVs as well 
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as homozygosity mapping, the DNA of one affected individual (44577) was used to 
genotype on Affymetrix (Affymetrix, Santa Clara, CA) 250k SNP array. The DNA of one 
patient (57803) was not available at the time of genotype analysis. The Affymetrix 
Genotyping Console (v.2.0) and Illumina BeadStudio genotyping module software 
(Illumina, Inc., San diago, CA) were used to generate the genotype calls. Stretches of 
homozygosity were identified by visual inspection. To detect copy number variations, 
the Affymetrix 250k SNP array data were analyzed by using Copy Number Analyzer 
for GeneChip (CNAG).7
Next generation sequencing
The DNA of patient 44577 was selected for targeted NGS. Based on the data 
resulting from homozygosity mapping, four homozygous regions (Table 1) were 
targeted on a 385k sequence capture array (Roche NimbleGen, Madison, WI). The 
array design comprised all coding and noncoding exons of these regions including 
surrounding sequences to cover the splice sites and untranslated regions. The array 
design harbored additional targeted regions used for similar analysis of homozygous 
regions in four other families. In total, the design included 5971 targets, comprising 
1,943,753 bp. Sequence capture was done according to manufacturer’s instructions 
(Roche NimbleGen) using the Titanium optimized protocol. In brief, 5 µg of genomic 
DNA was used for the preparation of DNA for sequence-capture hybridization. A final 
amount of 3µg pre-hybridization ligation-mediated (LM)-PCR-amplified DNA was 
hybridized to the customized array eluted after 72 h of hybridization and amplified 
by post-hybridization LM-PCR. The amplified captured sample was then used as input 
for emulsion PCR amplification and subsequent sequencing using a quarter lane 
of a Roche 454 GS FLX Titanium. Data analysis was done using the Roche Newbler 
software (v.2.3) using the human genome build hg18 (NCBI Build 36.1). Additional 
mapping and coverage statistics were extracted from the mapping output files using 
customized software. Sequence variations were automatically detected during 
mapping and annotated with known gene (refSeq genes from http://genome.ucsc.
edu/) and SNP information (dbSNP129) using in-house analysis software.4
Quantitative PCR (qPCR) analysis 
SYBR green-based genomic real-time qPCR analysis was performed on a 7500 
Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) by using Power 
SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) according to 
the manufacturer’s instructions. Primers were developed by the Primer3 program 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi)8 (Supplementary Table 
1) and validated as described before.9 qPCR quantifications were performed in 
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duplicate on 2 ng/µl DNA and included a water control. All comparative threshold 
cycle (Ct) values were within the range of DNA dilutions used to validate the primers. 
The melting curves of all PCR products showed a single PCR product. All controls 
were negative. Copy numbers were measured relative to the reference gene, cystic 
fibrosis transmembrane conductance regulator (CFTR). DNA copy number differences 
between samples were calculated by the 2ΔΔCt method.10
figure 1: Pedigree of Pakistani family PKMR07. 
(a) Filled symbols indicate the affected individuals and double horizontal lines indicate the 
consanguineous marriages. (b) No coverage of five exons of the TPO gene (box) in our patient 
(44577) was found as compared to other four samples from different projects, indicating a 
homozygous deletion of five (11-15) exons. The vertical black bars indicate the coverage of 
the targeted regions and the intensity of the darkness of these bars represents how well they 
are covered.
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Biochemical tests
Biochemical tests to analyze the serum levels of TSH (normal range: 0.4-4 µIU/
ml), T3 (normal range: 84-172 ng/dl) and T4 (normal range: 4.5-12.5 µg/dl) were 
performed at Shaukat Khanum Memorial Cancer Hospital (SKMCH) laboratory, 
Pakistan (Table 2) as previously described.11
ReSuLTS 
Initially, the consanguineous Pakistani family PKMR07 was ascertained as an 
autosomal recessive ID family (Figure 1a). No remarkable dysmorphic features 
were observed. No records of biochemical tests were available and these were not 
conducted at the time of sample collection. Genome wide homozygosity mapping 
was carried out by using two different SNP array platforms. Available DNA samples 
of all family members [except patient 57803 (DNA sample was not available) and 
44577 (this individual was genotyped on Affymetrix 250k array)] were investigated 
on an Illumina 6k array. The resolution of this array is high enough to identify the 
large homozygous stretches that are expected in highly consanguineous populations 
such as the Pakistani population. The DNA of one patient (44577) was genotyped 
by using an Affymetrix 250k SNP array to detect possible CNVs as well as to confirm 
homozygous regions found by the Illumina 6k array. The CNV analysis revealed a 
homozygous deletion of ~100kb at 2q37.1, encompassing the placental alkaline 
phosphatase genes ALPP and ALPPL2 and the noncoding RNA gene ECEL1P2. 
Segregation analysis showed that this deletion did not cosegregate with the disease. 
Two apparently healthy individuals, the mother (44572) and one unaffected child 
(44576), carried this homozygous deletion, whereas one of the affected members 
(44574) appeared to be heterozygous for the deletion (data not shown). No additional 
phenotypic features were observed in connection with this deletion and there was 
no apparent effect on fertility as the female with the homozygous deletion gave birth 
to four children.
Homozygosity mapping data revealed four homozygous regions on chromosomes 
2p25.3-p25.2, 5p13.2-p13.1, 15q11.2-q13.1 and 15q25.1-q25.2 that are shared by all 
patients and not by other family members (Table 1). The homozygosity in these four 
regions was confirmed by both SNP arrays (6k and 250k). To elucidate the molecular 
cause in this family a targeted NGS approach was followed. A quarter run of the Roche 
454 GS FLX Titanium yielded 104,541,023 mapped bases for sample 44577, of which 
92% were located on or near (within 500bp proximity) the targeted region, resulting 
in an average coverage of 29x in our regions of interest. In total, 3582 variants were 
detected as high confidence calls (HCdiffs). These included 637 variants in exons and 
90 in splice sites. All variants were annotated using a custom analysis pipeline as 
previously described.4 However, no plausible causative DNA variants were identified 
95
NoVEL MUTATIoNS IN KNoWN AUToSoMAL RECESSIVE INTELLECTUAL DISABILITY GENES | 
upon prioritization for novel exonic and splice site variants located in the regions of 
interest that were homozygous and not known as SNPs. Careful inspection of the 
alignment annotation file revealed that there was no coverage for five consecutive 
targeted regions between positions 1,470,849 and 1,523,267 on chromosome 2p25 
indicating that there might be a homozygous deletion encompassing exons 11-15 of 
the gene TPO. This coverage deficiency (missing reads) was specific for sample 44577, 
as these regions were well covered in four other samples (from independent studies) 
that were enriched using the same sequence capture array (Figure 1b). Re-analysis of 
the 250k SNP microarray data revealed that the only SNP present in the homozygous 
deleted region had a log2 ratio -1.4, supporting a possible deletion (Supplementary 
Figure 1). Deletions of single SNPs are often spuriously found and therefore not 
reported as possible deletions. High resolution arrays (e.g., Affymetrix 6.0 or Illumina 
HumanomniExpress BeadChip array) may have found this deletion but these are not 
commonly used in DNA diagnostics world-wide. To validate the identified deletion 
we performed a qPCR, which is a highly efficient technology that is routinely used 
in our department for the detection and validation of CNVs. All the available family 
members as well as patient 57803 (the DNA sample of this patient was only available 
at the time of validation and segregation analysis) were used for qPCR. Genomic 
qPCR with primers from several exons of the TPO gene (Supplementary Table 1) 
showed that the deletion is present and cosegregates with the disease (Figure 2). 
This novel deletion creates a frame shift (p.Tyr591HisfsX21) and the mRNA produced 
may be targeted for nonsense mediated RNA decay (NMD).12 on the basis of these 
results, the patients of PKMR07 family were expected to have CH. Biochemical tests 
were conducted retrospectively and revealed high serum TSH (>75.000-29.100 
µIU/ml) and normal to low T3 (123.000-71.800 ng/dl) and T4 (10.300-3.230 µg/dl) 
levels compatible with our genetic findings (Table 2). To measure the ID levels, the 
intelligence quotient (IQ) of the patients was evaluated. Patient 44574 presented 
with moderate to severe ID (IQ, 20-34), whereas patients 44577 and 57803 presented 
with moderate ID (IQ, 35-49).
Table 1 Genomewide homozygous regions of PKMR07 used for targeted NGS
Chromosome Start position
(bp)a
End position
(bp)a
Size (Mb)b Exon count
2p25.3-p25.2 24,049 6,584,064 6.5 157
5p13.2-p13.1 35,392,931 38,615,082 3.2 325
15q11.2-q13.1 21,375,839 25,732,503 4.3 100
15q25.1-q25.2 76,694,400 82,602,778 5.9 451
Total 1033
a Base pair positions according to the human genome build hg18 (NCBI Build 36.1).
b Mega base pairs resulting from homozygosity mapping.
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figure 2: Genomic qPCR showing the cosegregation and confirmation of the homozygous 
deletion of 5 exons (11-15) of the TPO gene. 
All three available parents (44571, 44572, 44573) and one unaffected (44576) were carriers, all 
three patients (44574, 44577 and 57803) were shown to be homozygous, and one unaffected 
member (44575) was homozygous wild type (see Supplementary Figure 1, compatible with 
the mapping data) for this intragenic deletion suggesting a cosegregation with the disease.
Table 2 Clinical features of the affected individuals of PKMR07
Patient ID 44574 44577 57803
Age at evaluation 24 years 20 years 18 years
Hypothyroidism level
TSHa (normal range, 0.4-4 µIU/ml)
T4b (normal range, 4.5-12.5 µg/dl)
T3c (normal range, 84-172 ng/dl)
Severe
>75.000
3.230
71.800
Mild
59.400
5.870
123.000
Mild
29.100
10.300
99.400
aThyroid stimulating hormone.
bThyroxin.
cTriiodothyronine.
DISCuSSIoN
In the present study we report a consanguineous Pakistani family, PKMR07, 
presenting with an autosomal recessive form of ID (Figure 1a). At the time of sample 
collection no other prominent features in relation to any common cause of ID were 
noticed. The patient samples were collected in Pakistan and, later on, all further 
studies were carried out in Nijmegen, The Netherlands. By using the combination of 
homozygosity mapping and NGS, we identified a homozygous intragenic deletion of 
five exons (11-15) of the TPO gene (Figure 1b). To confirm this result, a genomic qPCR 
was used, which showed complete cosegregation of the homozygous deletion with 
the disease (Figure 2). This novel homozygous deletion (p.Tyr591HisfsX21) results in a 
premature stop codon by shifting the normal reading frame. Next, biochemical tests 
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showed high serum TSH and normal to low T3 and T4 levels (Table 2). As a result, 
all three patients (44574, 44577 and 57803) presented with moderate to severe ID 
due to the late diagnosis of CH. TPO encodes the thyroid peroxidase enzyme, and a 
large number of different mutations of the TPO gene are already known to contribute 
as a major cause of CH.13 The thyroid hormone plays a vital role in the maturation 
of the central nervous system (CNS),14 and its absence therefore results in severe 
consequences. Pakistan is a developing country with a large and growing population, 
and a national neonatal screening program for various genetic and metabolic 
disorders has not been set up. There are only few hospitals in Pakistan conducting 
neonatal screening including CH. Beside monogenic disorders such as β-thalassemia 
and Glucose-6-phosphate dehydrogenase (G6PD) deficiency, CH is the most frequent 
inborn error of metabolism in the Pakistani population with a prevalence of 1/ 
1600 live births.15 This is 2.5 times more than that in the Western World.2,15 If the 
affected individuals of a family such as PKMR07 would have been diagnosed and 
institutionalized in early postnatal life, major problems such as ID would not have 
developed. Administration of thyroid hormone will be started now in the patients of 
PKMR07. This will not improve the intellectual level of the patients at this age but can 
be helpful in reducing the intensity of several other secondary problems related to 
the general homeostasis. our finding strongly demonstrates that there is a dire need 
to develop a national neonatal metabolic screening policy in developing countries, 
which could save thousands of lives. It can be anticipated that screening programs 
will be developed that are based on NGS in the near future. For example, targeted 
enrichment of genes known to be involved in treatable genetic disorders or even 
larger collections of known disease genes followed by NGS may provide a powerful 
and affordable tool for early detection of a large number of genetic disorders in a 
single diagnostic analysis.  
In summary, we have identified a novel homozygous intragenic deletion of five 
exons of the TPO gene by using homozygosity mapping and targeted resequencing. 
our data show how an unbiased screening approach like NGS can identify even 
unexpected disease-causing mutations and thereby can help to find the correct 
diagnosis in a patient with an unspecified phenotype. on the other hand, the present 
study may also be instructive that there is a need for routine diagnostic work-up for 
common causes of ID in developing countries such as Pakistan.
aCKNoWLeDGeMeNTS 
We are thankful to all the family members of PKMR07 for the participation in this 
study. The research leading to these results has received funding from the European 
Union’s Seventh Framework Program under grant agreement number 241995, 
project GENCoDYS and grant agreement number 223143, project TECHGENE. Z.I was 
supported by Higher Education Commission (HEC), Islamabad, Pakistan.
98
| CHAPTER 4.1
RefeReNCeS
1. Al-Gazali L, Hamamy H, Al-Arrayad S: Genetic disorders in the Arab world. BMJ 2006; 333: 
831-834.
2. Rastogi MV, LaFranchi SH: Congenital hypothyroidism. Orphanet J Rare Dis 2010; 5: 17.
3. Medeiros-Neto GA, Billerbeck AE, Wajchenberg BL, Targovnik HM: Defective organification 
of iodide causing hereditary goitrous hypothyroidism. Thyroid 1993; 3: 143-159.
4. Hoischen A, Gilissen C, Arts P et al: Massively parallel sequencing of ataxia genes after 
array-based enrichment. Hum Mutat 2010; 31: 494-499.
5. Vissers LE, de Ligt J, Gilissen C et al: A de novo paradigm for mental retardation. Nat Genet 
2010; 42: 1109-1112.
6. Grimberg J, Nawoschik S, Belluscio L, McKee R, Turck A, Eisenberg A: A simple and efficient 
non-organic procedure for the isolation of genomic DNA from blood. Nucleic Acids Res 
1989; 17: 8390.
7. Nannya Y, Sanada M, Nakazaki K et al: A robust algorithm for copy number detection using 
high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer 
Res 2005; 65: 6071-6079.
8. Rozen S, Skaletsky H: Primer3 on the WWW for general users and for biologist 
programmers. Methods Mol Biol 2000; 132: 365-386.
9. Marcelis CL, Hol FA, Graham GE et al: Genotype-phenotype correlations in MYCN-related 
Feingold syndrome. Hum Mutat 2008; 29: 1125-1132.
10. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 2001; 25: 402-408.
11. Robin NI, Hagen SR, Collaco F, Refetoff S, Selenkow HA: Serum tests for measurement of 
thyroid function. Hormones 1971; 2: 266-279.
12. Boutron A, Acquaviva C, Vianey-Saban C et al: Comprehensive cDNA study and quantitative 
analysis of mutant HADHA and HADHB transcripts in a French cohort of 52 patients with 
mitochondrial trifunctional protein deficiency. Mol Genet Metab 2011; 103: 341-348.
13. Ris-Stalpers C, Bikker H: Genetics and phenomics of hypothyroidism and goiter due to TPo 
mutations. Mol Cell Endocrinol 2010; 322: 38-43.
14. Cao XY, Jiang XM, Dou ZH et al: Timing of vulnerability of the brain to iodine deficiency in 
endemic cretinism. N Engl J Med 1994; 331: 1739-1744.
15. Afroze B, Humayun KN, Qadir M: Newborn screening in Pakistan - lessons from a hospital-
based congenital hypothyroidism screening programme. Ann Acad Med Singapore 2008; 
37: 114-113.
99
NoVEL MUTATIoNS IN KNoWN AUToSoMAL RECESSIVE INTELLECTUAL DISABILITY GENES | 
Supplementary Table 1 Genomic qPCR primers to validate the TPO intragenic deletion
Fragment Name Sequence (5´-3´)
TPO-qPCR-ex09-forward TGCACCAGGCTTTCTTCAG
TPO-qPCR-ex09-reverse GAAGAGTTCATGGGGACCAG
TPO-qPCR-ex10-forward TTTGTGCTGTCCAATTCCAG
TPO-qPCR-ex10-reverse GTGTGCAAGGGAAGGAACTG
TPO-qPCR-ex11-forward CAAGCATCCTGACAACATCG
TPO-qPCR-ex11-reverse CAGAGCCTTCATCTGCTTCC
TPO-qPCR-ex13-forward GTGCACTGTGAGGAGTCTGG
TPO-qPCR-ex13-reverse GCTGGAAATCCCATCCTTC
TPO-qPCR-ex15-forward TGATTTGCAGGTGGTAAGTCC
TPO-qPCR-ex15-reverse GCTTCGGGAAAATAAAGCAG
TPO-qPCR-ex16-forward CTCTACCCTCCACAGTCACG
TPO-qPCR-ex16-reverse TGTGGATTTAGTGCCAGTGC
CFTR 3’-UTR-forward GGGTCTTGATAAATGGCTTCC
CFTR 3’-UTR-reverse TCTGGCTTGCAAAACACAAG
All oligonucleotides were designed using the program Primer3 (http://frodo.wi.mit.edu).
Supplementary figure 1: Homozygosity mapping data and CNV analysis on chromosome 2. 
The blue horizontal bars represent the homozygosity mapping data and CNV analysis. Red 
horizontal bar indicate the samples genotyped with Illumina 6k array. Purple horizontal bar 
indicate one patient (44577) genotyped with Affymetrix 250k SNP array. There was only one 
SNP rs3772074 (log2 ratio -1.4, flagged red) present in the deleted homozygous region of TPO 
gene.
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aBSTRaCT
Congenital disorders of glycosylation (CDG) are a large group of recessive multisystem 
disorders caused by impaired protein or lipid glycosylation. The CDG-I subgroup is 
characterized by protein N-glycosylation defects originating in the endoplasmic 
reticulum. The genetic defect is known for 17 different CDG-I subtypes. Patients 
in the few reported DPAGT1-CDG families exhibit severe intellectual disability (ID), 
epilepsy, microcephaly, severe hypotonia, facial dysmorphism and structural brain 
anomalies. In this study, we report a non-consanguineous family with two affected 
adults presenting with a relatively mild phenotype consisting of moderate ID, 
epilepsy, hypotonia, aggressive behavior and balance problems. Exome sequencing 
revealed a compound heterozygous missense mutation, c.85A>T (p.I29F) and 
c.503T>C (p.L168P), in the DPAGT1 gene. The affected amino acids are located in the 
first and fifth transmembrane domains of the protein. Isoelectric focusing and high-
resolution mass spectrometry analyses of serum transferrin revealed glycosylation 
profiles that are consistent with a CDG-I defect. our results show that the clinical 
spectrum of DPAGT1-CDG is much broader than appreciated so far.
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INTRoDuCTIoN
Congenital disorders of glycosylation (CDG) are a large class of neurometabolic 
disorders that involve defects in protein N- and O-glycosylation and lipid glycosylation. 
Defects in N-glycosylation are traditionally divided in CDG type I (CDG-I) and CDG 
type II (CDG-II).1 These subtypes are owing to assembly defects in the endoplasmic 
reticulum and to processing defects in the golgi apparatus, respectively. More than 
50 CDGs are reported,2 including 17 types of CDG-I.3 one of the less frequent types 
is DPAGT1-CDG, (formerly CDG-1j, MIM # 608093), which is caused by mutations in 
the DPAGT1 gene.4 DPAGT1 encodes UDP-N-acetylglucosamine-dolichyl-phosphate 
N-acetylglucosaminephosphotransferase, the enzyme that catalyzes the first step 
in the dolichol-linked oligosaccharide pathway.5 So far, there are four reports in 
which the cause and the features of DPAGT1-CDG have been described. In 2003, 
Wu et al4 described a first patient with DPAGT1-CDG having a missense mutation, 
c.660A>G (p.Y170C) in combination with an unknown splicing defect. The patient 
presented with severe hypotonia, seizures, intellectual disability (ID), microcephaly 
and exotropia. Subsequently, Vuillaumier-Barrot reported two siblings who were 
compound heterozygous for a missense mutation, c.890A>T (p.I297F) and a splice 
site mutation, c.162-8G>A. The clinical presentation was not described.6 In 2011, 
Imtiaz et al7 described a third report belonging to a large Saudi Arabian family with 
homozygous missense mutation, c.902G>A (p.R301H). The patients presented with 
severe hypotonia, ID, seizures and microcephaly. The patients died in the early age. 
Recently, a fourth report has been illustrated by Wurde et al8, with a homozygous 
missense mutation, c.341C>G (p.A114G) in a consanguineous Turkish family. The 
patients presented with hyper excitability, seizures, bilateral cataract, progressive 
microcephaly and hypotonia. The patients died in early infancy.8 In this study, we 
report a non-consanguineous Pakistani family with two adult affected members 
showing a relatively mild phenotype consisting of moderate ID, epilepsy, hypotonia 
and speech problems. This family was classified as an ID disorder of unknown 
etiology. However, exome sequencing revealed a compound heterozygous mutation 
in DPAGT1. Transferrin isoelectric focusing (TfIEF) and high-resolution mass 
spectrometry supported the diagnosis of a CDG-I. 
MaTeRIaLS aND MeTHoDS
Patient material
A non-consanguineous family (PKMR13) with moderate ID was ascertained from 
the central part of the Punjab province, Pakistan (Figure 1a). Informed consents 
were obtained from all the participating subjects. This study was approved by the 
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Institutional Review Board (IRB) of the Centre of Excellence in Molecular Biology 
(CEMB), University of the Punjab, Lahore, Pakistan and the local ethics committee of 
the Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. DNA 
isolation was carried out by using standard protocols.9 
figure 1: Family structure and photographs of the patients. 
(a) Pedigree of PKMR13. Filled symbols indicate the affected individuals and single horizontal 
line indicate the marriage connection. The Diagonal line indicates deceased individual. (b) 
Photographs of two affected (III:3 and III:4) individuals presenting with moderate ID, epilepsy, 
hypotonia, speech problems, aggressiveness and atypical facial dysmorphism.
Genotyping and Copy number variation analysis
We have used two SNP microarray platforms (Illumina 6k array and Affymetrix 
250k array) for genotyping. We used three individuals (II:1, III:2 and III:3) to genotype 
on an Illumina 6k SNP array platform. To test for copy number variations (CNVs) and 
for possible homozygous regions, the DNA of one affected individual (III:4) was used 
to genotype by Affymetrix 250k SNP array. The Affymetrix Genotyping Console (v.2.0) 
and Illumina BeadStudio genotyping module software (Illumina, Inc., San Diego, CA) 
were used to generate the genotype calls. Given the high rate of consanguineous 
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unions in Pakistan we searched for regions of homozygosity of at least 1Mb by visual 
inspection. To investigate copy number variations, the Affymetrix 250k SNP array 
data were analyzed by using Copy Number Analyzer for GeneChip (CNAG).10
Next generation sequencing
DNA of patient III:4 was used for exome sequencing. Next generation sequencing 
(NGS) and analysis was carried out as described before.11 In brief, exome enrichment 
was performed using the SureSelect Human All Exon 50 Mb Kit (Agilent, Santa Clara, 
CA), covering ~21,000 genes. The enriched exome library was equimolarly pooled 
in a set of four samples, including three other unrelated samples. The pool was on 
the basis of a combined library concentration of 1 pM. Subsequently, the obtained 
pool was used for emulsion PCR and bead preparation, using the EZbead system, 
following manufacturer’s instructions (Life Technologies, Carlsbad, CA). For each 
pool of four exome libraries, a full sequencing slide was used on a SoLiD 4 System, 
thereby anticipating that all four samples would be represented as a quarter of the 
total beads sequenced (Life Technologies). 
We obtained 5.34 Gb of sequence that could be mapped to the human hg19 
reference genome using Bioscope software version 1.3 (Life Technologies). This 
resulted in a median coverage of 63-fold, with 87% of targets covered at least 10-
fold. A total of 12,590 variants were detected in the coding regions and canonical 
splice sites. We then applied a prioritization scheme similar, as described earlier in 
order to identify the pathogenic mutation.12 To this end, we excluded variants known 
in dbSNPv132 as well as variants from our in-house database. The latter consisted of 
369 exome samples from healthy individuals and patients with other rare diseases. 
This analysis reduced the number of candidate DNA variants to 410.
on the basis of expectation of a recessive inheritance model, we further prioritized 
these variants and identified 49 candidate genes; 31 with potential homozygous 
variants (determined by >80% variant reads), and 18 genes with compound 
heterozygous variants (determined by >20% variant reads). Variants predicting 
synonymous changes were filtered out. The remaining variants were evaluated by 
inspecting the raw read alignment files (Binary Sequence Alignment/Map format 
(BAM files)) to verify the presence and the minimal percentage (20%) of the variant 
reads. All these filtering steps revealed eight variants, including four homozygous 
variants, as well as four compound heterozygous variants.
Sanger  sequencing
All the potential variants were analyzed by Sanger sequencing. Primers for the 
amplification of exons carrying a DNA variant were designed by using the Primer3 
program (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www. cgi).13 The primers 
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were designed to amplify the 300-650bp DNA segments encompassing the 
respective mutations. PCR amplification was carried out on 40ng of genomic DNA 
with Taq DNA polymerase (Invitrogen, Carlsbad, CA). PCR amplicons were purified by 
using NucleoFast 96 PCR plates (Clontech Lab, Mountain View, CA), according to the 
manufacturer’s protocol. Sequence analysis was performed with the ABI PRISM Big 
Dye Terminator Cycle Sequencing V3.1 Ready Reaction Kit and the ABI PRISM 3730 
DNA Analyzer (Applera Corp, Foster City, CA). 
Biochemical assays for analysis of transferrin N-glycosylation
TfIEF in serum of patient III:3 was carried out as described.14 For high-resolution 
mass spectrometry of transferrin, a 5 µl serum sample was incubated with anti-
transferrin beads as described.15 The eluate was analyzed on a microfluidic 6540 LC-
chip-QToF instrument (Agilent Technologies) using a C8 protein chip. Data analysis 
was performed using Agilent Mass Hunter Qualitative Analysis Software B.04.00. The 
Agilent BioConfirm Software was used to deconvolute the charge distribution raw 
data to reconstructed mass data.
ReSuLTS
Family PKMR13 was ascertained as an autosomal recessive ID family. There were 
two affected adults (III:3 and III:4) in this family, who are currently 34 and 32 years of 
age (Figure 1a). Both affected individuals were normal at birth, following an uneventful 
pregnancy and delivery. They started saying first word at the age of 1.5-2 years. They 
started walking at the age of 1.5 year. Affected individuals III:3 and III:4 showed normal 
development and behavior till the age of 5 and 2 years, respectively. Individual III:3 
developed epileptic seizures and showed aggressive behavior and hypotonia at the 
age of 5 years. Patient III:4 developed epileptic seizures, aggressive behavior and 
hypotonia at the age of 2 and a half years, 6 months after recovery from measles 
and typhoid. This infection appears to be irrelevant for the phenotype of patient 
III.4, given the fact that an identical phenotype was observed in patient III.3, who 
never had measles or typhoid. Abnormal behavior was also noted by the physician, 
who diagnosed mental illness for both affected members and prescribed medication 
for epilepsy. No records of previous medication or investigations were found at the 
time of sample collection in 2008. Presently, the affected siblings show mild atypical 
facial dysmorphism (Figure 1b) aggressive behavior, hypotonia and epilepsy. They 
also have very poor speech and presented a moderate ID. Head circumference of 
both patients was normal. Additionally, patient III:3 had night blindness (Table 1). 
The phenotypic features of affected individuals are not progressive. 
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 figure 2: Structure and location of the DPAGT1 gene on chromosome 11q23.3. 
The position of the two missense mutations, c.85A>T and c.503T>C is indicated in exons 1 
and 4, respectively. Chromatograms revealing the complete segregation of both variations 
(shaded) with the phenotype in PKMR13.
Genome wide genotyping and CNV analysis was performed by using two different 
SNP array platforms (6k Illumina and 250k Affymetrix). Genotyping by using Illumina 
6k SNP array analysis was carried to perform homozygosity mapping. Whereas, 
Affymetrix 250k SNP array was performed to allow the detection of CNVs. As the 
resolution of Illumina 6k array was not high enough to use it for CNV calling. No 
pathogenic CNVs were detected in this family. SNP genotyping revealed two shared 
small homozygous regions on chromosomes 19p12 (1.7Mb) and 21q21.3 (4.1Mb). 
No massive homozygous regions were detected, which is in-line with the fact that 
parents were not related.
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To investigate the genetic cause in this family we conducted an exome sequencing 
approach. The exome of patient III:4 was sequenced using the 50 Mb SureSelect 
human exome kit (Agilent Technologies), targeting 96.47% of all genes from the NCBI 
RNA reference collection. The variants were filtered out according to the recessive 
mode of inheritance (for details, see materials and methods section).
Table 1 Clinical and Phenotypic features of affected individuals of PKMR13
Patient ID III:3 III:4
Gender F M
Age 34 32
IDa level Moderateb Moderateb
Speech Not understandable Not understandable
Eye abnormality Night blindness No
Epilepsy Yes Yes
Hypotonic Yes Yes
Gait Balance problem Balance problem
Behavioral problems Aggressive Aggressive 
Weight (kg) 62 90
Height (inches) 63 71
Head circumference (cm) 53.5 56.5
Abbreviations: F, female; M, male.
aIntellectual disability.
bModerate intelligence quotient (IQ 35-49).
The filtering steps resulted in four potential homozygous variants affecting the 
genes; HRNR, C4ORF37, WDR41, TMCC3, and four potential compound heterozygous 
variants in the genes; PLXNA4, PKHD1L1, DPAGT1, and CKAP2 (Table 2). None of 
the private variants was identified within two homozygous regions determined by 
homozygosity mapping. Sanger sequencing was used to confirm the exome results 
and mode of segregation of these variants within the family. As shown by conventional 
Sanger sequencing, none but one of the variants segregated with the disease 
phenotype according to an autosomal recessive model of inheritance. The exception 
was a compound heterozygous change in DPAGT1, which is located at chromosome 
11q23.3 (Figure 2). Both affected individuals were compound heterozygous for two 
missense changes of DPAGT1, c.503T>C (p.L168P) on the maternal allele and c.85A>T 
(p.I29F), which seemed to be derived from the deceased father (Figure 2). These 
mutations were highly conserved as indicated by a high phyloP score (conservation 
score) of 4.9 and 4.8 (Table 2) and the conservation of the amino acids at positions 
p.Ile29 and p.Leu168 down to the Fruitfly (Figure 3b). We used three bioinformatics 
based prediction programs such as Polymorphism Phenotyping2 (polyPhen2),16 Sorting 
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Intolerant from Tolerant (SIFT),17 and SNPs&Go,18 to predict the possible causative 
nature of the identified mutations. The variant c.503T>C was predicted to be likely 
damaging/deleterious by all three prediction programs, and the variant c.85A>T was 
predicted to be likely damaging by SIFT and SNPs&Go, while benign by polyPhen2. 
DPAGT1 encodes a transmembrane protein with 10 transmembrane domains.4 The 
substituted amino acids are located in the first and fifth transmembrane domains, 
respectively (Figure 3a), of which the p.L168P mutation introduces a potent helix 
breaker that will disrupt the helical confirmation of the respective transmembrane 
domain.19 We have screened 240 ethnically-matched chromosomes for the change 
c.85A>T and 274 chromosomes for the change c.503T>C. None of the under study 
mutations was found in the control chromosomes. Both mutations were not present 
in dbSNPv135, 1000 genomes data set, and in the Exome Variant Server, NHLBI 
Exome Sequencing Project (ESP), Seattle, WA (http://evs.gs.washington.edu/EVS/). 
figure 3: Schematic representation of DPAGT1 protein and location of the mutations. 
(a) The white circles indicate hydrophilic residues, whereas gray circles indicate the hydrophobic 
residues of the protein. The mutations found in this study are indicated by red circles (p.I29F and 
p.L168P), located in the first and fifth transmembrane domains of the protein respectively. The 
mutations that are already described in literature are shown by purple circles. (b) Positions of 
the amino acid substitutions I29F and L168P (indicated by pink bar), which are highly conserved 
down to the Fruitfly, predicting the disruptive effect on the normal function of the protein.
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Table 2 Candidate genes identified by exome sequencing
Chromosome Gene cDNA postion Amino acid position phyloPa
Homozygous variants
1 HRNR 1805C>A S602Y 1.6
4 C4orf37 1274G>A R425H 2.3
5 WDR41 862_864del H288del -
12 TMCC3 268G>A D90N 4.5
Compound heterozygous variants
7 PLXNA4 1415G>A G472E -1.3
4040G>A R1347H 3.7
8 PKHD1L1 7437C>A H2479Q 0.4
8282G>A G2761E 5.7
11 DPAGT1 85A>T I29F 4.8
503T>C L168P 4.9
13 CKAP2 565A>G N188D 1.7
1767A>C L588F -2.3
Abbreviations: cDNA, complementary DNA.
aConservation score.
DPAGT1 is involved in protein N-glycosylation in the endoplasmic reticulum 
and initiates dolichol-PP-glycan synthesis by formation of GlcNAc-PP-dolichol 
from dolichol-P. Defects in dolichol-PP-glycan synthesis lead to the CDG type I, 
characterized by the lack of complete glycan chains on otherwise N-glycosylated 
proteins. Isoelectric focusing (IEF) of serum transferrin, patient III:3 showed a 
very mild CDG type I profile with a slight increase of asialo- and disialotransferrin 
as compared to the control (Figure 4a). To confirm the loss of complete N-glycan 
chains, high-resolution analysis of immunopurified transferrin was carried out on a 
LC-C8-chip-QToF mass spectrometer. After deconvolution of the m/z spectra, peaks 
were observed with masses 75144.17 and 77351.62 Da, indicating non-glycosylated 
and mono-glycosylated transferrin, respectively. Semiquantitative analysis resulted 
in ratios of 0.0143 and 0.0991 for the a-/di-oligosaccharide ratio and the mono-/
di-oligosaccharide ratio respectively. Reference ranges were determined from the 
analysis of 56 controls, which resulted in ranges of 0.000137- 0.0104 for the a-/
di-oligosaccharide ratio and 0.00535- 0.0270 for the mono-/di-oligosaccharide 
ratio (manuscript in preparation). This clearly shows the loss of complete N-glycan 
chains (Figure 4b), confirming the CDG-I diagnosis. In view of the lack of fibroblasts 
for subsequent enzymatic confirmation, we searched the exome sequencing data 
using a CDG-I gene script as we carried out before in CDG-I genes identification.20 No 
other genomic variants were identified, further confirming the link between DPAGT1 
mutations and loss of complete N-glycans in these two patients. 
111
NoVEL MUTATIoNS IN KNoWN AUToSoMAL RECESSIVE INTELLECTUAL DISABILITY GENES | 
figure 4: Glycosylation analysis. 
(a) Transferrin isofocusing for CDG screening. Zero, 2, 4 indicate, respectively, the asialo-, 
disialo-, and tetrasialotransferrin isoforms. In patient III:3, an increase of asialo- and 
disialotransferrin is visible as compared to the control. (b) C8-chip-QToF mass spectrum of 
serum immunopurified transferrin. The gray bar indicates the transferrin protein.
DISCuSSIoN
We have ascertained an autosomal recessive family with two affected individuals 
presenting with moderate intellectual disability, epilepsy, hypotonia, speech 
problems, abnormal gait, aggressive behavior (Table 1), and mild dysmorphism 
because of compound heterozygous mutations in the DPAGT1 gene. The causative 
nature of these mutations was supported by following: 1) The absence of these 
variants in a large number of control alleles analyzed in our own center or available 
in public genetic databases. 2) Both mutations p.I29F and p.L168P are predicted to 
be likely pathogenic and affect highly conserved amino acids in a transmembrane 
domains of DPAGT1; 3) Analysis of transferrin N-glycosylation finally confirmed the 
loss of complete glycan chains, the evidence for a CDG-I type glycosylation defect.
DPAGT1 encodes UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosamine-
phosphotransferase, the enzyme which is involved in the initial steps of dolichol-linked 
oligosaccharide biosynthesis. Homozygous deletion of DPAGT1 in mice was shown 
to be embryonic lethal, most probably because of the widespread cell death.21 The 
mechanism(s) by which hypoglycosylation causes ID and dysmorphism is not known. 
Most recently, the DPAGT1 gene has been described as a target of Wnt/β-catenin 
signaling pathway, which have multiple vital and crucial roles in development.22 This 
pathway might explain the brain structural anomalies which can arise during the 
morphogenetic process of the brain development.
DPAGT1-CDG is a relative rare CDG-I subtype with only three clinically described 
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cases.4,7,8 Previously described patients showed a severe phenotype consisting of 
ID, seizures, severe hypotonia and microcephaly. The brain structural abnormalities 
are described in three patients showing delayed myelination and global atrophy.4,7,8 
However, in comparison to the reported cases, our patients presented with relatively 
mild clinical features. The affected individuals in this study are the first examples of 
an adult presentation with a DPAGT1 defect. For the most frequent CDG-I subtype, 
PMM2-CDG (formerly CDG-Ia), several adolescent patients have been reported 
presenting with cerebellar hypoplasia.23,24 In addition, DPM3-CDG has been reported 
in a 27-year old female with muscle dystrophy and dilated cardiomyopathy,25 while 
DoLK-CDG has recently been associated with nonsyndromic dilated cardiomyopathy 
in patients between 5-18 years of age.26 Moreover, TUSC3-CDG and MAGT1-CDG 
are implicated in non-syndromic ID patients, with the age range of 25-62 years.27 It 
can be anticipated that other CDG-I subtypes will be associated with mild/moderate 
phenotypes as well and that mutations in CDG-I genes might be more common than 
thought until now.
Given the rapidly increasing power of sequencing capacity, it is expected that 
large-scale sequencing protocols such as exome sequencing and whole genome 
sequencing, will be implemented in genetic diagnostic testing within the next years. 
These high-throughput sequencing analyses typically reveal many DNA variants for 
which the clinical relevance is not evident, including variants in genes that are known 
to be involved in CDG subtypes. The expanding clinical spectrum for DPAGT1-CDG 
and other CDGs will necessitate functional analyses to establish the causative nature 
of such variants, especially in mild cases with only slightly abnormal screening results. 
Here, we have used highly sensitive and high-resolution mass spectrometry of serum 
transferrin for fast and specific confirmation of abnormal protein N-glycosylation. 
our study emphasizes to consider a congenital disorder of glycosylation in adult 
patients with ID. 
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aBSTRaCT
Bardet-Biedl Syndrome is a multisystem autosomal recessive disorder characterized 
by central obesity, polydactyly, hypogonadism, learning difficulties, rod-cone 
dystrophy and renal dysplasia. Bardet-Biedl Syndrome has a prevalence rate ranging 
from 1 in 100,000 to 1 in 160,000 births although there are communities where 
Bardet-Biedl Syndrome is found at a higher frequency due to consanguinity. We 
report here, a Pakistani consanguineous family with two affected sons with typical 
clinical features of Bardet-Biedl Syndrome, in addition to abnormal liver functioning 
and bilateral basal ganglia calcification, the latter feature being typical of Fahr’s 
disease. Homozygous regions obtained from SNP array depicted three known genes 
BBS10, BBS14 and BBS2. Bidirectional sequencing of all coding exons by traditional 
sequencing of all these three genes showed a homozygous deletion of 10 nucleotides 
(c.1958_1967del), in BBS10 in both affected brothers. The segregation analysis 
revealed that the parents, paternal grandfather, maternal grandmother and an 
unaffected sister were heterozygous for the deletion. Such a large deletion in BBS10 
has not been reported previously in any population and is likely to be contributing to 
the phenotype of Bardet-Biedl Syndrome in this family.
117
NoVEL MUTATIoNS IN KNoWN AUToSoMAL RECESSIVE INTELLECTUAL DISABILITY GENES | 
INTRoDuCTIoN
 Bardet-Biedl Syndrome (BBS [oMIM 209900]), is a rare genetically heterogeneous 
autosomal recessive developmental disorder characterized by primary features 
like retinitis pigmentosa, postaxial polydactyly, obesity, intellectual disability (ID), 
hypogonadism and renal dysfunctions. The secondary features may include hepatic 
fibrosis, language deficits, behavioral traits, facial dysmorphism, dental anomalies, 
developmental delay and cardiac abnormalities.1 BBS was first described in 1920 by 
Bardet and Biedl.2 The genetics of BBS are complex and there are a large number of 
variations in genotype and phenotype of the disease.3 BBS is a ciliopathy; therefore 
the mutated genes resulting in the disease are mostly involved in the synthesis of 
ciliary proteins.4 Many in vitro and in vivo studies of the BBS genes and their products 
have shown that BBS occurs due to the defects of the primary cilium and basal body 
functions, which cause aberration of both transport and paracrine signals such as 
planar cell polarity pathways.5 To date 17 genes have been identified to cause BBS 
including BBS1 (11q13),6 BBS2 (16q21),7,8 BBS3 (3p12-q13),9 BBS4 (15q22.3),9 BBS5 
(2q31),10 BBS6 (20p12),11 BBS7 (4q27),12 BBS8 (14q32.11),13 BBS9 (7p14),14 BBS10 
(12q21.2),15 BBS11 (9q33.1),16 BBS12 (4q27),17 BBS13 (17q23),18 BBS14 (12q21.3),19 
BBS15 (2p15),20 BBS16 (1q43)21 and BBS17 (LZTFL1) (3p21.31).22 Mutations in these 
genes have been shown to explain BBS in 70% of the families studied.18 Genome wide 
SNP array analysis is a powerful tool used in molecular diagnostic studies, which is 
helpful in resolving genetically heterogeneous and complex diseases such as BBS.23
 In the current study we report two affected brothers from a consanguineous 
Pakistani Punjabi family (MRQ19); both the brothers were homozygous for 
c.1958_1967del, which is a novel deletion in BBS10 that is likely to be causing the 
BBS pathology in this family.
MeTHoDS
Clinical studies
A consanguineous Pakistani family MRQ19 (Figure 1) presented with characteristic 
features of BBS to the Neurology Clinic of Shifa International Hospital, Islamabad. 
The family had two affected male siblings and one normal female sibling. 
 Approval for this study was granted by the Ethics Committee/Institutional Review 
Board of Shifa College of Medicine/Shifa International Hospital, Islamabad. Informed 
written consent was obtained from all the participating subjects. The proband (IV:1; 
Figure 1), is the eldest male child of first cousin Pakistani parents from Punjab; he was 
born at full term after an uneventful pregnancy. obesity and post axial polydactyly in 
both hands were noted at birth. 
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figure 1: Pedigree of MRQ19. 
Unfilled circles and squares represent unaffected females and males, respectively. Filled 
squares are affected males. M represents the mutant allele, + is for wild type allele. M/M is for 
homozygous mutant affected genotype and +/M is for carriers of the mutation.
His milestones were delayed, and he had myopia, learning disabilities, and he learned 
to walk at the age of 3 years and began to speak at 4½ years. At the time of the clinical 
examination his behavior was shy, introvert and he was anxious, at 15 years of age 
his face had a moon like appearance due to obesity, as his height was 156.02 cm (88th 
centile), and weight was 75 kg (3rd centile), but his pupillary distance was normal (58 
mm). At the time of the eye exam he had complaints of night blindness for several 
years, his pupillary distance was normal (58 mm), whereas his visual acuity was 6/60 
and he had CF < 1 m (counting finger vision). In addition, he had astigmatism and 
myopia. Funduscopy revealed pigmentary degeneration which confirmed retinitis 
pigmentosa. His brain CT (Computed tomography) scan showed no intracranial 
hemorrhage, mass effect or midline shift. However, benign vascular calcification was 
noted in the bilateral basal ganglia. Subtle non-specific tiny parenchyma calcification 
near the vertex was seen (Figure 2a, b and c); no other abnormal density was present 
in the brain parenchyma. There was neither an extra axial collection nor the sella 
and pineal region showed any abnormality, grey and white matter differentiation 
was well maintained but slight sclerosis and opacification of the right mastoid air 
cells was seen. Fullness was observed in nasopharynx but no osseous abnormality 
was noted. Enlarged adenoids were seen, while the X rays of both hands showed 
no fracture, dislocation, lytic or sclerotic lesion in the visualized bones. A bilateral 
supernumerary digit was observed having a small metacarpal, proximal and distal 
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phalanx (Figure 3), while the soft tissues were unremarkable. The metabolic screen 
and renal function tests showed normal range of different parameters. However, 
the liver enzymes were raised: Serum Glutamate Pyruvate Transaminase (SGPT), 
was 140 U/L, Serum Glutamic-oxaloacetic Transaminase (SGoT), was 66 U/L and 
Alkaline phosphatase was 369 U/L. The CBC (Complete Blood Count) and heart rate 
were unremarkable. In addition, the boy had hypogonadism with micropenis and 
undescended testis. The other affected sibling of the proband was also male; he was 
the third child of his parents, born after a normal pregnancy of 40 weeks. At the 
time of the clinical assessment he was 4 years old, he had night blindness and his 
vision was deteriorating gradually. He was also obese and had a small penis with 
undescended testis. He started speaking a few words and walking at the age of 4 
years, his detailed clinical data were not available. 
figure 2: CT images of the proband. 
(a) Non contrast CT image showing a diffuse symmetrical parenchymal calcification involving 
dentate nuclei. (b) Non contrast CT image showing dense calcification involving basal ganglia 
and thalamus. (c) Non contrast CT image showing calcification in the grey white matter 
interface of frontal lobe on both sides.
Molecular Studies
 Blood samples of the affected and healthy members of the family were collected in 
EDTA vacutainers (Becton Dickinson, Franklin Lakes, NJ). Genomic DNA was extracted 
from the blood using a standard phenol-chloroform extraction method.24 Genotyping 
of the affected members IV:1 and IV:3 was performed using the Affymetrix 250K 
(Santa Clara, CA) SNP microarray in order to perform homozygosity mapping  and 
obtain the copy number variation (CNV) data. The Affymetrix Genotyping Console 
(v.2.0), software was used to generate the genotype calls. 
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figure 3: X-ray of hands of proband. 
X-ray of both the hands showing postaxial polydactyly.
To investigate CNVs, 250K SNP array data were analyzed by using Affymetrix 
Copy Number Analyzer for Gene Chip (CNAG).25 The regions of homozygosity 
were determined by using the online homozygosity mapper software (www.
homozygositymapper.org). All three identified candidate genes were sequenced 
by using Sanger sequencing. The primers for the amplification of the entire coding 
regions and splice sites of BBS10 (Table 1), BBS14 and BBS2 (not shown) were 
designed using Primer3 software (http://frodo.wi.mit.edu/). After amplification the 
purified PCR products were sequenced with the help of dye-termination chemistry 
(Big Dye Terminator, ver. 3 on a 3730 DNA analyzer; Applied Biosystems, Foster 
City, CA), according to the manufacture’s protocol and the resulting sequences 
were analyzed using the SeqPilot software JSI (Sequence Pilot, JSI Medical Systems, 
Kippenheim, Germany).
ReSuLTS
 In order to identify the genetic defect in the under study family, genotyping was 
performed using 250K SNP array. No pathogenic CNVs were identified; however, 
homozygosity mapping revealed several homozygous regions including two regions 
on chromosome 12q21.31-12q21.2 (0.1-Mb), 12q21.2-12q22 (14-Mb) and one 
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on chromosome 16q21.1-16q21(14-Mb) encompassing known BBS genes, BBS10, 
BBS14 (CEP290) and BBS2, respectively. Using DNA sequencing, mutation analysis 
of the proband IV:1 was performed for BBS10, BBS14 and BBS2. Multiple regions of 
the former gene were amplified using the primers given in Table 1, while the latter 
two genes were amplified as a single fragment covering the entire gene. Mutation 
analysis of BBS10, BBS14 and BBS2 revealed a homozygous deletion of 10 nucleotides, 
c.1958_1967del (p.Ser653Ilefsx4), in exon 2 of BBS10 (NM_024685.3), which resulted 
in a substitution of serine by isoleucine due to the frame shift that also causes the 
creation of a premature termination codon after four illegitimate amino acids. 
Segregation analysis in the family showed that the identified mutation completely 
co-segregated with the phenotype, where the father (III:4), mother (III:5), grandfather 
(II:1), grandmother (II:3), and unaffected sister (IV:2) were all heterozygous for this 
mutation while both the affected brothers (IV:1, IV:3; Figure 4) were homozygous 
for the mutation; the DNA of the other family members was not available for carrier 
testing. No other mutation was found in BBS10, or in BBS2 or BBS14. 
figure 4: Sequencing chromatograms. 
(IV:1, IV:3) proband and affected brother carrying the homozygous deletion of 10 nucleotides 
in exon 2, (II:2, II:1) wild type homozygous paternal grandmother and heterozygous unaffected 
paternal grandfather, (III:5, III:4) heterozygous unaffected mother and father, (IV:2) unaffected 
heterozygous sister of proband.
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DISCuSSIoN
 BBS is a rare heterogeneous developmental disorder involving intellectual 
disability, for which to date 17 genes have been identified, in these genes many 
mutations have been reported, which are the cause of BBS.22 our study defines a 
novel pathogenic deletion mutation in BBS10, which will be helpful in delineating 
the causative BBS mutations. The phenotype in the current family is identical to that 
described previously,2,4 except that in addition to the classical features the proband 
had benign vascular calcification in bilateral basal ganglia, which is a characteristic 
feature of idiopathic basal ganglia calcification (Fahr disease; [oMIM 213600]), 
a rare dominant neurological disorder with characteristic deposits of calcium and 
resultant cellular apoptosis of the basal ganglia and cerebral cortex, regions of the 
brain which control movement.26,27 In addition to the neurological features in the 
proband the liver function was also aberrant with elevated levels of SGPT, SGoT and 
Alkaline phosphatase. To date 71 mutations (http://www.hgmd.cf.ac.uk) including 19 
deletions have been reported in the gene BBS10 (C12ORF58; [MIM 610148]). The 
10 nucleotide deletion in BBS10 in the current report in a Pakistani family is a novel 
mutation, which has not been reported previously.
Table 1 Primer sequences of BBS10 with their product sizes
Exon_Fragment F/R Primer sequence
Product 
size
01 F 5’-tgtaaaacgacggccagtttctgccttcgcgtacaac-3’ 535bp
01 R 5’-caggaaacagctatgaccgggacaagagctccacagag-3’
02_01 F 5’-tgtaaaacgacggccagttggttttaagatgtgggaagc-3’ 536bp
02_01 R 5’-caggaaacagctatgacccaaatacaccaatcccactttt-3’
02_02 R 5’-caggaaacagctatgaccgcgaaaaggcctgtggtg-3’ 635bp
02_02 F 5’-tgtaaaacgacggccagttgctaaagagagaacattgtgtagg-3’
02_03 F 5’-tgtaaaacgacggccagtttccacttctggatcagagttt-3’ 636bp
02_03 R 5’-caggaaacagctatgaccggcctttgtattgagccatt-3’
02_04 F 5’-tgtaaaacgacggccagtaccagtgcatggtctcattg-3’ 632bp
02_04 R 5’-caggaaacagctatgaccaaacacaaccagctggcata-3’
02_05 F 5’-tgtaaaacgacggccagtccaaacagttgaaacgctga-3’ 532bp
02_05 R 5’-caggaaacagctatgaccttccaaacctgtctgactgc-3’
02_06 F 5’-tgtaaaacgacggccagttgccatcaatcagaagaaacc-3’ 500bp
02_06 R 5’-caggaaacagctatgaccggtctggtgaccttagtgtgc-3’
F=forward primer, R=reverse primer, bp=base pair
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 BBS10 is a group II chaperonin protein belonging to the Homotrimeric Cation 
Channel (TRIC), family located within the basal body of the primary cilium of 
differentiating preadipocytes.5 It is the part of the BBS/CCT complex composed of 
MKKS, BBS10, BBS12, TCP1, CCT2, CCT3, CCT4, CCT5 and CCT8. Lack of BBS6, BBS10 
and BBS12 in cultured cells has been shown to be the cause of failure of the assembly 
of a functional BBSome, which is the primary cause of BBS in patients with mutations 
in these genes.5 In the current family MRQ19 the 10 nucleotides deletion in exon 2 
results in a frame shift, which causes a premature termination at the following fourth 
amino acid, which could result in a nonfunctional protein that would ultimately 
prevent the assembly of the proteins in the CCT/BBSome complex. The inhibition of 
BBSome assembly can be the cause of pathogenesis in the patients.
 As obesity is a cardinal feature of BBS, it has been shown that BBS10 protein is 
located within the basal body of the primary cilium and its inhibition of expression 
can impair ciliogenesis, which would ultimately lead towards an increase in 
phosphorylation of glycogen synthase kinase 3 pathway (GSK3) and induce the 
peroxisome proliferator-activated receptor, nuclear accumulation hence increasing 
adipogenesis, which would lead towards increased fat accumulation and ultimately 
towards obesity.28 As BBS10 protein dysfunction can impair a long cascade of 
reactions, we thus postulate that the mutation present in the family MRQ19 produces 
a truncated protein due to frame shift and the subsequent absence of the BBS10 
protein expression at the basal body of the primary cilium would activate the whole 
pathway of impaired and pathogenic adipogenesis.
 The mutation present in the family MRQ19 is predicted to lead to a loss of 
function of the BBS10 protein, by producing a truncated protein and/or nonsense-
mediated RNA decay. A similar disruptive effect is predicted for the Cys91fsX95 
mutation, which accounts for almost half of all BBS10 patients.29 In general, the 
phenotype in the family MRQ19 is similar to that of the previously reported BBS10 
cases, except for the bilateral calcification of the basal ganglia. Also in a Danish study, 
BBS10 truncating mutations were found to be associated with a severe phenotype, 
including polydactyly, hypogenitalism, retinitis pigmentosa and renal aberrations, but 
brain calcification was not reported in that study.30 Given the highly consanguineous 
structure of the family MRQ19, it is possible that the bilateral basal ganglia calcification 
is due to a homozygous mutation in an as yet unknown gene. Alternatively, basal 
ganglia calcification is a feature associated with reduced penetrance in BBS10. 
Pleiotropic effects and oligogenic inheritance are well known in BBS.31 Interestingly, 
experiments with zebra fish show that the simultaneous suppression of BBS10 
protein grossly exaggerated the expression of the phenotypes.17 Thus, we also 
consider the possibility that the severe brain phenotype in patients from the family 
124
| CHAPTER 4.3
MRQ19 could be due to genetic interaction with DNA variants at another (BBS) locus. 
This possibility is further alluded to by the consanguineous structure of the family as 
well as the observed homozygosity at the BBS2 and BBS14 loci.
CoNCLuSIoN
 In conclusion, we suggest a severe phenotype for BBS patients in family MRQ19, 
who are homozygous for c.1958_1967del (p.Ser653Ilefsx4), in BBS10. The findings 
may have implications for genetic counseling in BBS10 (p.Ser653Ilefsx4), with an 
early onset of retinal disease and calcification of the brain ganglia and lower renal 
pathology, which may imply a more favorable prognosis. The study also provides 
support for the establishment of a diagnostic molecular genetic testing in Pakistani 
BBS patients.
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aBSTRaCT
AnkyrinG, encoded by the ANK3 gene, is involved in neuronal development and 
signaling. It has previously been implicated in bipolar disorder and schizophrenia by 
association studies. Most recently, de novo missense mutations in this gene were 
identified in autistic patients. However, the causative nature of these mutations 
remained controversial. Here, we report inactivating mutations in the Ankyrin 3 
(ANK3) gene in patients with severe cognitive deficits. In a patient with a borderline 
intelligence, severe attention deficit hyperactivity disorder (ADHD), autism and 
sleeping problems, all isoforms of the ANK3 gene, were disrupted by a balanced 
translocation. Furthermore, in a consanguineous family with moderate intellectual 
disability (ID), an ADHD-like phenotype and behavioral problems, we identified 
a homozygous truncating frameshift mutation in the longest isoform of the same 
gene, which represents the first reported familial mutation in the ANK3 gene. The 
causality of ANK3 mutations in the two families and the role of the gene in cognitive 
function were supported by memory defects in a Drosophila knockdown model. Thus 
we demonstrated that ANK3 plays a role in intellectual functioning. In addition, our 
findings support the suggested association of ANK3 with various neuropsychiatric 
disorders and illustrate the genetic and molecular relation between a wide range of 
neurodevelopmental disorders.
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INTRoDuCTIoN
Intellectual disability (ID), defined by an IQ<70, is a cognitive disorder of major 
medical and socioeconomic importance. It is usually first diagnosed in infancy, 
childhood or adolescence and affects ~1-3% of the population worldwide.1 At least 
half of the cases appear to be genetic in origin.2,3 Causative Mendelian mutations have 
been identified in more than 400 genes.4 However, the majority of ID genes has yet to 
be uncovered and most patients are still undiagnosed due to this extensive genetic 
heterogeneity.5 ID can manifest as the only clinical feature, but is often accompanied 
by a wide range of symptoms. These additional characteristics can be helpful in 
guiding the clinical diagnosis of a specific disorder. Particular common co-morbidities 
include neurological and psychiatric features, such as epilepsy, Autism Spectrum 
Disorder (ASD), Attention Deficit Hyperactivity Disorder (ADHD) and other behavioral 
problems. For example, 40% of ID patients show features of ASD.6 Conversely, ID 
is seen in 50-85% of patients reported with ASD.6 ASD affecting 1 out of 150 live 
births is characterized by groups of symptoms and signs such as deficits in social 
interaction, communication difficulties and restricted stereotyped behavior.7 ADHD, 
with the core features of hyperactivity, inattention and impulsivity, is also frequently 
associated with ID. It is the most commonly diagnosed neuropsychiatric condition 
in children with a prevalence of 3-5% globally.8 Both ADHD and ASD show a high 
estimated heritability of 76%9 and 90%8, respectively. A well-known example of an 
ID disorder with autistic features and ADHD-like symptoms is the fragile X syndrome, 
the most common form of monogenic ID.10 
There is an increasing number of examples showing that the phenotypic overlaps 
between ID and other mental disorders is reflected by overlaps between the 
molecular underpinnings of these conditions. First, recent studies in twins suggest 
that common genetic factors underlie this co-morbidity.11 Secondly, Copy Number 
Variations (CNV) and Genome Wide Association Studies (GWAS) have suggested 
chromosomal regions implicated in autism that are also susceptibility sites for 
ADHD.12-14 Finally, mutations and polymorphisms in several genes have been shown 
to cause variable neurodevelopmental and neuropsychiatric phenotypes, such as ID, 
schizophrenia, ASD and other neurological disorders.14-16 
Here, we report on the characterization of a balanced translocation leading to 
heterozygous disruption of the AnkyrinG gene (ANK3 [MIM 600465]) in a patient 
with a cognitive deficit, ADHD and ASD. In an independent study, we identified a 
homozygous frameshift mutation in the same gene in a family with autosomal 
recessive ID, hypotonia, spasticity and sleep disturbances. ANK3 has already been 
implicated in a number of mental disorders such as bipolar disorder, schizophrenia, 
and autism but so far remained to be controversially discussed.17-24 our data reveal 
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the first familial case of ANK3 and suggest that variants in ANK3 can lead to various 
cognitive/psychiatric phenotypes. Finally, we use a Drosophila model to provide 
further experimental support for the role of ANK3 in short-term memory, a core 
domain of cognition that is commonly affected in ID,25 autism26 and ADHD.27
ReSuLTS
Disruption of the ANK3 gene by a balanced translocation
In a patient referred to the genetic diagnostic department upon indication of 
behavioral problems including ADHD, ASD and cognitive problems, we identified 
a balanced translocation involving chromosome 2 and 10, using conventional 
karyotyping. Cognitive testing revealed a disharmonic cognitive profile with a verbal 
IQ of 67 and a performance IQ of 97 (see Materials and Methods for a detailed 
clinical description). After refining the translocation breakpoints to 2q11.2 and 
10q21.2 using fluorescent in situ hybridization (FISH) and chromosome painting 
(Figure 1a), CNV analysis was performed to exclude submicroscopic imbalances at 
the translocation breakpoints or elsewhere in the genome. At a practical resolution 
of 75 kb, no imbalances at the translocation breakpoints were detected using CNV-
WebStore.28 No further pathogenic CNVs were found on genome-wide analysis. 
Specific amplicons were designed spanning the breakpoints on the flow sorted 
derivate chromosomes der(2) and der(10). These amplicons were sequenced and 
mapped against the human genome reference sequence to positions 95,427,597 and 
61,875,979 on chromosome 2 and 10, respectively (Figure 1b). 
Detailed sequence analysis showed an overlap of four nucleotides (ACCC) at 
the breakpoint between both translocation partners, which was only retained on 
der(2). In addition, a loss of five nucleotides (AATGG) from the reference sequence 
of chromosome 2 was detected (Figure 1c). The combination of micro-homology 
with small insertions and deletions is characteristic of non-homologous end 
joining (NHEJ) following a double-stranded break.29 Both breakpoints were located 
within annotated transcripts. on chromosome 2, ankyrin repeat domain 20 family 
member 8P (ANKRD20A8P) is disrupted in its second to last intron. ANKRD20A8P is 
a pseudogene. The translocation breakpoint on chromosome 10 mapped to intron 
30 of NM_020987.3 of the ANK3 gene and interrupts all ANK3 transcript variants 
(Figure 2d).
Expression of the disrupted transcripts and other genes near the breakpoints was 
investigated using real-time PCR (RT-PCR) on RNA extracted from three independent 
lymphoblastoid cell cultures of the patient and eight cultures from healthy controls 
(Figure 3). Two probes were designed for ANK3, located proximal and distal to the 
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breakpoint. To exclude the position effect on genes previously associated with 
cognitive disorders, we included early growth response 2 (EGR2 [MIM 129010]) and 
jumonji domain-containing protein 1C (JMJD1C [MIM 604503]) located, respectively, 
at 2.7 and 2.8 Mb from the breakpoint on chromosome 10.30,31 Both ANK3 probes 
detected significant underexpression of the gene (Mann-Whitney U, P < 0.001), 
whereas expression of the neighboring genes was unaffected (P>0.05). Four randomly 
sampled genes located at large distance on chromosome 2 (ATPase family, AAA 
domain containing 2B (ATAD2B)), NDC80 kinetochore complex component, homolog 
(SPC25) and chromosome10 (pitrilysin metallopeptidase 1 (PITRM1)), suppressor of 
clear, c. elegans, homolog of (SHOC2 [MIM 602775]) did not show altered expression 
levels, suggesting no global consequences on gene expression. No expression of 
ANKRD20A8P was detected in the lymphoblasts of healthy controls or the patient. 
This clearly indicates absence of an ANK3-ANKRD20A8P fusion transcript from der(2) 
in the patient lymphoblasts. 
figure 1: Molecular analysis of the balanced translocation. 
(a) Chromosome painting results confirm location of chromosome 2 (green) centromere to 
be located on derivate chromosome 2, with the attachment of q21-q26 of chromosome 10 
(yellow). (b) Genomic context of translocation breakpoints (indicated by red boxes). Top: 
chromosome 2 breakpoint disrupts the ANKRD20A8P transcript. Bottom: chromosome 10 
breakpoint disrupts all transcript variants of ANK3. (c) 2: Breakpoint sequences. Red: Sequence 
present on derivate chromosome 2. Green: Sequence present on derivate chromosome 10. 
Box: 4 nucleotide overlap in sequence between both chromosomes. Strikethrough: Sequence 
missing from both derivates. Possible recombination paths are indicated by dashed lines.
Identification of a homozygous ANK3 frameshift mutation
A Pakistani family, PKMR14 (Figure 2a and b), was included from a parallel study 
on autosomal recessive ID upon identification of a homozygous truncating variant in 
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ANK3, shared by three affected siblings from consanguineous parents. The affected 
siblings presented with moderate ID, hypotonia, spasticity and severe behavioral 
problems. Homozygosity mapping and CNV analysis were performed using SNP arrays 
(for details see Materials and Methods section). No pathogenic CNVs were detected. 
Homozygosity mapping revealed a single homozygous region that was shared 
amongst the affected individuals of this family. This 20.4 Mb homozygous stretch 
is located on chromosome 10q21.1-22.1; chr10:52,930,315-73,381,926 (hg19) 
and encompasses > 80 genes (Figure 2c). Subsequently, whole-exome sequencing 
was conducted for patient V:1. Stringent filtering resulted in 23 homozygous and 6 
compound heterozygous possibly pathogenic variants (Supplementary Table 1), out 
of which only a single homozygous variant was located in the identified homozygous 
region on 10q21.1-22.1 shared by the affected family members. The segregation of 
the homozygous variant was confirmed by Sanger sequencing (Figure 2a).
figure 2: Identification of a homozygous frame shift mutation in a Pakistani family, PKMR14.
(a) Pedigree structure of consanguineous Pakistani family PKMR14. Filled symbols indicate the 
affected members and the double horizontal lines demonstrate the consanguineous marriage. 
Chromatograms showing a complete segregation of g:61829644/c.10995del variant with 
phenotype are shown (b) Photographs of patients V:1,V:2 and V:3, presenting no obvious 
features of facial dysmorphism. (c) Schematic representation of the 10q21.1-22.1 region that 
is homozygous in all three affected members (V:1,V:2,V:3) of family. The shared homozygous 
region among all three affected members was of 20.4Mb (chr10: 52,930,315-73,381,926), which 
is indicated with blue lines. The genome assembly UCSC hg19 was used for the coordinates in 
the genetic map. (d) Ank3 protein structure with Ankyrin repeats domain (grey color), spectrin 
binding domain (yellow color), a serine rich domain (green color) and death domain (Violet 
color). The position of the homozygous frame shift mutation is indicated as p.Thr3666LeufsX2. 
The position of the balanced translocation is indicated by the flash symbol.
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Furthermore, it was not detected in 268 ethnically matched chromosomes, dbSNP 
(135v), 200 Danish exomes,32 the 1000 genomes data set33 and the Exome Sequencing 
Project (ESP, Seattle, WA (http://evs.gs.washington.edu/EVS/).This single base pair 
deletion (c.10995delC) results in a frame shift and leads to a premature stop codon 
in exon 42 of ANK3. Exon 42 is a large 7.8 kb exon which is unique to the largest 
isoform of ANK3 (NM_020987.3) (Figure 2d). The homozygous nucleotide deletion 
predicts a premature stop codon at position 3666 (p.Thr3666LeufsX2), which makes 
the mutant mRNA a target for nonsense mediated mRNA decay (NMD).34,35 Together, 
the genetic data indicate that the ANK3 mutation is causative for the phenotype in 
family PKMR14. No cell lines were available to confirm the NMD and other functional 
impact of this homozygous frame shift mutation. 
figure 3: Expression analysis. Results are presented as the relative expression in patient 
lymphoblast compared to healthy controls. Significant differences (P < 0.001) are indicated 
by (*).
Table 1 Clinical features of PKMR14 patients
Patient V:1 V:2 V:3
Age 25 Years 22 Years 18 Years
Gender F F M
ID level Moderate (IQ<50) Moderate (IQ<50) Moderate (IQ<50)
Speech delay + + +
Hypotonia + + +
Spasticity + + +
Hyperactivity + + +
Epilepsy - - +
Aggressiveness + + +
Sleeping disorder + + +
134
| CHAPTER 5
Disruption of the ANK3 homolog affects short-term memory in Drosophila
Common to ID, autism and ADHD are defects in cognitive processes such as 
memory. We therefore set out to provide independent indication for the role of 
ANK3 in cognition using an animal model. Drosophila is a powerful organism for 
research into the genetics of learning and memory and is an established model for 
cognitive disorders.36 The fly genome harbors two Ankyrin genes, Ank and Ank2. 
We studied Drosophila Ank2, the closest homolog of human ANK2 and ANK3. Like 
human ANK3, but different from human ANK2, fly Ank2 is expressed specifically in 
the nervous system37,38 and has recently been demonstrated to be crucial for synaptic 
organization.39,40 Since Ank2 mutants are lethal, we used inducible transgenic RNA 
interference (RNAi) to knockdown Ank2 in a tissue-specific manner and analyze the 
effects on behavior. Pan-neuronal knockdown using the promoter line UAS-dicer2; 
elav-Gal4 phenocopied the previously reported synaptic Ank2 mutant phenotype 
at the larval neuromuscular junction. Synapses were small, show less synaptic 
boutons and were characterized by absence of intrabouton space. Highly significant 
reduction in synapse area and length was found with P- values 4.1e-9 and 0.0025, 
respectively (Figure 4a), confirming efficiency of the RNAi line. Using the UAS-dicer2; 
247-Gal4 driver, we next ablated Ank2 in the mushroom bodies, the learning and 
memory center of the fly brain, and assessed learning and memory in the courtship 
conditioning paradigm. We found that these mutants have normal learning but a 
significant reduction (P < 0.05, 10,000 bootstrap replicates) in short-term memory 
(Figure 4b). This suggests that Ank2 knockdown flies are affected in a specific aspect 
of cognition and do not show global neurologic defects. To further support this 
conclusion, we quantitatively monitored Drosophila locomotion of individual flies 
over a period of several days. Both knockdown of Ank2 in the mushroom body and 
pan-neuronal knockdown did not affect locomotion, demonstrating that overall 
fitness of these knockdown conditions is not affected (Figure 4c). our results suggest 
that Drosophila Ank2 is crucial for memory function. 
DISCuSSIoN
ANK3 has previously been suggested to play a role in a number of psychiatric 
and cognitive disorders. Multiple independent GWAS strongly indicate that ANK3 
is associated with bipolar disorder.17-19,41 However, other studies failed to replicate 
these findings.21,22 In addition, SNPs in ANK3 have been associated with late-onset 
Alzheimer’s disease42 and schizophrenia.23,24 This was supported by a joint GWAS 
of the Bipolar Disorder and Schizophrenia working groups of the Psychiatric GWAS 
Consortium that showed genome-wide significant associations with bipolar disorder 
and schizophrenia for a SNP in the 5´ UTR region of ANK3 (rs10994359).43 
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figure 4: Analysis of synapse morphology, learning, memory and locomotion in Drosophila 
knockdown (RNAi) models of the Ank3 homologue, Ank2. 
(a) Synapse morphology at the larval Neuromuscular junction (NMJ), revealed by anti-DLG1 
labeling. Knockdown of Ank2 (Ank2 RNAi) using vdrc UAS-RNAi line 207238 and the pan-
neuronal driver elav-Gal4 phenocopies the reported mutant synapse phenotype. 18 NMJs of 
the Ank2 knockdown condition were compared to 384 NMJs from control lines. Representative 
images are shown. (b) Learning and memory in Ank2 mushroom-body specific knockdown flies 
versus their genetic background control in the courtship conditioning paradigm. Loss of Ank2 
causes a statistically significant reduction in courtship-based short-term memory. Error bars 
indicate S.E.M. of the average learning index from four individual testing days (P < 0.05, 10,000 
bootstrap replicates). (c) Activity profiling of mushroom body-specific and pan-neuronal Ank2 
knockdown models shows normal locomotion in both conditions. Average 30-min bin activity 
is calculated for 24-h with a 12-h light: dark cycle. Error bars indicate 95% confidence intervals.
Further studies indicated that the ANK3 risk variant for bipolar disorder has a 
significant impact on sustained attention.44,45 Sustained attention has been studied 
extensively in the context of both ASD and ADHD and is affected in both disorders.46,47 
Moreover, the ANK3 rs9804190 C allele was significantly associated with decreased 
ANK3 mRNA levels in the superior temporal gyrus of schizophrenia patients.48 Here, 
we show that inactivating mutations in the ANK3 gene result in a severe cognitive 
deficit. A heterozygous disruption of all isoforms of the ANK3 gene results in a 
cognitive deficit, sleeping problems, autism, severe ADHD and aggressive behaviour. 
The first reported familial ANK3 mutation, a homozygous frameshift mutation 
affecting the longest isoform of the same gene causes recessive ID, epilepsy, sleeping 
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disorder, hypotonia, spasticity, hyperactivity and aggressive behaviour. A causative 
role of ANK3 in several of these cognitive functions and features is further supported 
by decreased short-term memory performance in a Drosophila model. 
The AnkyrinG protein encoded by ANK3 is located mainly at the nodes of Ranvier 
and the axon initial segment (AIS), two sub-compartments of neurons responsible 
for action potential generation.49 AnkyrinG consists of four domains, a globular head 
domain containing membrane-binding ankyrin repeats, a spectrin cytoskeleton-
binding domain, a serine rich domain and an extended tail domain containing a 
death domain (Figure 2d). There are multiple isoforms of AnkyrinG, three of which 
are brain specific (190, 480 and 270 kDa). The 480 and 270 kDa isoforms harbor 
a unique large tail domain encoded by the exon 42 (for the 270 kDa only part of 
this exon), containing a serine rich O-GlcNAc glycosylated part necessary to restrict 
these two larger isoforms to the AIS and nodes of Ranvier.50 AnkyrinG is recruited 
together with voltage dependent Sodium channels at the nodes of Ranvier,51 where 
AnkyrinG stabilizes the Na+ channels by crosslinking them to the spectrin-actin 
cytoskeleton proteins, thus ensuring proper action potential propagation.52 The 
involvement of ankyrinG in the composition of the AIS also implies an involvement 
in action potential generation by ion channels located at the diffusion barrier. In 
addition, it was shown that AnkyrinG is required to maintain the axo-dendritic cell 
polarity.53 Cerebellar depletion of the 270/480 kDa ankyrinG isoforms leads to axonal 
protrusions that resemble dendritic spines, containing postsynaptic densities and 
typical postsynaptic proteins such as SHANK2 [MIM 603290]. These axonal spines 
were contacted by presynaptic glutamatergic boutons and lack typical ultrastructural 
features of AIS, such as cytoplasmic bundles of microtubules.53 Interestingly, the 
identified homozygous frameshift mutation is predicted to specifically affect the 
synthesis of the 270/480 kDa isoforms, which may similarly result in disruption 
of the axo-dendritic polarity in patients carrying this mutation. The breakpoint in 
the translocation carrier inactivates these isoforms as well as all other isoforms of 
AnkyrinG. Surprisingly, although only a single copy of the ANK3 gene is interrupted 
by the translocation, we measured a residual expression of this gene of only 25% in 
lymphoblastoid cell lines. This reduced expression might explain why the balanced 
translocation carrier is affected, whereas heterozygous mutation carriers appear to 
be unaffected. The significant reduction beyond the expected 50% may reflect the 
complex allele-specific regulation of ANK3 transcription, as demonstrated recently.54 
The complex transcriptional regulation may also account for the observations in a 
patient with a balanced translocation disrupting both forkhead box P1 (FOXP1 [MIM 
605515]) on chromosome 3p13 and ANK3 on chromosome 10q21.2.14 In this patient, 
ANK3 expression is unaffected by the translocation and the neurodevelopmental 
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abnormalities were postulated to be the result of the inactivation of the FOXP1 
gene. De novo chromosomal aberrations leading to reduced ANK3 expression have 
been associated previously with an ASD phenotype and/or ADHD-like problems 
and/or developmental delay55 (DECIPHER UPP001479 and AR256229, personal 
communication with Dr Vogel, Aarhus University Hospital). In addition, very recently 
Bi et al.56 reported two de novo ANK3 missense mutations in the same exon as our 
homozygous frameshift mutation in 4/47 ASD patients and one recurrent de novo 
missense mutation in exon 41.56 Finally, Sanders et al.57 also reported a de novo 
missense mutation in exon 42 of ANK3 in a patient with ASD.57
It thus appears that ANK3 mutations and polymorphisms are associated 
with a wide spectrum of mental disorders presenting a continuum of mild-to-
severe neuronal and cognitive manifestations. The severe end of this spectrum is 
represented by inactivating mutations affecting the neuronal isoforms of AnkyrinG. 
Several de novo missense mutations and structural variants have been associated 
with ASD so far. However, given the isolated occurrence of the respective patients it 
is not known whether these represent monogenic traits or whether these variants 
are contributory to the phenotype. Indeed, oligogenic inheritance is suspected in 
some cases because of the normal ANK3 expression in a patient with a translocation 
disrupting ANK3 and another established ID gene (FOXP1).14 Finally, at the least 
severe end of the spectrum are ANK3 polymorphisms which confer an increased risk 
to psychiatric conditions such as bipolar disorder, autism and dementia. Although 
these disorders are traditionally considered as distinct diseases, they share several 
behavioral and cognitive characteristics, together with a convergence on processes 
involving the development and regulation of neuronal signal transduction.58,59 Thus, 
our findings suggest that ID genes are excellent candidates for studying the etiology 
of genetically more complex disorders, for which the molecular underpinnings are 
usually poorly understood.
Mutations and variants in several other genes implicated in a comparably wide 
spectrum of mental disorders have been described.4 These included genes such as 
glutamate receptor, ionotropic, N-methyl-D-aspartate, subunit 2b (GRIN2B [MIM 
138252]), SHANK2, contactin-associated protein-like 2 (CNTNAP2 [MIM 604569]), 
neurexin 1 (NRXN1 [MIM 600565]), transcription factor 4 (TCF4 [MIM 602272]), 
euchromatic histone methyltransferase 1 (EHMT1 [MIM 607001]) and FOXP1.11,13,48-
58 An intriguing finding emerging from these studies is that clusters of affected 
genes involved in networks of neuronal motility, synaptic development and axonal 
guidance, and genes encoding transcription factors and epigenetic regulators are 
significantly enriched in these disorders.4,60,61 The ANK3 variants reported here fit well 
in this “common pathways” model, as AnkyrinG is implicated in several of the core 
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processes implicated in cognitive disorders, especially axonal guidance, transmission 
of nerve impulses and maintenance of cell polarity. Furthermore, the conditionally 
ablation of Drosophila Ank2 (the fly homolog of ANK3) recapitulated synaptic defects 
previously identified in Ank2 mutant condition, and allowed us to implicate this 
essential gene in short-term memory. Defects in short-term memory have been 
reported in ID (although many conditions are too severe to conduct quantitative 
tests) and ID models, but also in autism and ADHD.25-27 
We hypothesize that there will be many more genes for which genotype-
phenotype associations await discovery in mental disorders. Given that the first 
and most compelling evidence for a role of these genes in mental disorders was 
typically obtained by studying monogenic mutations in ID individuals with or 
without associated (neural) deficits, we believe that targeted analysis of ID genes in 
psychiatric disorders may reveal such genotype-phenotype associations. Moreover, 
in many cases such approach will immediately provide a biological correlate for a 
complex psychiatric disorder, which is often not the case in hypothesis-free GWAS. 
MaTeRIaLS aND MeTHoDS
Case report balanced translocation patient
The proband was the second child of a healthy mother and first child of the 
father. The parents are non-consanguineous. He was born prematurely at 32 weeks 
with a birth weight of 2 kg and length of 44cm (both on the 50th centile). There is no 
record of neonatal problems. Gross motor development was initially normal as he 
sat unsupported at 7 months and crawled at 8 months. He walked unsupported at 
the age of 18 months and cycled when he was 6 years. Language development was 
delayed and speech therapy was initiated when he was 2.5 years old. As from nursery 
class, behavioural problems were noted: he was constantly fidgety, hyperactive, 
attention-seeking and exhibited aggressive behaviour towards his classmates for 
no obvious reasons. At 5 years of age the diagnosis of ADHD was suspected and a 
year later formal cognitive testing by WPPSI-R showed borderline intelligence with a 
verbal IQ of 67, a performance IQ of 97 and a total IQ of 76. He was orientated into 
a special needs school and Ritalin treatment was initiated. on clinical examination 
at the age of 10 years, both weight and height were on the 25th centile and head 
circumference was on the 3rd centile. His facial appearance was somewhat peculiar 
as he had mild upslant of the palpebral fissures, a broad nose and flat philtrum. He 
had 2 sacral dimples and on abdomen and back several patches of depigmented skin 
were present as seen in vitiligo. Fragile X testing was negative.
 Extensive neuropsychological testing was performed at the age of 14 years. The 
ADI-R (Autism Diagnostic Interview- Revised) from mother and half-sister showed 
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scores above the cut-off for autism in the patient. Questioning on social interaction 
revealed that he was a loner and he did not have any friends. There was poor quality 
of social interaction and hardly any facial expression. Further assessment of his 
autism was obtained through an ADoS-G (Autism Diagnostic observation Schedule). 
Scores on communication and social interaction were well above the cut-off for 
autism. The score regarding repetitive behavior and imagination was on the cut-off. 
Additional evaluation of language fundamentals by a speech therapist revealed poor 
expressive and receptive language equivalent to that of a 6-year-old. 
 The mother reported an unusual sleep disturbance. The boy wakes up in the 
middle of the night, several times a week, gets dressed and starts his daily activities.
Ethics statement
The study was approved by the Institutional Review Board (IRB) of the Centre of 
Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore, Pakistan 
and the local ethics committee of the Radboud University Medical Centre, Nijmegen, 
The Netherlands.
Family report PKMR14
A consanguineous Pakistani family PKMR14 was ascertained from the southern 
part of Punjab, Pakistan. This family has three affected individuals: females V:1, 
V:2 and male V:3 (Figure 2a). At counseling they were 25, 22 and 18 years of age, 
respectively. The birth of all three affected individuals was uneventful. At the age of 
12, individual V:3 developed epilepsy with tonic clonic seizures of severe intensity. The 
two affected females V:1 and V:2 did not show epilepsy. All of the affected members 
faced sleep disturbances before 10 years of age. Individual V:3 was treated with 
sleeping pills for 5-7 years. Nowadays, all affected members sleep at normal times, 
but they regularly fall asleep during daytime. Unaffected individuals of the family did 
not show any sleeping disturbances. All patients are very aggressive, hyperactive and 
beat others when they are in anger. Grinding of teeth is common to them especially 
in aggressive outbursts. Breathing and heart beat patterns were found normal in the 
affected members. They presented with moderate ID (IQ level <50), hypotonia and 
spasticity (Table 1). Clinical evaluation did not reveal any dysmorphic features in the 
patients of this family (Figure 1b). Computed tomography (CT) scan of two affected 
individuals (V:2,V:3) was performed at Multan MRI center, Multan, Pakistan. The CT 
scan did not reveal any structural brain abnormalities. 
Chromosomal analysis and molecular characterization
Metaphase spreads were prepared from lymphocyte cultures using standard 
procedures. FISH analysis was performed as described before.62 Chromosomes 
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were flow sorted as described elsewhere.63 Sorted material was amplified using a 
REPLI-g mini kit following standard protocol (Qiagen, Hilden, Germany). PCR primers 
were designed using Primer3,64 and checked for unfavourable dimerization with 
UNAfold.64,65 PCRs were performed using Gotaq polymerase (Promega, Madison, WI) 
following standard protocol. Sequencing was performed as described below. 
Real-time PCR
mRNA expression was examined by an optimized three-step real-time 
quantitative PCR assay following the protocol described before.66,67 Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH [MIM 138400]), hypoxanthine guanine 
phosphoribosyltransferase 1 (HPRT [MIM 308000]) and tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase activation protein, zeta isoform (YWHAZ [MIM 
601288]) were selected as reference genes. qPCR primers were designed using 
an in-house automated pipeline (http://medgen.ua.ac.be/~gvandeweyer/index.
php?page=spanprimers), conforming to requirements of intron-spanning location, 
no SNP content, no dimer formation at the 3 ́ end of the primers, and low amplicon 
folding, with no folding in primer-binding sites. Primer sequences are available on 
request. 
Homozygosity mapping and CNV analysis
Homozygosity mapping in individuals IV:1, IV:2, V:1, V:3, V:4, V:5 and V6 of the 
PKMR14 family was performed by using the Illumina 6k SNP microarray platform.  one 
of the affected individuals (V:2) was genotyped on a higher resolution platform, an 
Affymetrix 250K SNP array, to investigate CNVs and also to confirm the homozygosity 
data. The resolution of Illumina 6k array is high enough to identify the large regions of 
homozygosity that are expected in consanguineous populations such as Pakistan.  For 
CNV analysis, the Affymetrix 250k SNP array data were analyzed using Copy Number 
Analyzer for GeneChip (CNAG).68 The Affymetrix Genotyping Console (version 2.0) 
and Illumina BeadStudio genotyping module software (Illumina, Inc, San Diego, CA) 
were used to generate the genotype calls. The regions of homozygosity of at least 
1 Mb were observed by visual inspection. CNV analysis for the translocation carrier 
was performed using the Illumina HumanCNV370-Duo BeadChip (Illumina Inc., San 
Diego, CA) according to standard protocol. The chip was scanned on the BeadStation 
and image data were normalized using BeadStudio (3.1.3.0) and Illumina’s genotyping 
module (v3.3.4). Copy number analysis was performed using CNV-WebStore at a 
practical resolution of 75kb.28 All data were mapped using Human Genome Build 
hg19.
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Whole-exome sequencing
Exome sequencing of patient V:1 was carried out by capturing the exome 
using the SureSelect Human All Exon 50Mb Kit (Agilent, Santa Clara, CA) followed 
by multiplexed analysis on a SoLiD 4 System sequencing slide (Life Technologies, 
Carlsbad, CA). Color space reads were mapped to the hg19 reference genome with the 
SoLiD BioScope version 1.3 software, which utilizes an iterative mapping approach. 
A total of 67% of bases (3.75Gb) came from the targeted exome, resulting in an 
average target coverage of 43-fold, and 73% of targeted exons were covered more 
than ten times. Single-nucleotide variants were subsequently called by the Di-Bayes 
algorithm with high call stringency. Called variants were combined and annotated 
with a custom analysis pipeline.69,70 A total of 19,554 variants were identified. of 
these, 9,427 variants were located in the exonic sequence or located in canonical 
splice sites, defined as the dinucleotides up and downstream of exonic sequence. 
For this exome, the transitions/transversions (Ti/Tv) ratio (genotype quality control 
parameter) of 2.64 was obtained. We then applied a filtering scheme excluding 
variants observed in dbSNP (v132) and in our in-house database, containing data on 
177 exomes (consisting of healthy individuals and patients from other rare disorders). 
This filtering step reduced the number of variants to a total of 548, of which 381 were 
predicted to lead to non-synonymous changes and/or altered transcripts. Assuming 
a recessive pattern of inheritance, 41 homozygous (with >70% variant reads) and 
seven compound heterozygous (20-80% variant reads) variants were retained. As a 
next filtering step based on the quality of the raw sequence reads we applied a Binary 
Sequence Alignment/Map format (BAM file) inspection to verify the presence and 
the minimal percentage (20% for heterozygous and 70% for homozygous variants) 
of the variant reads. As the number of variant reads in the automatically computed 
output file often contradict with the actual number of variant reads present in 
BAM files. This filtering step resulted in 23 possible homozygous and six compound 
heterozygous variants (Supplementary Table 1).
Sanger sequencing in PKMR14
Sanger sequencing was used to confirm the candidate variant identified on 
chromosome 10 at position 61829644 (hg19). Primers for the amplification of 
part of the DNA encompassing the candidate variant were designed by using 
the Primer3 program.64 A 454 bp fragment carrying the candidate mutation was 
amplified by using primers 5 ́- TAACCGAGGGGATGATGAAG- 3 ́ (forward) and 5 ́- 
ACTGGATGTGCCTTCCTGAC -3 ́ (reverse). PCR amplification was carried out on 50ng of 
genomic DNA with Taq DNA polymerase (Invitrogen, Carlsbad, CA). A Nucleofast 96 
PCR plate (Clontech Lab, Mountain View, CA) was used to purify the PCR amplicons, 
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according to the manufacturer’s protocol. Sequence analysis was performed with the 
ABI PRISM Big Dye Terminator Cycle Sequencing V3.1 ready Reaction Kit and the ABI 
PRISM 3730 DNA Analyzer (Applera Corp, Foster City, CA).
Drosophila stocks and breeding
Flies were raised on standard medium (cornmeal/sugar/yeast) at 25oC for the 
courtship conditioning paradigm, and at 28oC for evaluation of synapse morphology 
and activity monitoring. They were kept at 60% humidity on a 12 h light: dark 
cycle. RNA interference was induced in a tissue-specific manner with the UAS-GAL4 
system.71 The Ank2 RNAi line and its genetic background control were obtained from 
the Vienna Drosophila Research Center (vdrc stocks 107238 and 60100, respectively). 
The pan-neuronal driver w; UAS-dicer2; elav-Gal4 was assembled in-house using w; 
UAS-dicer2 (vdrc stock 60008) and w; elav-Gal4 stocks (Bloomington Drosophila stock 
center, Indiana University, stock 8760). The mushroom body specific driver w+,UAS-
dicer;247-Gal4 was a gift from K. Keleman (IMP Vienna).
Drosophila synapse morphology
Type 1b neuromuscular junctions (NMJs) at muscle 4 of w/Y; UAS-dicer2/UAS-
Ank2 RNAi; elav-Gal4/+ (UAS-Ank2 RNAi) and w/Y; UAS-dicer2; elav-Gal4/+ (control) 
male wandering L3 larvae were analyzed after dissection, a 30 min fixation in 3.7% 
PFA and immunolabeling with an anti-Discs large 1 antibody (supernatant, 1:25) 
(Developmental Studies Hybridoma Bank, University of Iowa). NMJ pictures were 
obtained using a Leica automated brightfield multi-color epifluorescent microscope. 
Images were automatically processed and measured by an advanced self-made 
ImageJ/Fiji macro.
Drosophila learning & memory
Courtship conditioning72 was performed as previously described73 using males 
of the genotypes w+,UAS-dicer/Y;247-Gal4/UAS-Ank2 RNAi;+/+ (UAS-Ank2 RNAi) 
and w+,UAS-dicer/Y;247-Gal4/+;+/+ (control). Males were collected at eclosion and 
kept in isolation until four days of age. They were then trained by pairing with a 
single premated female for 5 hours. After training, males were transferred to a 1 cm 
diameter chamber and filmed for 10 minutes in the presence of a new premated 
female, either immediately after training (learning) or after 1h (Short-term memory). 
Courtship behavior of male flies towards females was quantified using Actual FlyTrack 
software (Actual Analytics Ltd.). The mean Courtship Index (CI, the percentage of 
time spent on courtship during a 10 min interval) of trained males and of socially 
naïve males was used to calculate the Learning Index (LI), which is defined as the 
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percent reduction in mean courtship activity in trained males compared to naïve 
males; LI = (CI
naive
 − CItrained)/CInaive. For all conditions, we analyzed between 66 and 
137 male-female pairs over the course of seven days. For non-parametric statistical 
comparison of learning indexes between Ank2 knockdown and control flies, we used 
a custom SAS (SAS Institute Inc.) script to perform bootstrapping as described.74 
Briefly, CI values were randomly sampled with replacement to generate 10,000 
hypothetical LIs, which were used to determine the 95% confidence interval of the 
difference between LI(control) and LI(knockdown). This analysis revealed a significant 
difference between LI(control) and LI(knockdown) (P<0.05).
Drosophila activity monitoring
Locomotor activity of individual 3-5 day old male flies was recorded with the 
Drosophila Activity Monitor (DAM) system (Trikinetics, Waltham, MA). Activity of 
≥21 flies per genotype was recorded over 4 days on a 12-h light: dark cycle. The 
30-min bin activity measurements for individual flies were averaged into one day, 
after which the average activity of a genotype was calculated with 95% confidence 
intervals. Genotypes were as indicated in synapse morphology and learning and 
memory sections above.
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Supplementary Table 1 Candidate genes identified by exome sequencing
Chromosome Gene cDNA postion Amino acid position phyloPa
Homozygous variants
1 FLVCR1 1074G>C M358I 1.0
2 FAM161A 1959G>T E653D 0.4
3 CCDC54 58A>G N20D 1.3
3 MORC1 2717G>A C906Y 1.6
3 ATP6V1A 1637C>T A546V 4.6
3 PODXL2 1033C>T P345S 1.6
4 SCLT1 506T>C M169T 1.8
5 GFM2 1685T>A F562Y 1.6
6 ENPP1 2462G>A R821H 0.8
7 CYP3A4 92G>A G31E 0.2
7 TRIM56 1459C>T L487F 2.4
7 LAMB4 350G>C R117T 2.8
8 KCNU1 1736G>T R579M -0.03
10 DCLRE1C 1083G>C K361N -0.1
10 ANK3 10995delC T3666LX2 1.5
11 MRGPRX2 850T>C S284P -0.3
12 TAS2R43 599G>T C200F 0.08
12 TAS2R43 460C>G R154G 0.3
13 C13ORF18 1406C>T S469L 5.5
16 FLYWCH1 2077A>T T693S -0.2
17 GEMIN4 2081C>T P694L 3.9
17 AMAC1 361G>A A121T 0.7
18 SERPINB2 653G>C G218A 0.4
Compound heterozygous variants
2 NBEAL1 4876A>G I1626V 1.6
8009A>G K2670R 3.0
10 NOC3L 1670A>T H557L 4.7
1675G>C V559L 2.5
10 ZDHHC6 1150A>G I384V 0.9
1175G>C C392S 5.9
14 SYNE2 7010G>A C2337Y -0.7
9974C>T A3325V 1.8
15 TRPM1 1310G>T G437V 2.6
4435C>T R1479C 3.6
18 ALPK2 3583G>A V1195M -1.6
3749C>T P1250L 1.9
aConservation score.
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aBSTRaCT
The combination of homozygosity mapping and next generation sequencing (NGS) has 
proven to be a powerful technique to identify autosomal recessive genetic defects. 
In this study, we present three adult sisters with moderate to severe intellectual 
disability (ID) and neurologic-tremor. Metabolic screening, FMR1 testing and copy 
number variation (CNV) analysis could not explain the cause of the phenotype in 
this family. Homozygosity mapping revealed a single homozygous region of 12.8 
Mb on chromosome 1p21.1-p12. Subsequent exome sequencing revealed a single 
homozygous missense c.484G>A (Gly162Arg) mutation in the SLC6A17 gene, which 
mapped to the identified homozygous region. SLC6A17 is a synaptic vesicular 
transport protein, involved in the transport of four amino acids, proline, glycine, 
leucine and alanine. The identified variant affects a highly conserved and three 
different bioinformatics programs predicted this variant as “possible pathogenic”. 
3D modeling predicted that the introduction of the substitution of a large charged 
arginine for the small glycine at position 162 will change the conformation of the 
protein. our finding adds this gene to the rapidly expanding list of novel candidate 
genes for autosomal recessive intellectual disability.
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INTRoDuCTIoN
Intellectual disability (ID) is a neurodevelopmental disorder that has a great 
impact on the quality of life of affected individuals and their families.1,2 Despite its 
high prevalence of 2% in the population, so far only 60% of individuals with ID have 
a known etiology.3 The identification of causative gene mutations is complicated by 
the enormous genetic heterogeneity, which is observed for all types of inheritance 
(dominant, recessive and X-linked). In particular for non-specific types of ID, the 
identification of causative gene mutations has hampered by the lack of phenotypic 
features that may guide molecular analyses in diagnostics as well as in a research 
setting. To date, a handful of genes have been implicated in non-specific forms of 
autosomal recessive ID (ARID).4,5 only recently the combined application of SNP 
microarrays for homozygosity mapping and the advancement of next generation 
sequencing (NGS) technologies, has accelerated the elucidation of causative genes 
in ARID, mostly in consanguineous families and specific syndromes.6 In addition, 
NGS has proven to be very powerful to identify the genetic defects in small outbred 
families including non-syndromic ARID.7-9 
In this report, we studied a family with three affected siblings from apparently 
un-related parents. By using exome sequencing in combination with homozygosity 
mapping, we were able to identify a single private homozygous missense variant in 
the gene SLC6A17, which is predicted to be pathogenic. 
MaTeRIaLS aND MeTHoDS
Family ascertainment
Family W10-3099 with three affected females (II:4, II:5 and II:6) (Figure 1) was 
ascertained during a cohort study comprising over 250 individuals, both children and 
adults, with ID of unknown etiology. These individuals were selected from a large 
cohort of more than 2,000 individuals living in residential settings for people with 
intellectual disabilities in the eastern part of the Netherlands.10 All of them received 
a clinical genetic evaluation, including SNP array analysis, phenotype guided DNA 
analysis and a metabolic screen. Individuals with negative results were candidates 
for further NGS studies. The study was approved by the local ethics committee of the 
Radboud university medical centre, Nijmegen, the Netherlands. Informed consent 
was obtained from the parents or legal representatives of the participants. 
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figure 1: Pedigree of family W10-3099, photographs of patients and chromatograms revealing 
the complete segregation. 
Filled symbols indicate the affected individuals and the single horizontal line shows marriage. 
The diagonal line crossing symbols indicate the deceased individuals. The asterisks indicate the 
patients used for homozygosity mapping and CNV analysis, while an arrow shows an individual 
used for exome sequencing. Photographs of three affected individuals presented moderate 
to severe ID and neurologic tremor. Chromatograms reveal the complete segregation of the 
homozygous missense mutation with the phenotype in family W10-3099.
Homozygosity mapping and copy number variation analysis
To detect possible copy number variations (CNVs), Affymetrix 250k SNP array 
data was analyzed with the Copy Number Analyzer for GeneChip (v2.0)11 (Affymetrix, 
Santa Clara, CA). Genotype calls were generated with Affymetrix Genotyping Console 
(v2.1) software. The shared regions of homozygosity (RoH) were determined using 
PLINK (v1.06).12 In each window of 50 SNPs, up to five SNPs with a missing call and 
a maximum of two heterozygous called SNPs were allowed. We used a cut-off of 
1Mb for identifying shared RoH.13 The RoHs in additional cohort of >5000 idiopathic 
ID cases were determined by the same criteria as described above. We selected 
patients having RoHs ≥5 Mb in size only, encompassing SLC6A17. 
  
Next generation sequencing
 Exome enrichment was performed with the Aligentv2 XT, multiplex (BC7) 
enrichment kit (Agilent, Santa Clara, CA). Emulsion PCR and bead preparation was 
performed using the EZbead system, according to the manufacturer’s instructions 
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(Life Technologies, Carlsbad, CA). We used the SoLiDv4 platform (Life Technologies, 
Carlsbad, CA). A total 8.4 Gb sequence was obtained and mapped to the human hg19 
reference genome by using LifeScopev2.1 software (Life Technologies, Carlsbad, CA).
Sanger sequencing
 Primers for the amplification of exons and exon-intron boundaries were designed 
with the Primer3 program,14 for SLC6A17 (NM_001010898) gene as well as other 
identified rare variants in the respective genes. PCR products were purified using 
NucleoFast 96 PCR plate (Clontech Lab, Mountain View, CA), according to the 
manufacturer’s protocol. We used ABI PRISM Big Dye Terminator Cycle Sequencing 
V3.1 Ready Reaction Kit and the ABI PRISM 3730 DNA Analyzer (Applera Corp, Foster 
City, CA), to perform sequence analysis.
Molecular modeling
The 3D-structure of the SLC6A17 protein has not yet been solved experimentally. 
Therefore, we used the structure of the Leucine transporter (LeuT protein) as a 
template to build a homology model of the SLC6A17 protein. The LeuT structure can 
be found in PDB-file 3GWU.15 The PDB-file that was used as a modeling template 
contains a sequence of LeuT protein of Aquifex aeolicus VF5, which has a sequence 
identity of 24.4% with that of the SLC6A17 protein over a stretch of 447 residues. The 
(partial) model was built using the automatic modeling script in the YASARA16 and 
WHAT IF17 Twinset with standard parameters.18
ReSuLTS
Clinical description
Family W10-3099 was ascertained as an ARID family. This family has three 
affected females, II:4, II:5, and II:6 (Figure 1). Pregnancy and birth of three affected 
individuals were uncomplicated. In the neonatal period, they cried excessively. 
Psychomotor development was delayed from birth. The exact moment of these 
childhood milestones was not available as the patients II:4, II:5, and II:6 were seen at 
64, 62, and 60 years of age respectively, and no previous documentation was present. 
At adult age they had a moderately to severely impaired developmental level. Their 
behavior was characterized by mood instability, aggression and self mutilation. 
During adulthood they had developed a progressive essential tremor, presenting 
as an intentional tremor and slight tremor at rest. one of the affected sisters (II:5) 
had a renal anomaly, including a double renal pelvis with double ureter. They had a 
normal height (5th-20th centile) and normal head circumference (20th–50th centile). 
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Facial dysmorphisms included large ears, prominent chin, narrow palpebral fissures, 
long philtrum and a slightly high and narrow palate (Figure 1). In addition they had 
small hands (<3rd centile) (Table 1). They had a waddling walking pattern. Metabolic 
screening in serum and urine of individual II:6 and in serum of individual II:4 included 
quantification of amino acids, creatin biosynthesis, carnitines, very long chain fatty 
acids, transferrin subfractions, mucopolysaccharides, purines and pyrimidines, and 
organic acids. 
Table 1 Clinical features of individuals II:4, II:5 and II:6
Patients ID II:4 II:5 II:6
Age, years 64 62 60
Height, cm (percentile) 161 (<P10) 164 cm (P15) 165 (P20)
Head circumference, cm 
(percentile)
56 (>P50) 55.4 (P25) 54 (P20)
Intellectual disability Moderate-severe Moderate-severe Severe
Behaviour Inappropriate laughter, 
compulsive,
Mood instability
Mood instability Agressive, 
Compulsive,
Mood instability
Tremor Progressive Progressive Progressive
Hand length (percentile) P3 Small P3
other Congenital renal anomaly 
(double renal pelvis with 
double ureter);
Malignancies 
Hypothyrodism,
Malignancies
Genetic analysis
 Analysis of the FMR1 gene in individual II:4 did not reveal a positive diagnosis 
of Fragile X syndrome (FXS). CNV analysis did not reveal any pathogenic aberrations. 
We performed homozygosity mapping on individuals II:4, II:5 and II:6. A single 
shared RoH of 12.8Mb in size was identified on chromosome 1p21.1-p12 (Figure 
2), suggesting that parents of these sisters were distantly related. To identify the 
genetic defect in this family, we performed exome sequencing. Patient II:6 was used 
for exome sequencing. We obtained a median coverage of 103 fold, with 89% of 
targets covered at least ten-fold. A total of 14,986 variants were identified in coding 
regions and canonical splice sites. A prioritization was done as described before.19,20 
Variants that are known in dbSNPv134 and in our in-house database, consisting of 
672 samples from healthy individuals and patients with other rare disorders, were 
excluded. After applying this filter, the number of variants was reduced to 299. 
157
A NEW CANDIDATE GENE FoR AUToSoMAL RECESSIVE INTELLECTUAL DISABILITY | 
Further prioritization was performed on the basis of an autosomal recessive model of 
inheritance, resulting in 21 candidate genes; 18 with potential homozygous variants 
(>80% variant reads) and three with compound heterozygous variants (20-80% 
variant reads). All these variants were analyzed by inspecting the raw read alignment 
files [Binary Sequence alignment/Map format (BAM files)], in order to determine 
the presence and the minimal percentage (20%) of the variant reads, which reduced 
the number of candidate genes to ten with homozygous and two with compound 
heterozygous variants. We excluded two genes, TAS1R3 and MUC16 - because these 
are commonly found in the exome data to carry either homozygous or compound 
heterozygous variants. Another gene, CWH43 was excluded, as frequent (1.2%) 
truncating variant was identified in this gene in Exome Variant server (EVS), NHLBI 
Exome Sequencing Project (ESP), Seattle, WA (http://evs.gs.washington.edu/EVS/). 
After this, seven homozygous variants and one compound heterozygous variant were 
left over (Table 2). All the identified variants were tested with Sanger sequencing. None 
but a single homozygous variant c.484G>A, p.Gly162Arg (SLC6A17) segregated with 
the phenotype (Figure 1). This variant is located in the identified homozygous region 
on chromosome 1p21.1-p12 (Figure 2). It has a phyloP score of 6.3 (Table 2) and a 
Grantham score of 125. The glycine at position 162 was found to be highly conserved 
down to Zebrafish (Figure 3b). The uncharged glycine 162 that is replaced by a basic 
arginine residue, is located in the third transmembrane domain of the protein (Figure 
3a). We used three prediction programs - polyPhen2,21 SIFT,22 and SNPs&Go23 - to 
predict the nature of the identified missense variant. All three prediction programs 
classified c.484G>A as a “possibly damaging” variant. The missense mutation 
was absent from dbSNP (v137), 1000 genomes data, and in EVS. In order to find 
other possible homozygous mutations, we selected 18 unrelated ID patients (both 
consanguineous and non-consanguineous) having shared homozygosity of a region 
>5Mb encompassing SLC6A17. Sanger sequencing was performed in these patients to 
sequence all the exons and intron-exon boundaries of SLC6A17 gene. The sequencing 
analysis did not reveal any rare/pathogenic variants except few known SNPs (Data 
not shown). 
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figure 2: Location of the gene and the identified homozygous mutation. 
Ideogram of chromosome 11 showing the homozygous region of 12.8 Mb (indicated with 
a horizontal black line) on p21.1-p12 position, encompassing  SLC6A17 (red box). The 
homozygous mutation was found in exon 4 of the gene. Mutation visualization in IGV (1.5.61v) 
browser. Individual reads containing the mutation are displayed. Red reads indicate the forward 
direction, whereas blue reads indicate the coverage of the region in the reverse direction. The 
reads are mapped and displayed on the positive strand.
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figure 3: Schematic representation of SLC6A17 protein including the conservation and location 
of the amino acid change p.Gly162Arg (a and b).
Table 2 All private variants identified by exome sequencing
Chromosome Gene cDNA postion Amino acid position phyloPa
Homozygous variants
1 SLC6A17* 484G>A Gly162Arg 6.3
2 IGFBP5 283C>T His95Tyr 2.4
3 RSRC1 562C>G Gln188Glu 4.3
7 ZMIZ2 1592G>A Arg557His 5.5
10 ACSL5 1215C>G Ile1405Met 0.2
16 NPW 419G>T Arg140Leu 0.04
19 HNRNPUL1 2005C>A Gln669Lys 5.4
22 MYO18B IVS29-1 5.0
Compound heterozygous variants
9 NUP214 283A>G Ile95Val -0.04
NUP214 5420G>A Gly1807Glu 4.9
a conservation score-phyloP
*only segregated variant
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Molecular modeling
To collect further evidence for the causality of the mutation, three dimensional 
(3D) protein structure prediction analysis was performed. In our model, residue 
Gly162 is located in an alpha-helix that also contains residues that form the substrate 
binding site (Figure 4b). Gly162 is not in contact with the substrate but instead 
is located on the opposite side of the helix and covered by helix 4. Glycine is the 
smallest residue type, having no side chain at all. The mutation converts this residue 
into an arginine, which is a large hydrophilic amino acid. It is likely that this side chain 
will not fit at position 162 and that it will clash with Leucine 231 located on helix 4 
(Figure 4a, b and c). Mutation Gly162Arg will therefore affect the protein structure 
and as a result interfere with the fate and the function of the protein.
figure 4: Molecular modeling. 
(a) overview structure of the SLC6A17 protein. The magenta color indicates wild type residue, 
Gly 162 and yellow balls indicate substrate. Grey cylindrical shapes show alpha helices; (b) 
close-up of the wild type residue (magenta); (c) close-up of the mutated residue (green and 
red) which clashes with helix 4 at position Leu 231.
DISCuSSIoN
In this study, we have identified a novel gene, SLC6A17, which is likely responsible 
for ARID and tremor. Polyphen2, SIFT and SNPs&Go predicted “damaging” effects of 
the identified missense mutation on the protein function. Moreover, 3D modeling 
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revealed that this amino acid substitution likely results in a conformational change of 
the protein influencing the normal SLC6A17 function. 
SLC6 family genes encode structurally related Na+-dependent transporter 
proteins. They are responsible for the re-uptake of many neurotransmitters.24 
SLC6A17 encodes a vesicular transporter protein, also known as XT1/NTT4.25 This 
protein is exclusively localized in the nervous system, specifically in glutamatergic and 
some GABAergic neurons.26,27 SLC6A17 functions as a selective transporter of four 
amino acids, proline, glycine, leucine and alanine.28,29 Proline has a role in producing 
electrophysiological actions in the brain.30,31 Moreover, it has been demonstrated that 
physiologically increased levels of L-proline are localized in a plethora of neurons,32 
but further studies to get more insights are required to understand the specific role of 
proline in synaptic transmission.28 Glycine acts both as an inhibitory neurotransmitter 
and as an activator of ionotropic glutamate N-methyl-D-aspartate (NMDA) receptors. 
NMDA receptors are distributed all over the brain and wire different functions such 
as synaptic plasticity, and development of learning and memory. NMDA receptors 
activation require glycine as well as glutamate. It is known that fluctuation in the 
extracellular concentration of glycine can alter the functions of NMDA receptors. 
Several independent studies have shown that such NMDA alterations are involved 
in neurodevelopmental and neuropsychiatric disorders such as cognitive impairment 
and schizophrenia.33,34 The role of leucine and alanine in synaptic transmission is 
not known.28 Interestingly, another gene from the same Na+-dependent transporter 
family, the creatine transporter, SLC6A8 has been already implicated in a syndrome 
(oMIM 300352), with ID as a main feature.35 It is proposed that dysfunction of the 
inhibitory neurotransmitters, GABA and glycine, plays a role in the development of 
essential tremor.36-38 The impairment of GABAergic system is also involved in FXS and 
Fragile X associated tremor/ataxia syndrome (FXTAS).39 
In conclusion, we have identified a novel candidate gene, SLC6A17 associated with 
ARID. Further studies need to be performed to likely assign SLC6A17 an established 
ARID gene. At the moment, we have initiated in vitro and in vivo studies to prove the 
pathogenicity of the missense mutation in this gene.
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Consanguinity - focus on Pakistan
 Consanguineous marriage is defined as the union of two individuals having a 
common ancestor.1 It is estimated that worldwide 10.4% of marriages occur among 
relatives,2 but this percentage is much higher in Arab and central Asian countries. 
Consanguineous marriages are an important determinant of autosomal recessive 
diseases.3 Pakistan belongs to the group of countries where the rate of consanguinity 
is very high (>60%) with 17-38% first cousin marriages.4,5 Consanguinity is one of 
the main causes of infant mortality and intellectual disability (ID) in Pakistan.6 There 
are several factors that directly or indirectly play a role in the still increasing rate of 
consanguinity in Pakistan. Religious, demographic and social factors influence the 
prevalence of blood marriages.1,7 People tend to follow a number of social values. 
They prefer to get married within the same religion or even within the same sect of 
the religion (for example Sunni, Shia, Wahabi), within the same cast or sub-cast (for 
example Syed (Bukhari, Gilani etc), Rajpoot (Rana, Bhatti etc), Jutt (Cheema, Warraich 
etc)), within province or district, with a person speaking the same language. In the 
Punjab province, people also prefer a partner whose grandparents came from the 
same district or the village of India at the time of partition in 1947. Status and welfare 
are also important factors (Figure 1). Such economic factors seem to be the strongest 
binding force, as families want to keep the wealth within the circle of relatives. In 
addition, they also preserve familial wealth by saving large dowries for brides to be 
paid to non-relatives. Therefore, large age differences between spouses are observed 
frequently in the society. The level of complexity of the Pakistani community is also 
seen among the Pakistanis who have migrated to other countries. In August 2010, a 
television program (“Pakistanis inbreeding themselves to death” on British television, 
presented by T. Ahmad, a Britain news reporter) revealed that a third of all children 
born with genetic diseases in Britain belong to the Pakistani community,8 whereas 
Pakistanis constitute only about 1.5% of the total British population.9 Moreover, 
genetic counseling in this population is also found to be more difficult as compared 
to other ethnic communities for reasons of guilt and shame. Therefore, those who 
are at risk of being mutation carriers will remain uninformed by such psychosocial 
behavior,10 leading to continuous transmission of pathogenic alleles. There is 
an urgent need to increase the general awareness about the adverse effects of 
consanguinity in societies where blood marriages are very common. To achieve this, 
the Pakistani community should be informed about the positive effects of genetic 
analyses. Along these lines, a decline in the frequency of consanguineous marriages 
has been observed in some Arab countries such as Jordan11 and Lebanon.12 This was 
achieved by elevating the levels of female education, urbanization, industrialization 
and improved economic status of the families, much alike the transitions seen in 
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Western countries in the 19th and 20th centuries.13 These examples provide a clear 
roadmap to develop strategies in order to address the issues of increasing rate of 
consanguinity in Pakistan and other countries that have a high consanguinity rate. 
figure1: Schematic diagram indicating different factors contributing to a high consanguinity 
rate in Pakistan.
Challenges for clinical evaluation in developing countries
A better healthcare system does not only directly help the patients with common 
medical issues, but can also address issues of diagnosis and therapeutic options related 
to genetic disorders. In under-developed and developing countries including Pakistan, 
proper diagnosis of various genetic disorders is lacking. There are several reasons 
for this. First, other medical problems related to contagious/infectious diseases and 
malnutrition are more important and thus get most of the attention. Secondly, there 
is no link between hospitals/medical doctors with research institutes. Thirdly, there is 
no education system which can either train doctors in the field of genetics, or genetics 
researchers in the field of clinical evaluation. Finally, there is a lack of interest, funds 
and policies at the government level.
Metabolic disorders which are mostly autosomal recessive, account for a small 
percentage of occurrences of ID.14 Some of these metabolic ID disorders are treatable 
upon early detection.15 The burden of treatable metabolic disorders has been 
reduced in Western countries like, the Netherlands, Germany, France, and the United 
Kingdom, by implementation of national neonatal screening programs. Such programs 
are targeted at the early detection of relatively frequent metabolic and genetic 
disorders including primary congenital hypothyroidism. once an individual at risk is 
identified in the neonatal screening process, therapeutic interventions and disease 
management processes are initiated, and genetic counseling will become available to 
the corresponding families.
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During the course of this study we ascertained one family, PKMR07, and enrolled 
it as a non-syndromic autosomal recessive ID (ARID) family. No obvious clinical 
features were observed that suggested a recognizable clinical entity. However, upon 
homozygosity mapping and targeted NGS, we identified a homozygous deletion 
of several exons of the TPO gene (Chapter 4.1). Mutations in the TPO gene have 
been implicated in congenital hypothyroidism, a frequent cause of ID if not treated 
in childhood. Retrospective biochemical analysis revealed a positive diagnosis 
of hypothyroidism in patients of the family. If there would have been a neonatal 
screening program in Pakistan, the ID phenotype would have not developed in the 
patients of this family.16 Though our finding will not reverse the cognitive dysfunction 
in these patients, therapy at this stage still helps to normalize secondary problems 
by restoring the general body homeostasis. In addition, the family can benefit from 
adequate genetic counseling. 
In consanguineous populations geneticists are often confronted with large and 
complex pedigrees, involving multiple intra-familial unions and affected individuals 
in multiple sibships. In families with highly specific and recognizable clinical features, 
a conclusive clinical diagnosis might be made based on the presence of uniform 
characteristics. However, in the absence of additional features besides the ID, or when 
such features are subtle and/or variable it might happen that different independent 
etiologies are segregating within a single large family. Indeed, we found genetic 
evidence for two different etiologies occurring in separate sibships within a single ID 
family. In each of the sibships a homozygous mutation was identified in a different gene 
that had been linked to ID previously (Unpublished data). Thus, there is a continuous 
need for detailed clinical evaluation of all affected individuals in single families.
Pakistan is lacking a good system for gynecological practice and neonatal care. 
It is estimated that perinatal mortality ranges from 50-90/1000 total births in 
Pakistan.17 Intrapartal still-births and birth asphyxia are the main causes of perinatal 
mortality.18 Asphyxia at birth causes hypoxic ischemic encephalopathy (HIE), 15-20% 
of children with HIE die in very early neonatal life, while 25-30% surviving children 
exhibit irreversible neurodevelopmental anomalies including ID, cerebral palsy and 
microcephaly.19 The babies who need resuscitation should be provided on time with 
proper management to regulate oxygen supply, which is not the case in most of 
the hospitals in rural and urban areas of Pakistan. Related to this, there is a serious 
challenge with the recording of the clinical history and the childhood milestones 
during the process of family collection. There is a risk that children with birth-related 
problems are enrolled together with genetically affected sibs. The genetic cause in 
such a family will then remain unsolved unless this matter is sorted out, enabling a 
distinction between genetically and non-genetically affected individuals.
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Different ID conditions - extensive clinical and genetic investigations needed
There is a thin line of demarcation between syndromic ID (sID) and non-
syndromic ID (nsID). A detailed comparative examination of patients with a similar 
genetic basis is required to define the boundary between sID and nsID, which is 
often not possible due to poor diagnostic facilities or the lack of multiple patients 
with the similar etiology.20,21 The problem of limited numbers of patients with the 
same mutation precludes the recognition of consistent or regular features associated 
with the condition. For example, Fragile X syndrome (FXS) was initially considered 
as non-syndromic but is now considered as the most frequent genetic form of sID.22 
Likewise, OPHN1 defects were initially associated with nsID but comparative clinical 
examination of multiple patients carrying OPHN1 mutations revealed consistent 
associated features such as ataxia, epilepsy, and cerebellar hypoplasia.23,24 Clinical 
variability is another problem. This can be relatively limited in effect, leading to 
different levels of severity of symptoms or penetrance, but can also be severe and 
manifesting as clinically distinct disorders caused by allelic mutations in the same 
gene.25 For example, mutations in ARX can cause ten different types of clinically 
distinct forms of ID, depending on the mutation type and subsequent protein 
function.26 
PQBP1 was found mutated in the original family with Renpenning syndrome, 
but mutations in the same gene are also identified in other previously described 
syndromes such as Sutherland-Hahn syndrome.27-29 originally, mutations in SCN2A 
have been implicated in early-onset infantile epileptic encephalopathy, but recently 
mutations in the same gene have been identified that were associated with severe 
ID without the occurrence of severe seizures.30 In our study, we ascertained one 
family, PKMR13 as an idiopathic non-syndromic autosomal recessive ID family. Using 
exome sequencing, we were able to identify a compound heterozygous mutation in 
DPAGT1, which is a known cause of DPAGT1-Congenetial Disorder of Glycosylation 
(DPAGT1-CDG). Retrospective biochemical analysis revealed a mild glycosylation 
defect, which was associated with a relative mild phenotype with moderate ID in 
comparison to previously reported cases of DPAGT1-CDG (Chapter 4.2).31 It is likely 
that due to the advancement in the sequencing techniques and identification of 
more genetic defects in multiple patients, the borders of the phenotypic spectra of 
most of the existing clinical entities will become even more blurred or/and several 
new/overlapping phenotypic compositions will be recognized and documented.
at the crossroads of neurodevelopmental and neuropsychiatric disorders
There is growing evidence that different DNA variants in the same gene can 
give rise to a variety of different neurodevelopmental and psychiatric disorders.21 
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While ID may present as the sole clinical feature, it often co-occurs with one or 
more other cognitive disorders (CD) such as autism, autism spectrum disorder (ASD) 
and Attention-Deficit-Hyperactivity-Disorder (ADHD).21 ID is present in 50-70%32 
patients defined with an autism spectrum disorder: autism, pervasive developmental 
disorder not otherwise specified (PDD-NoS), childhood disintegrative disorder, and 
Rett syndrome.33 Vice versa, 40% of ID patients show autistic features34 and also, 
ASD and ADHD often co-occur in the same patients.35,36 These observations suggest 
that the same genes can affect a multitude of cognitive abilities and disabilities, 
which is known as the “Generalist gene” hypothesis coined by Robert Plomin.37 
Indeed, recent genetic studies have revealed that mutations in one gene can give 
rise to a wide variety of different CDs. For example, mutations in TCF4 and EHMT1 
are identified in ID patients with and without ASD features and in patients with 
isolated ASD or  schizophrenia (SCZ).38 Mutations in NRXN1 and CNTNAP2 can give 
rise to ID, ASD, ADHD, SCZ, and Tourette syndrome as well as combination of these 
neurological features.39 Many other proteins have been shown to be implicated in 
various CD conditions, either occurring in isolations or in different combinations of 
CD phenotypes.21 We identified inactivating mutations in a novel candidate gene 
for CD, ANK3, giving rise to a phenotype of ID, ASD and ADHD in two independent 
families (Chapter 5 and Figure 2). our results extend the body of evidence that these 
connections indeed point towards common molecular pathways underlying various 
neurological disorders. These common pathways may provide targets for the design 
of therapeutic strategies that may be applicable to a wide range of neurological 
disorders. 
figure 2: Genes that are commonly disrupted in autism spectrum disorder/neurodevelopmental 
disorders including ID (pink circle), neuropsychiatric disorders including schizophrenia (blue 
circle), and genomic disorders including ID (grey circle). The genes that are discussed above are 
encircled red. Note that EHMT1 is the only gene to be associated with all disease categories. 
This figure is adapted from Talkowski et al, 2012.38
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Next generation sequencing (NGS) - benefits and challenges
The increasing capacity and rapidly decreasing costs of next generation sequencing 
(NGS) has accelerated the identification of novel mutations underlying genetic 
disorders representing all the modes of inheritance. Due to ongoing technological 
advances, the benefits of NGS are increasing. NGS has provided the opportunity to 
use this technique as whole-genome sequencing (WGS) (costs <5000$/sample) or 
whole-exome sequencing/exome sequencing (costs <500$/sample).
Benefits
Currently, exome sequencing is the standard technique used to elucidate the 
molecular basis of (heterogeneous) monogenic disorders. The enriched exomes 
cover nearly all the protein-coding genes, which constitute ~1.5% of the genome.40 
About 85% of Mendelian disease causing mutations are located within the protein-
coding regions.41,42 Exome sequencing became popular because of the cheaper costs, 
improvements in the bioinformatics tools, relatively easy interpretation of the data 
and less time consumption on the experiments as compared to WGS. 
The combination of the classical mapping techniques with targeted NGS has 
been powerful for finding autosomal recessive defects.43,44 We have also successfully 
used this strategy and identified plausible candidate genes in five out of ten families 
(Chapter 3). However, there are also disadvantages to such targeted NGS strategies 
as compound heterozygous and homozygous mutations in small homozygous regions 
(<1Mb) are not taken into account. The relevance of this omission is exemplified by 
the finding of a pathogenic compound heterozygous mutation in DPAGT1 in one of 
our families, PKMR13 (Chapter 4.2).31
Recent significant decrease in the costs of exome sequencing, development and 
refinement in bioinformatics based tools, made exome sequencing the preferred 
“all-in-one” technique that is able to reveal homozygosity regions, CNVs, and 
pathogenic variants. As a proof-of-principle, in 2011 Pippucci et al.,45 developed 
a strategy, denoted EX-HoM (Exome HoMozygosity). They studied two affected 
siblings born to first-cousin parents for a recessive disease. They directly used 
two affected siblings for exome sequencing, and sequencing data revealed several 
homozygous regions (>1Mb), accounting for 290Mb in total. The causative gene 
search in these homozygous regions identified only three candidate variants, among 
which a FA2H mutation was the most plausible one. To overcome the problems of 
genetic heterogeneity and the need of large pedigrees, the EX-HoM (combining 
homozygosity mapping and sequencing) can be a single-step approach to identify 
genetic defects. Recently, Seelow et al.46 offered a new module integrated in the 
HomozygosityMapper program (http://www.homozygositymapper.org/), in which 
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the raw NGS data can be uploaded to identify regions of homozygosity. The analysis of 
NGS data by such programs obviates the prior performance of costly SNP genotyping. 
In short, SNP-based homozygosity mapping will become obsolete and it will be more 
efficient and cost-effective to use available family members for exome sequencing. 
NGS can also be used for the identification of CNVs. This can be achieved 
by comparison of the read depth of the captured exons of a patient with control 
samples. By searching a loss of read depth coverage, we identified a homozygous 
intragenic deletion of several exons of a known gene for ID (Chapter 4.1). Several 
statistical methods, such as coNIFER47 and cn.MoPS48 have been developed to detect 
CNVs using NGS data. 
Exome sequencing has been used to identify dominant de novo mutations in 
sporadic moderate-severely affected ID cases.49,50 Moreover, this technique has 
facilitated the identification of recessive gene mutations in large consanguineous 
families (This thesis) as well as in small outbred families.51 In fact, the identification 
of recessive mutations in outbred families appears to be highly efficient as usually 
less homozygous variants need to be confirmed and validated by Sanger sequencing, 
which may out-weight the disadvantage of small family size. Besides whole-exome 
or whole-genome analyses, NGS techniques can also be used to target specific sets 
of genes that are known to underlie specific groups of disorders, such as ataxia and 
hereditary blindness, or groups of genes selected based on their biological function. 
For example, Hamdan et al. sequenced 197 synaptic related genes in 95 sporadic nsID 
cases and identified pathogenic variations in ~11% of the nsID cases.52 A company, 
called “Ambry Genetics” (http://ambrygen.com/tests/xlid-next-gen-panel-formally-
known-xlmr), developed a panel to resequence >81 XLID genes. As most of the genes 
for XLID are already known, this type of sequencing platform would be excellently 
cost effective to screen all the families with XLID compatible pattern of inheritance.
Challenges
There are several ethical issues related to the implementation of the exome or 
WGS into prenatal and postnatal diagnostics. There is an ongoing debate within 
genetics societies and in the general community about the fact that NGS may reveal 
unsolicited information that is not relevant for the disorder under investigation. The 
question is which information should be reported back to the patients/families? What 
should be contained and why? What about co-incidental findings pertaining to risk for 
future health issues of the patient as well as family members? An extra complication 
in the case of ID is that the patients are unable to make any decisions themselves 
because of the cognitive deficits, so their parents or legal representatives have to 
decide whether they want to know about any un-enquired relevant genetic findings. 
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In any case, appropriate operation protocols and informed consent addressing 
such issues should be in place prior to commencing with a NGS project. Given the 
challenges regarding privacy and protection of the medical records, it is highly 
warranted that clinical geneticists and other stakeholders make a comprehensive 
roadmap to address all these issues for implementation of such robust genome-wide 
techniques in a diagnostic setting.
In addition to these ethical challenges, there are also technological challenges 
that need to be solved. Current enrichment protocols for exome sequencing only 
take into account the coding parts of the largest isoform of a gene. Consequently, 
non-coding parts of genes and exons that are expressed in a restricted tissue-specific 
pattern might be missed, and thus might pose consequences for proper diagnosis 
for a certain disease. Hopefully these issues will be addressed by the introduction of 
third generation sequencing techniques, as described in detail in Chapter 1.
Application of NGS for detection of recessive mutations in consanguineous 
families from inbred populations can result in multiple variants that map to large 
homozygous regions shared by the affected individuals of the respective families. 
This was not an issue in the past, when the classical mapping and subsequent Sanger 
sequencing of a selected number of candidate genes was performed. Also in the 
present project we identified several families in which mutations affecting multiple 
genes segregated with the phenotype (Chapter 3). 
What makes a DNa change, a pathogenic variant?
 The identification of multiple disease-associated variants complicates the 
assignment of the truly causative mutation for the phenotype under investigation. 
Also during my project, multiple DNA variants were identified segregating with 
the phenotype in single families. Similarly, proof of causality is also needed when 
targeted NGS or exome sequencing reveals only a single segregating variant in a 
family. In general, there are three non-exclusive strategies to determine which of 
such variants is causative:
(i) Recurrent genetic findings
The identification of recurrent variants- mutations in the same gene in different 
individuals- is considered to be the most powerful evidence to assign the possible 
pathogenic role of dysfunction of a certain gene. For this, cohorts containing patients 
either with nsID or with similar sID phenotypes have to be screened. In Nijmegen, 
clinical data of a large cohort of >5000 patients with hitherto unexplained ID has 
been collected. During this study, we have screened groups of patients selected 
from this cohort on the basis of overlapping homozygosity or/and phenotype to 
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identify independent mutations in plausible candidate genes (Chapters 3, 5 and 6). 
Unfortunately, we did not identify any additional variants in those screenings. As 
ARID is an extremely heterogeneous group of disorders,44 it will be essential to extend 
the screening to even larger groups of patients of different ethnic backgrounds. To 
that end, as a partner of the GENCoDYS consortium (http://www.gencodys.eu/), 
we are sharing our novel data with other groups who are carrying out comparable 
genetic investigations. Extension of such collaborations with groups Worldwide could 
be a rich source to be used to find recurrences. In addition, the development and 
continuous curation of DNA variant databases analogous to publically available CNV 
databases such as DECIPHER and ECARUCA53,54 is in progress and should promote the 
identification of matching gene mutations in patients with an overlapping phenotype.
While such large scale genotype-phenotype databases are still under development, 
it is obvious that the identification of additional mutations in a single gene is most 
easy when the associated phenotype is recognizable and pronounced, as was the 
case in our proof-of-concept study on the identification of mutations in SH3PXD2B 
in Frank-Ter Haar syndrome (Chapter 2). For undefined ID phenotypes there is still a 
long way to go as exemplified by the results of exome sequencing in 44 ARID families 
(Chapter 3) from our cohort. Preliminary data of 31/44 families analyzed so far, 
revealed novel mutations in known ARID genes in nine families, single segregating 
mutations in plausible novel ARID genes in eight families. The remaining 14 families 
either had multiple genes segregating with phenotype in the family, or nothing was 
conclusive after the analysis of all the identified variants (Unpublished data). only 
screening of large numbers of patients with overlapping phenotypes and/or disease 
loci overlapping the candidate genes will enable to identify recurrent mutations and 
thus allow to assigning new ID genes. 
(i) Cellular modeling (In vitro studies)
In vitro studies might also be helpful in supporting the pathogenic role of the 
identified variant. A wide variety of biological assays can be used, either in patient-
derived cells or in transfected cell approaches. An example of a supportive biochemical 
analysis is provided in chapter 4.2, in which we showed that compound heterozygous 
mutations in DPAGT1 led to reduced glycosylation of transferrin in serum of affected 
individuals, supporting the mild DPAGT1-CDG phenotype in the corresponding family. 
For studying causality of ID candidate genes, electrophysiological studies using 
transfected rodent primary neuronal cell lines appear to be particularly powerful 
- In this approach, neuronal cells are transfected either with a cDNA construct 
carrying either the mutant or wildtype allele of the gene of interest. Subsequently, 
neuronal cells will be patched to measure spontaneous synaptic activity or activity 
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under various stimulation paradigms.55 Alternatively, shRNA-mediated knockdown 
of the gene of interest can be performed followed by similar electrophysiological 
analyses to determine the effects on synaptic plasticity.56 We are currently using 
such in vitro techniques to strengthen the proof of causality of dominant and 
recessive ID gene mutations, including the homozygous missense mutation in the 
SLC6A17 gene (Chapter 6). A promising addition to the repertoire of cellular assays 
is provided by the use of human induced pluripotent stem cells (hIPSC).57,58 hIPSC 
are a type of pluripotent stem cells derived from reprogramming somatic cells such 
as fibroblasts,59 and can be differentiated into different lineages such as neurons.60 
Thus, by this approach it is possible to obtain physiologically relevant patient-derived 
cells suitable for electrophysiological and other studies.61
(ii) Animal modeling (In vivo studies)
In vivo studies can also provide additional proof about the causality of a candidate 
gene. The choice of the animal model depends on the properties of the gene, 
conservation, suitability to obtain desired phenotype, time consumption and the 
budget. In case of inactivating mutations, knockdown/knockout animal models are 
a good source to observe phenotypic consequences. In our proof-of-concept study 
on Frank-Ter Haar syndrome (Chapter 2), we established pathogenicity by identifying 
SH3PXD2B mutations in several independent families. In addition, the causality of 
the disruption of the identified gene was further supported by studies in a knockout 
mouse model, which recapitulated most of the phenotypic features of the human 
phenotype.62 In Chapter 5, we identified inactivating mutations in the gene ANK3, 
and have successfully used Drosophila melanogester to support the pathogenicity. 
Testing the functional consequences of specific missense mutations is also 
possible, but more difficult and time-consuming. For example, a missense mutation 
(Ile304Asn) in FMR1 associated with FXS has been modeled in mice. The mouse 
recapitulated the human phenotype as well as most of the features of null-Fmr1 
mice.63 
Therapy
ID is traditionally considered as a developmental and irreversible disorder that 
has a big impact on patients, their families as well as on total healthcare system. 
ID is often accompanied by other cognitive and behavioral deficits such as ASD 
and ADHD as well as variety of morphological defects. Though it is not possible to 
reverse all the morphological defects especially when the patients are adults or 
have passed the critical developmental phase, a minor elevation in the cognitive 
or behavioral performance would improve the quality of life of the patients.64 Until 
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recently, therapeutic options were deemed unfeasible as IDs were considered as an 
irreversible lifelong disorder. However, extensive studies in animal models, especially 
in mouse and Drosophila, paved the way towards the elucidation of the molecular 
processes and subsequently identification of potential therapeutic agents. Given the 
extreme heterogeneity of the condition, it is anticipated that most ID families will 
have a unique genetic cause.21 Recent advances revealed the elucidation of several 
common molecular pathways and mechanisms of disease for different ID disorders.
These observations may be a starting point towards the formulation of common 
therapeutic agents that might be used for treatment of different disorders that affect 
common pathways. Studies with animal models for ID have shown that behavioral, 
electrophysiological and cognitive deficits can be improved by targeting various 
synaptic pathways with pharmacological manipulations, even when applied post-
development. A prominent example is FXS. Mouse and Drosophila have been used to 
demonstrate that the deficiency of Fragile X protein (FMRP) affects several pathways, 
particularly mGLUR5- and GABAA-dependent synaptic signaling. The same animal 
models were instrumental to show that compounds reversing these affected synaptic 
pathways were able to reverse the learning and memory deficits.65-69 The first results 
of clinical trials with these compounds (e.g. fenobam and AFQ056) in FXS patients 
gave moderately positive results and are ground for furthering these with different 
variables and in larger patient cohorts.70,71 Also for other ID conditions, studies in 
animal models show promise towards the therapeutic interventions against variety 
of CDs,72 including Angelman syndrome,73 Rett syndrome,74 neurofibromatosis,75,76 
Rubinstein-Taybi syndrome,77 Kleefstra syndrome,78 and tuberous sclerosis.79,80 
Human trials are under way for some of these conditions.21,78,81
final remarks
ID is a one of the most serious health concerns in the World. For the past five 
years, the pace of the identification of genetic defects in neurodevelopmental 
conditions is enhanced to many folds after the introduction of massive sequencing 
techniques. This will increase our knowledge about the molecular and genetic causes 
of hitherto unveiled entities and will help filling in the pieces-of-puzzles in respective 
pathways that are disrupted in disease and subsequently will pave the way towards 
therapeutic interventions in a more efficient way. The field of ID therapeutics is in a 
development phase and hopefully some therapeutic options will emerge in the near 
future. At present, this large group is best served by improved medical care, which 
can be optimized by offering conclusive genetic diagnosis. Knowledge of the genetic 
basis of the ID disorder will allow optimal management of the disease, genetic 
counseling, and prognostic testing. In general, the early detection of the genetic cause 
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of disease will provide the best opportunities for this kind of personalized medicine. 
The benefits of early detection are evident by comparing medical genetic practice 
between countries. In the Pakistani population recessive disorders are common and 
especially some metabolic disorders have a high prevalence. Implementation of a 
national neonatal screening program would help in decreasing the disease load in 
the population. As more families will be diagnosed with frequent metabolic disorders 
leading towards ID, they can immediately benefit from available therapies. As in 
the patients of PKMR07, the therapy for hypothyroidism has already been started 
(Chapter 4.1). 
The high consanguinity rate in combination with the lack of awareness of the 
associated risks for the recurrence of recessive genetic disorders is another threat 
for the Pakistani population. Genetic counseling of the affected families would be 
essential in order to stop disease propagation. In December 2000, Israel passed a 
legislation concerning the genetic testing, genetic counseling, and to protect the 
rights to privacy of the patients regarding genetic findings.82 Such actions taken by 
other countries, especially where the consanguinity rate is high, will help to educate 
families regarding spreading the disease alleles to next generations and to reduce 
overall disease burden to the society. The extensive genetic studies as presented in 
this thesis will definitely help in finding novel and existing causes of ID, which in turn 
will help affected families in the terms of genetic counseling. As described in Chapter 
1, genetic studies in the highly consanguineous Iranian population have contributed 
a considerable proportion of causes of non-syndromic autosomal recessive ID. 
Investigation of other consanguineous populations at a similar scale would help in 
reducing the total disease burden through proper genetic counseling. our study 
described in this thesis has already revealed several known and novel genetic 
findings and will undoubtedly uncover further causes of ID in Pakistani population. 
Intensified continuation of such investigations is highly warranted to stop the disease 
propagation in the general Pakistani society. 
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SuMMaRy
Intellectual disability (ID) is defined by the significant deficits in intellectual 
functioning and adaptive behaviors, with an onset before the age of 18 years. ID 
is extremely heterogeneous group of disorders and affects 2-3% of the general 
population. Non-genetic and genetic factors contribute approximately equally to the 
etiology of ID. Malnutrition, socio-economic circumstances, prenatal and perinatal 
complications, trauma and low birth weight are the main non-genetic contributors 
to the development of ID. Genetic causes include chromosomal abnormalities, 
mutifactorial, and monogenic disorders. Monogenic disorders are classically 
dissected into X-linked, autosomal dominant, and autosomal recessive forms of 
disease. The aim of this study was to elucidate the genetic defects responsible for 
autosomal recessive intellectual disability (ARID). The genetics of ARID has been 
highly elusive so far, because of the paucity of large consanguineous families and 
extreme heterogeneity of the condition. The main focus of this study was the 
investigation of the genetic causes of ARID in the Pakistani population, where the 
consanguinity rate is more than 60%. In the last phase of my Ph.D. research I have 
exploited innovative  next generation sequencing (NGS) techniques, such as exome 
sequencing, which has accelerated the identification of “disease genes” underlying a 
heterogeneous group of ID disorders (Chapter 1).
Chapter 2 describes a proof-of-concept study, where we have shown that 
homozygosity mapping in consanguineous families is a powerful technique to 
localize the genetic defect for an autosomal recessive disorder. Here, we studied a 
small cohort of Frank-Ter haar syndrome (FTHS) patients, in which skeletal dysplasia, 
eye and cardiac abnormalities are the main hallmarks of the disease. We performed 
homozygosity mapping in 12 FTHS families. A single shared locus on chromosome 
5q35.1 was identified in patients of nine families. Subsequent mutation analysis 
revealed five different mutations in SH3PXD2B in seven families, including one family 
in which prior mapping was not performed. To further investigate the role of this 
gene in vivo, we studied a Sh3pxd2b knock-out mouse model. Mice lacking Sh3pxd2b 
showed skeletal, eye, and cardiac anomalies and recapitulated many defects 
associated with FTHS phenotype. 
Chapter 3 provides an overview of the ARID studies in consanguineous families 
ascertained from the Pakistani population. In total, 100 ID families were ascertained. 
We selected 54 families with an apparent autosomal recessive mode of inheritance 
to investigate by targeted NGS approaches and by whole-exome sequencing. A 
combination of array-based homozygosity mapping and NGS was applied for study 
of the first ten families. our results revealed novel mutations in three known ARID 
genes, TPO, DPAGT1, and AIMP1. A truncating mutation was identified in a novel 
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ARID gene, ANK3. In addition, three single plausible candidate ARID genes, FAIM2, 
THUMPD1, and ZNF498 were identified. In two families, two plausible candidate 
genes were identified: TMEM132E and MYO1D in one family, and CCDC23 and 
KLHL21 in another. one family remained inconclusive. The high number of identified 
causative mutations clearly shows the power of homozygosity mapping and the use 
of NGS to detect recessive genetic defects in consanguineous families. Most recently 
we have obtained NGS results in the remaining 44 families. of which, 31 families have 
been analyzed so far. our preliminary data shows that results of the latter studied 
group of families are comparable with the previously studied ten ARID families.
Chapter 4 comprises three sub-chapters, 4.1, 4.2, and 4.3. In chapter 4.1, we 
studied a consanguineous family by applying a combination of homozygosity 
mapping and targeted NGS. We identified a homozygous intragenic deletion of 
several exons of TPO gene. Retrospective biochemical tests revealed a positive 
diagnosis for hypothyroidism in this family (Chapter 3). In chapter 4.2, a non-
consanguineous family was studied by exome sequencing, which revealed a novel 
compound heterozygous mutation in DPAGT1. Subsequent biochemical assay 
confirmed the diagnosis of CDG-I type glycosylation defect (Chapter 3). In chapter 
4.3 we investigated another Pakistani family. Patients from this consanguineous 
family presented the characteristic clinical features of Bardet-Biedl syndrome (BBS) 
and were subjected to the array-based homozygosity mapping. The identified 
homozygous regions encompassed three known BBS genes, BBS2, BBS10, and BBS14. 
Direct sequencing of these three genes identified a novel homozygous deletion of 
ten nucleotides (p.Ser653Ilefs*4) in BBS10.
Chapter 5 elaborates on the identification of a novel gene, ANK3 (Chapter 3). 
Here, we have identified truncating mutations in ANK3 in two different families 
with severe cognitive deficits. Ankyrin 3 is an adaptor protein that links spectrin 
cytoskeleton to the integral membrane proteins. It has a crucial role in maintaining 
the neuronal polarity and molecular organization of the axon initial segments. We 
generated a knockdown Drosophila model, in order to support the causality of ANK3 
mutations in the two families and the role of the gene in cognitive function. We 
observed neuromuscular junction phenotype with small synapses, less synaptic 
boutons, and absence of intrabouton space. In addition, short-term memory defects 
were identified in flies.
In chapter 6, we investigated a Dutch family with three affected females. The 
affected members presented with ID and neurologic-tremor. We performed exome 
sequencing in this family and identified only a single segregating homozygous 
missense variant, which affected the SLC6A17 gene. Bioinformatics-based prediction 
programs and molecular modeling supported the causality of the identified variant. 
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We aim to further investigate the role of this gene in vitro as well as in vivo, which 
will hopefully allow us to confirm SLC6A17 as a potential pathogenic cause of the 
observed phenotype. 
Chapter 7 is about the general discussion and future perspectives. The 
identification of genetic defects that compromise the intellectual functioning is 
bitterly needed to improve diagnosis, prognosis and genetic counseling. Extensive 
studies as exemplified in this thesis are required to explore underlying causes 
of ID in order to reduce the overall disease burden by proper management and 
counseling, especially in developing countries such as Pakistan. The causes of high 
rate of consanguinity in Pakistan are discussed in detail. There are many challenges 
for proper clinical evaluation in Pakistan. Some of the important challenges have 
been highlighted. This chapter also provides an in-depth discussion about the 
benefits and shortcomings of NGS. My Ph.D. research as well as other recent NGS 
studies have demonstrated the clinical and diagnostic utility of NGS for solving the 
etiology of heterogeneous disorders such as ID. This technology provides an “all 
in one” platform to perform homozygosity mapping and to detect genetic defects 
from copy number variations to single nucleotide change. The robustness of NGS 
methodologies has already unveiled many unexpected genetic findings and has 
broadened the phenotypic spectra of genetic disorders. The advantage of the 
use of consanguineous families in mapping studies appears to have turned into 
a disadvantage for NGS, due to the relative large number of potential causative 
homozygous variants that segregate in consanguineous families. The identification 
of the pathogenic variant among multiple segregating variants can be achieved by 
recurrent genetic findings. Given the extreme heterogeneity in ID, with an estimated 
number of >2000 genes underlying ID, there is a large need for sharing the results 
of NGS studies in ID patients amongst laboratories. In addition, in vitro and in vivo 
analysis of genes and gene mutations in appropriate models may provide support for 
causality. Such model systems can also be exploited to identify and dissect molecular 
pathways that are commonly disrupted by mutations in different ID genes. The novel 
insights that can be obtained from such studies are a prerequisite for developing 
strategies for therapeutic intervention. It is to be hoped that the identification of 
common mechanisms of disease can be translated into therapeutic strategies aimed 
to restore commonly disrupted molecular and cellular mechanisms in ID, regardless 
of the specific gene defect. 
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SaMeNVaTTING
Verstandelijke beperking is een ontwikkelingsstoornis waarbij sprake is van 
significante beperkingen in het intellectueel functioneren en adaptief gedrag, met 
een aanvangsleeftijd jonger dan 18 jaar. Verstandelijke beperkingen vormen een 
extreem heterogene groep afwijkingen die voorkomt bij 2-3% van de bevolking. 
Niet-genetische en genetische factoren spelen een gelijkwaardige rol bij de etiologie 
van verstandelijke beperking. ondervoeding, sociaal-economische omstandigheden, 
prenatale en perinatale complicaties, trauma en een laag geboortegewicht zijn 
de belangrijkste niet-genetische risicofactoren voor de ontwikkeling van een 
verstandelijke beperking. Genetische oorzaken omvatten chromosomale afwijkingen, 
multifactoriële en monogene aandoeningen. Monogene aandoeningen zijn klassiek 
onderverdeeld in X-gebonden, autosomaal dominante en autosomaal recessieve 
vormen van overerving. Het doel van deze studie was het ophelderen van genetische 
defecten onderliggend aan autosomaal recessieve vormen van verstandelijke 
beperkingen (ARID). De genetica rond ARID is tot op heden uiterst weerbarstig gebleken 
door de afwezigheid van grote consanguine families en extreme heterogeniteit van 
de aandoening. De algemene focus van deze studie was het onderzoek naar de 
genetische oorzaken van ARID in de Pakistaanse populatie, waar de incidentie van 
consanguine huwelijken meer dan 60% bedraagt. In de laatste fase van mijn PhD 
onderzoek heb ik innovatieve next generation sequencing (NGS) technieken zoals 
exoom sequencing ingezet. Dit heeft de identificatie van “ziektegenen” onderliggend 
aan deze heterogene groep aandoeningen met verstandelijke beperking aanzienlijk 
versneld. (Hoofdstuk 1).
Hoofdstuk 2 beschrijft een experimenteel ontwerp waarbij we aantonen dat 
homozygosity mapping in consanguine families een krachtige techniek is om het 
genetisch defect voor autosomaal recessieve aandoeningen te lokaliseren. In deze 
studie onderzochten we een klein cohort patiënten met Frank-Ter Haar syndroom 
(FTHS) waarbij dysplasie van het skelet, oog en hartafwijkingen de belangrijkste 
kenmerken van het ziektebeeld vormen. Homozygosity mapping werd uitgevoerd 
in 12 FTHS families. Eén enkel gedeeld locus op chromosoom 5q35.1 werd 
geïdentificeerd in patiënten uit negen van deze families, waaronder een familie 
waarin patiënten een homozygote microdeletie hadden in dit gebied. Mutatieanalyse 
onthulde vijf verschillende mutaties in SH3PXD2B in zeven families, inclusief een 
familie waarin mapping niet eerst was uitgevoerd. om de rol van het gen in vivo 
verder te onderzoeken is een Sh3pxd2b knock-out muismodel bestudeerd. Muizen 
zonder Sh3pxd2b vertoonden skelet, oog en hartafwijkingen en lieten, samengevat, 
veel defecten zien overeenkomstig met het FTHS phenotype.
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Hoofdstuk 3 geeft een overzicht van de ARID studies in consanguine families uit 
de Pakistaanse populatie. In totaal werden 100 families met verstandelijke beperking 
onderzocht. Hieruit werden 54 families geselecteerd voor verder onderzoek door 
middel van homozygosity mapping, targeted NGS en sequencing van het volledige 
exoom. Een combinatie van array gebaseerde homozygosity mapping en NGS werd 
toegepast bij het onderzoek van de eerste tien families. onze resultaten onthulden 
nieuwe mutaties in drie bekende ARID genen, TPO, DPAGT1, en AIMP. Een truncerende 
mutatie werd geïdentificeerd in een nieuw ARID gen, ANK3. Daarnaast werden drie 
plausibele ARID kandidaatgenen geïdentificeerd: FAIM2, THUMPD1, en ZNF498. In 
twee families zijn twee plausibele kandidaatgenen geïdentificeerd: TMEM132E en 
MYO1D in een familie, CCDC23 en KLHL21 in een tweede. Eén familie bleef onduidelijk. 
Het hoge aantal gevonden causale mutaties laat duidelijk de kracht van homozygosity 
mapping en het gebruik van NGS zien voor het aantonen van recessieve genetische 
defecten in consanguine families. Recent hebben we NGS data ontvangen voor de 
resterende 44 families. 31 van deze families zijn reeds geanalyseerd. onze voorlopige 
data laat zien dat het percentage oorzakelijke mutaties en mogelijke mutaties voor 
deze groep vergelijkbaar is met dat van de eerder bestudeerde tien ARID families.
Hoofdstuk 4 omvat drie deel-hoofdstukken, 4.1, 4.2, en 4.3. In hoofdstuk 4.1 
werd een consanguine familie bestudeerd met een combinatie van homozygosity 
mapping en targeted NGS. In deze familie werd een intragene homozygote deletie 
van meerdere exonen van het TPO gen geïdentificeerd. Retrospectieve biochemische 
analyses gaven een positieve diagnose voor hypothyreoïdie in deze familie 
(Hoofdstuk 3). In hoofdstuk 4.2 werd een niet-consanguine familie onderzocht 
met exoom sequencing, waarbij een nieuwe samengesteld heterozygote mutatie 
in DPAGT1 werd ontdekt. Biochemische analyse bevestigde vervolgens de diagnose 
van een CDG-I type glycosyleringsdefect (Hoofdstuk 3). In hoofdstuk 4.3 werd een 
consanguine Pakistaanse familie onderzocht. Patiënten uit deze familie presenteerden 
de karakteristieke klinische kenmerken van het Bardet-Biedl syndroom (BBS) en 
werden onderzocht door middel van array-gebaseerde homozygosity mapping. 
De geïdentificeerde homozygote regio’s omvatten drie bekende BBS genen: BBS2, 
BBS10 en BBS14. Sanger sequencing van deze drie genen ontsluierde een nieuwe 
homozygote deletie van tien nucleotiden in BBS10 (p.Ser653Ilefs*4).
Hoofdstuk 5 gaat in op de identificatie van het nieuwe ID gen ANK3 (Hoofdstuk 
3). Hier beschrijven we de identificatie van truncerende mutaties in ANK3 in twee 
verschillende families met ernstige cognitieve beperkingen. Ankyrine 3 is een 
adapter-eiwit dat het spectrine cytoskelet verbind met de integrale membraan 
eiwitten. Het speelt een cruciale rol in het onderhouden van neuronale polariteit 
en de moleculaire organisatie van de initiële axon segmenten. om de causaliteit van 
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de ANK3 mutaties verder te bewijzen en om de rol van het gen in cognitieve functie 
te onderzoeken werd een knockdown Drosophila model gegenereerd. De Ank3-
mutante vertoonden afwijkingen van de neuromusculaire verbindingen gekenmerkt 
door kleine synapsen, vermindering van de synaptische blaasjes en afwezigheid van 
de tussenliggende ruimte van de blaasjes. Daarnaast werden defecten in het korte 
termijn geheugen van de vliegen waargenomen.
In hoofdstuk 6 werd een Nederlandse familie met drie aangedane vrouwen 
onderzocht. De aangedane familieleden vertoonden een verstandelijke beperking 
en neurologische tremor. Exome sequencing identificeerde een enkele segregerende 
homozygote missense variant in het SLC6A17 gen. Bioinformatica gebaseerde 
voorspellingsprogramma’s en moleculaire modellering ondersteunen de causaliteit 
van de variant. ons doel is om de rol van dit gen in vitro en in vivo verder te 
onderzoeken waarmee we onomstotelijk de pathogeniteit van de SLC6A17 mutatie 
kunnen aantonen. 
Hoofstuk 7 omvat de algemene discussie en vooruitblik op de toekomst. De 
identificatie van genetische defecten die ten grondslag liggen aan beperkingen van 
het intellectueel functioneren is bittere noodzaak om diagnostiek, prognose en 
genetische counseling te verbeteren. Goed management en counseling zijn nodig om 
de algehele ziektedruk te verlichten, vooral in ontwikkelende landen zoals Pakistan. 
Hiervoor zijn uitvoerige studies zoals beschreven in dit proefschrift nodig om de 
onderliggende oorzaken van verstandelijke beperking te verkennen. Er zijn veel 
uitdagingen rondom een goede klinische evaluatie in Pakistan, waarvan ik enkele 
belangrijke uitdagingen heb uitgelicht. Dit hoofdstuk geeft ook een uitgebreide 
discussie over de voordelen en tekortkomingen van NGS.
Mijn PhD onderzoek en andere recente NGS studies hebben de klinische en 
diagnostische bruikbaarheid van NGS aangetoond voor het oplossen van de etiologie 
van heterogene aandoeningen zoals verstandelijke beperking. Deze technologie 
levert een “alles in één” platform voor het uitvoeren van homozygosity mapping 
en het detecteren van genetische defecten variërend van copy number variatie 
tot geïsoleerde nucleotide veranderingen. De robuustheid van de NGS methodiek 
heeft reeds vele nieuwe genetische vondsten opgeleverd en heeft het fenotypische 
spectrum van genetische aandoeningen verbreed. Het voordeel van het gebruik 
van consanguine families voor homozygosity mapping lijkt een nadeel te zijn voor 
NGS, omdat een extra groot aantal potentieel causale homozygote veranderingen 
segregeren in deze families. De identificatie van de pathogene variant uit meerdere 
segregerende varianten kan worden bereikt door middel van terugkerende 
genetische vondsten. Gegeven de extreme heterogeniteit van verstandelijke 
beperking (met een geschat aantal van >2000 genen onderliggend aan de beperking) 
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is er een grote behoefte aan het delen van NGS resultaten in deze patiënten tussen 
laboratoria. Daarnaast kunnen in vitro en in vivo analyse van genen en genmutaties 
in geschikte modellen de causaliteit ondersteunen. Dergelijke modelsystemen 
kunnen worden gebruikt voor identificatie en ontleding van gemeenschappelijke 
moleculaire mechanismen die verstoord worden door mutaties in verschillende 
genen. De nieuwe inzichten die verkregen kunnen worden uit dergelijke studies zijn 
een voorwaarde om strategieën te ontwikkelen voor therapeutische interventie. Het 
is te hopen dat identificatie van gemeenschappelijke ziektemechanismen vertaald 
kan worden in therapeutische strategieën gericht op het herstellen van verstoorde 
moleculaire en cellulaire mechanismen in verstandelijke beperking, onafhankelijk 
van het specifieke gen defect. 
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LIST of aBBReVIaTIoNS
3D Three Dimensional
ADHD Attention-Deficit/Hyperactivity Disorder
ADID Autosomal Dominant Intellectual Disability
AIS Axon Initial Segment
ARID Autosomal Recessive Intellectual Disability
ASD Autism Spectrum Disorder
BAM Binary Sequence Alignment/Map format
BBS Bardet-Biedl Syndrome
CD Cognitive Disorder
CDG Congenital Disorder of Glycosylation
CEMB Centre of Excellence in Molecular Biology
CFTR Cystic Fibrosis Transmembrane Conductance Regulator
CH Congenital Hypothyroidism
CNAG Copy Number Analyzer for GeneChip
CNS Central Nervous System
CNV Copy Number Variation
CT Computed Tomography
DAM Drosophila Activity Monitor
EVS Exome Variant Server
EX-HoM Exome Homozygosity
FTHS Frank-Ter Haar Syndrome
FXS Fragile X Syndrome
G6PD Glucose-6-Phosphate Dehydrogenase
GAPDH Glyceraldehyde-3-Phosphate Guanine Dehydrogenase
GSK3 Glycogen Synthase Kinase 3 
GWAS Genome-Wide Association Study
HEC Higher Education Commission
HIE Hypoxic Ischemic Encephalopathy
hIPSC Human Induced Pluripotent Stem Cells
IBD Identity-by-Descent
ID Intellectual Disability
IoP Intraocular Pressure
IQ Intelligence Quotient
IRB Institutional Review Board
ISH In Situ Hybridization
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